Impact of Medicare Part D coverage gap on beneficiaries\u27 adherence to prescription medications by Desai, Urvi
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2011
Impact of Medicare Part D coverage gap on
beneficiaries' adherence to prescription
medications
Urvi Desai
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/2571
 
 
 
 
IMPACT OF MEDICARE PART D COVERAGE GAP ON BENEFICIARIES‟ 
ADHERENCE TO PRESCRIPTION MEDICATIONS 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
 
 
By 
 
 
URVI S DESAI 
Bachelor of Pharmacy, Sardar Patel University, India, 2006 
Doctoral Candidate, VCU School of Pharmacy, 2011 
 
 
 
 
ADVISOR: NORMAN V CARROLL 
Professor, Department of Pharmacotherapy and Outcomes Sciences  
VCU School of Pharmacy 
 
 
 
 
 
Virginia Commonwealth University, 
Richmond, Virginia 
August 2011 
ii 
 
 
 
 
 
 
 
 
 
 
To my family  
iii 
 
 
 
ACKNOWLEDGEMENTS 
Words can never be enough to thank the wonderful people: my family, mentors, and 
friends, without whom this journey would not have been possible. 
From the first steps I took as a child to where I am today, my parents, Mr. Sailesh Desai 
and Mrs. Vandana Desai have never doubted my capacity, only made me more aware of it every 
minute. In addition to providing the lessons of life, they ensured that my literal foundation was 
very strong. Their thoughtfulness, love and care are the forces that define my personality as it is 
today. Thank you, mom and dad. I thank my little brother, Gunjan, who always stood by me 
when needed. I love you, brother, and I am proud of you. 
The next bunch of my gratitude is extended to my „extended‟ family, especially to my 
mother-in-law, and father-in-law. They have really been a second set of parents to me. My sister-
in-law, Rujuta, deserves special thanks for everything she has done for me since the time before I 
was even engaged to her brother. I still remember the first time we went out and people 
questioned whether we were real sisters. We simply laughed and said „no, we mean more than 
that to each other‟ and I hope this relationship never changes!  
Of course, all of this would not be possible without the man I love, my dearest husband, 
Ruchit Marfatia. I thank him for his unconditional love and support ever since we started dating 
almost 10 years ago. His patience, never ending appreciation and recognition of everything I do 
personally and professionally, is what keeps me thriving.   
I am very grateful to Dr. Norman V Carroll, my dissertation advisor, for identifying the 
potential in me and constantly compelling me to challenge myself to reach new heights. I shall 
be indebted to him forever for believing in me and helping me make my dreams come true. It is 
due to his understanding and encouraging gestures that I was able to complete a very ambitious 
iv 
 
 
 
dissertation project while also managing a student organization, get married, and take care of my 
family. 
I wish to thank Dr. Darcy Mays for making me understand statistics! I had taken several 
courses in statistics earlier, but it was during his course that I really understood why we did what 
we did through statistics and use it for my dissertation!  
Thank you, Dr. Harpe, for being so patient with all my silly inquiries during the last two 
years. I would not have been able to develop and complete such a study without your support. I 
extend sincere gratitude to Dr. Michael Pyles and Dr. Leticia Moczygemba for their valuable 
feedback on my dissertation during the course of the study.  
I would also like to thank Dr. David Holdford, whose guidance in the days when I joined 
VCU helped me attain the academic excellence under the appropriate mentor. I thank Eric 
Edwards, who has continually helped me grow professionally. Special thanks to Dr. River 
Pugsley who taught me various statistical programs, especially SAS programming language. I 
don‟t know what my life would be like without Dr. Pugsley‟s wonderful teaching. 
My world would be colorless without the wonderful friends I spent time with during the 
past few years. I love and thank them all, especially Devangi Shah, my roommate and 
confidante. Thank you, Dipen and Avani, for being my go-to people, both personally and 
professionally, since day one at VCU. I also express sincere gratitude to Nidhi, Anal, Jwalant, 
Niyati, Nirja and Vivek for making me smile and feel loved during these challenging years. 
Last, but not least, I want to thank God for blessing me with the best life has to offer. Thank 
you Lord, and thank you everyone for making my life so beautiful. 
  
v 
 
 
 
TABLE OF CONTENTS 
LIST OF TABLES ...................................................................................................................... vii 
ABSTRACT ................................................................................................................................... x 
CHAPTER 1: INTRODUCTION .............................................................................................................. 1 
Section 1: Conceptual Framework .......................................................................................... 2 
Section 2: Prescription Drug Coverage and the seniors ........................................................................ 8 
Overview of the Remaining Document ............................................................................................... 20 
CHAPTER 2: LITERATURE REVIEW ................................................................................................ 21 
Section 1: Impact of Medicare Part D ................................................................................................. 22 
Section 2: Recent Literature on Medicare Part D Coverage Gap ........................................................ 29 
Gaps in Literature ................................................................................................................................ 40 
CHAPTER 3: RESEARCH OBJECTIVES AND SPECIFIC AIMS ................................................... 42 
Objective 1: To identify characteristics of beneficiaries reaching and not reaching the coverage gap 
in 2008................................................................................................................................................. 42 
Objective 2: To study the entry and exit times from the coverage gap in 2008 .................................. 44 
Objective 3: To study the impact of a complete gap in coverage on beneficiaries‟ adherence to 
prescription medications ..................................................................................................................... 45 
Objective 4: To study the impact of a „partial‟ gap in coverage on beneficiaries‟ adherence to 
prescription medications ..................................................................................................................... 45 
CHAPTER 4: METHODS ....................................................................................................................... 47 
Study Design ....................................................................................................................................... 47 
Database Preparation ........................................................................................................................... 47 
Selecting the sample of beneficiaries: general inclusion and exclusion criteria ................................. 55 
Methods to prepare the sample for each analysis ................................................................................ 58 
vi 
 
 
 
Measuring Medication Adherence ...................................................................................................... 68 
Data Analyses ..................................................................................................................................... 74 
CHAPTER 5: RESULTS ......................................................................................................................... 77 
Sample Size ......................................................................................................................................... 77 
Descriptive Characteristics .................................................................................................................. 79 
Medication Adherence ...................................................................................................................... 121 
Main Conclusions ............................................................................................................................. 135 
CHAPTER 6: DISCUSSION ................................................................................................................. 136 
Objective 1: ....................................................................................................................................... 136 
Objective 2: ....................................................................................................................................... 137 
Objectives 3 and 4: ............................................................................................................................ 139 
Strengths and Limitations ................................................................................................................. 145 
Conclusions and Future Research ..................................................................................................... 149 
BIBLIOGRAPHY ..................................................................................................................... 150 
CURRICULUM VITA ............................................................................................................. 159 
  
vii 
 
 
 
LIST OF TABLES 
Table 1: Variables used from the Beneficiary Summary File ..................................................................... 48 
Table 2: Consumer Price Index 2000-2008 ................................................................................................ 50 
Table 3: Variables used to identify beneficiaries with COPD/CKD/Cancer .............................................. 51 
Table 4: Variables included from Part D utilization file ............................................................................. 53 
Table 5: Chronic Disease Score Calculation ............................................................................................... 65 
Table 6: Sample Size by Therapeutic Class ................................................................................................ 78 
Table 7: Characteristics of beneficiaries overall and by type of coverage in the coverage gap ................. 80 
Table 8: Demographic characteristics of beneficiaries with no drug coverage in the coverage gap by 
therapeutic class .......................................................................................................................................... 81 
Table 9: Medication related characteristics of beneficiaries with no drug coverage in the coverage gap by 
therapeutic class .......................................................................................................................................... 82 
Table 10: Plan characteristics of beneficiaries with no drug coverage in the coverage gap by therapeutic 
class ............................................................................................................................................................. 83 
Table 11: Demographic characteristics of beneficiaries with some drug coverage in the coverage gap by 
therapeutic class .......................................................................................................................................... 84 
Table 12: Medication related characteristics of beneficiaries with some drug coverage in the coverage gap 
by therapeutic class ..................................................................................................................................... 85 
Table 13: Characteristics of beneficiaries in the “No Gap Coverage” group taking oral anti-
hyperlipidemic agents before and after matching ....................................................................................... 93 
Table 14: Characteristics of beneficiaries in the “No Gap Coverage” group taking Beta-blockers before 
and after matching ....................................................................................................................................... 95 
Table 15: Characteristics of beneficiaries in the “No Gap Coverage” group taking Diuretics before and 
after matching ............................................................................................................................................. 97 
Table 16: Characteristics of beneficiaries in the “No Gap Coverage” group taking ACE inhibitors before 
and after matching ....................................................................................................................................... 99 
Table 17: Characteristics of beneficiaries in the “No Gap Coverage” group taking Calcium channel 
blockers before and after matching ........................................................................................................... 101 
Table 18: Characteristics of beneficiaries in the “No Gap Coverage” group taking Proton Pump Inhibitors 
before and after matching ......................................................................................................................... 102 
viii 
 
 
 
Table 19: Characteristics of beneficiaries in the “No Gap Coverage” group taking oral anti-diabetic agents 
before and after matching ......................................................................................................................... 104 
Table 20: Characteristics of beneficiaries in the “Some Gap Coverage” group taking anti-hyperlipidemic 
agents before and after matching .............................................................................................................. 106 
Table 21: Characteristics of beneficiaries in the “Some Gap Coverage” group taking beta-blockers before 
and after matching ..................................................................................................................................... 107 
Table 22: Characteristics of beneficiaries in the “Some Gap Coverage” group taking diuretics before and 
after matching ........................................................................................................................................... 108 
Table 23: Characteristics of beneficiaries in the “Some Gap Coverage” group taking ACE inhibitors 
before and after matching ......................................................................................................................... 109 
Table 24: Characteristics of beneficiaries in the “Some Gap Coverage” group on calcium channel 
blockers before and after matching ........................................................................................................... 110 
Table 25: Characteristics of beneficiaries in the “Some Gap Coverage” group taking PPIs before and after 
matching .................................................................................................................................................... 111 
Table 26: Characteristics of beneficiaries in the “Some Gap Coverage” group on oral anti-diabetic agents 
before and after matching ......................................................................................................................... 112 
Table 27: Characteristics of beneficiaries on oral anti-hyperlipidemic agents based on “gap coverage” 
status ......................................................................................................................................................... 114 
Table 28: Characteristics of beneficiaries on beta-blockers based on “gap coverage” status ................... 115 
Table 29: Characteristics of beneficiaries on diuretics based on “gap coverage” status .......................... 116 
Table 30: Characteristics of beneficiaries using ACE inhibitors based on “gap coverage” status ........... 117 
Table 31: Characteristics of beneficiaries on calcium channel blockers based on “gap coverage” status 118 
Table 32: Characteristics of beneficiaries using PPIs based on “gap coverage” status ............................ 119 
Table 33: Characteristics of beneficiaries using oral anti-diabetic agents based on “gap coverage” status
 .................................................................................................................................................................. 120 
Table 34: Decrease in MPR in the “No Gap Coverage” group before matching ...................................... 122 
Table 35: Difference-In-Difference analyses of the MPRs in the “No Gap Coverage” group by therapeutic 
class after matching ................................................................................................................................... 124 
Table 36: Percent of beneficiaries in the “No Gap Coverage” group stopping medications during the 
coverage gap .................................................................................................. Error! Bookmark not defined. 
Table 37: Percentage of beneficiaries in the “No Gap Coverage” group considered adherent in the Pre-
Gap and the During Gap periods by therapeutic class .............................................................................. 126 
ix 
 
 
 
Table 38: Difference-in-difference of percentage of beneficiaries in the “No Gap Coverage” group 
considered adherent during the coverage gap ........................................................................................... 127 
Table 39: Decreases in MPR in the “Some Gap Coverage” Group by gap status before matching ......... 130 
Table 40: Difference-In-Difference analyses of decreases in MPRs in the “Some Gap Coverage” group by 
therapeutic class after matching ................................................................................................................ 130 
Table 41: Percent of beneficiaries in the “Some Gap Coverage” group stopping medications during the 
time corresponding to the coverage gap ................................................................................................... 131 
Table 42: Percentage of beneficiaries considered adherent* in the Pre-Gap and the During Gap periods by 
therapeutic class ........................................................................................................................................ 132 
Table 43: Difference-in-difference of percentage of beneficiaries in the “Some Gap Coverage” group 
considered adherent† during the coverage gap ......................................................................................... 133 
Table 44: Decreases in MPRs during the coverage gap by gap coverage type and therapeutic class ...... 134 
  
x 
 
 
 
ABSTRACT 
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Philosophy at Virginia Commonwealth University 
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Advisor: Norman V Carroll, Professor, Department of Pharmacotherapy and Outcomes Sciences 
 
  
INTRODUCTION: Medicare Part D provides prescription drug coverage to seniors through a 
benefit plan with a major deductible inserted in the middle. It is important to study the extent to 
which this structure affects seniors‟ adherence to prescription medications. Therefore, this study 
had the following objectives:  (1) To identify characteristics of beneficiaries reaching and not 
reaching the coverage gap, (2) To study the entry and exit times from the coverage gap, (3) To 
study the impact of a complete gap in coverage on beneficiaries‟ adherence to prescription 
medications, (4) To study the impact of a partial gap in coverage on beneficiaries‟ adherence to 
prescription medications 
METHODS: This was a retrospective quasi-experimental analysis with matched control groups 
using a nationally representative sample of Part D enrollees from 2008 Centers for Medicare and 
Medicaid (CMS) datasets. Adherence to each oral medication taken for one or more of the seven 
pre-defined therapeutic classes before and after reaching the coverage gap was measured using 
the Medication Possession Ratio (MPR). Appropriate statistical tests for significance were 
performed for each analysis 
xi 
 
 
 
RESULTS: A quarter of our sample (24.42%) reached the coverage gap in 2008. Most of the 
beneficiaries reaching the coverage gap did so by end of September. Those reaching the 
coverage gap and losing all coverage experienced significantly greater reductions in adherence 
(3% more for beta-blockers to 9% more for oral anti-diabetic agents), compared to those not 
reaching the coverage gap. A considerable proportion of beneficiaries stopped taking 
medications in both the groups and the proportion of beneficiaries considered adherent also 
dropped in both the groups during the coverage gap period. 
CONCLUSIONS: Medicare Part D beneficiaries face significant barriers to adherence and this is 
especially highlighted among those reaching the coverage gap. Interventions to improve 
adherence in this group should target all beneficiaries, especially those with several chronic 
conditions. 
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CHAPTER 1: 
 INTRODUCTION 
 
 This chapter presents background information about the concept of health insurance and 
demand, which is the underlying conceptual framework guiding this study, followed by historical 
issues surrounding prescription drug coverage for the seniors in the United States and the newly 
introduced Medicare Part D benefit. The first section of conceptual framework also contains 
information about the empirical evidence to support the theory that presence (or absence) of 
insurance affects utilization of healthcare services; especially prescription drugs. The second 
section details the historical issues surrounding prescription drug coverage for seniors. This 
section provides an overview of Medicare and its efforts to provide coverage for prescription 
drugs to beneficiaries prior to implementation of Medicare Part D. It also contains results from 
pre-Part D studies that explored the need for prescription drug coverage for the Medicare 
beneficiaries. Next, it contains information about the Medicare Prescription Drug and 
Modernization Act of 2003 and its provisions for prescription drug coverage, including the 
structure of Medicare Part D. It also explores the projected impact of this policy change on 
access to and use of medications using the pre-Part D literature. Finally, the chapter provides a 
brief overview of the remainder of the document. 
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Section 1: Conceptual Framework 
The Concept of Health Insurance 
Healthcare is an area of great uncertainty because illnesses are often difficult to predict 
and the associated treatments are often very costly. This leaves individuals in constant fear of 
losing a significant amount of their income in a relatively short period of time. Insurance is an 
arrangement that allows risk-averse people to reduce the uncertainty associated with these events 
by making regular contributions (premiums) to an agency that provides them assurance of 
financial assistance at the time of need. While it is not possible to predict the probability of 
illness per individual, the average probability of illnesses can be predicted fairly well for a large 
group of people. This is done based on the law of large numbers, which shows that for a given 
probability of illness, the distribution of the average rate of illness in a group will collapse 
around the probability of illness as the group size increases
1
. Thus, insurance reduces the 
variability of the insureds' income by pooling their risks into a large group.  
Most insurance agencies in the healthcare industry require that insured individuals share a 
percentage of the cost of treatment of an illness. This percentage to be paid by the insured at the 
time of the event is typically referred to as co-insurance
1
. For example, if the total cost of 
treatment is $100, then with a 20% co-insurance rate, the insured will pay $20 (out-of-pocket 
(OOP)) at the time of treatment and the insurer will pay the remaining $80. The purpose of 
requiring some form of cost sharing at the time of treatment (in addition to the premiums) is to 
make consumers more aware of the true costs of the treatment and to prevent unnecessary use of 
healthcare services
1
. This concept can be better explained using the economic theory of price 
elasticity of demand for goods and services. 
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The Economic theory of Price Elasticity of Demand 
The demand curve for most goods and services is downward sloping, indicating an 
inverse relationship between price charged and the quantity demanded. Thus, for a given service, 
as the price of the service increases, the quantity demanded decreases and vice versa. This 
relationship between price change and quantity demanded is explained economically using the 
concept of “price elasticity”. The price elasticity of demand can be defined as the ratio of percent 
change in quantity demanded to percent change in price of the service
2
. Thus, if the initial price 
for a given product is P0, the quantity demanded at this price is Q0 and if the price changes to P1 
and the quantity demanded changes to Q1, then 
 𝒑𝒓𝒊𝒄𝒆 𝒆𝒍𝒂𝒔𝒕𝒊𝒄𝒊𝒕𝒚 𝒐𝒇 𝒅𝒆𝒎𝒂𝒏𝒅 =    𝑸𝟏 − 𝑸𝟎 ÷ 𝑸𝟎 /  𝑷𝟏 − 𝑷𝟎 ÷ 𝑷𝟎  
The sign of the ratio indicates the direction of change in quantity demanded with respect 
to change in price. It is typically negative because quantity demanded decreases with increase in 
price or vice versa. The greater the absolute value of the price elasticity of demand, the greater is 
the effect of change in price on quantity demanded. In absolute terms (ignoring the sign), the 
farther the ratio is from 1,the greater the elasticity of demand for a product or service and the 
closer the ratio is to 1, the less the elasticity of demand for a product or service.
2
  
As mentioned earlier, the relationship between insurance cost sharing and utilization of 
healthcare products and services can be explained using this fundamental principle of price 
elasticity of demand. Economic theory suggests that presence of insurance (versus patients 
having to pay the full cost themselves) makes the demand for healthcare services less elastic, 
thereby, increasing the quantity demanded at any given market price.
3
 In other words, in the 
presence of insurance, changes in the market price for a service will not affect the consumer as 
much as they did when the price was paid out of pocket. This is illustrated in Figure 1 below. In 
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this figure, the graph presents a hypothetical example of the relationship between market price 
and quantity of a health service demanded for various price levels. It further provides 
information on the changes that would occur in the presence of different co-insurance rates. 
According to this figure, for a person with a 100% co-insurance rate (complete self-pay or no 
insurance), for a market price of $40, quantity demanded is X1; for $20, quantity demanded is 
X2 and for $10, the quantity demanded is X3. However, if the co-insurance rate drops to 50%, 
the quantity demanded will correspond to the quantity demanded at 50% of the actual market 
price. Thus, now, for market price of $40, the quantity demanded will be X2, because now the 
patient is paying only $20 and so he/she will demand the service as if the price was $20. If the 
co-insurance rate further decreases to 25%, the quantity demanded for a market price of $40 will 
be X3. 
 
 
 
 
 
 
 
 
 
Figure 1: Relationship between co-insurance and demand for healthcare services Adapted 
from Figure 9-7: The effect of coinsurance rate on healthcare demand on Pg: 184
3
 
 
This change in demand for services at any given market price is represented graphically 
by the outward rotation of the demand curve with decreasing co-insurance rates. Thus, 
Demand curve for 50% Co-insurance 
Demand curve for 100% OOP  
Market Price 
Demand curve for 25% Co-insurance 
$40 
$20 
$10 
X3 X2 X1 Quantity 
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decreasing co-insurance rates increases the utilization of healthcare services beyond what a 
patient would normally consume at any given market price. In other words, a decrease in patient 
cost sharing leads to an increase in utilization of healthcare services. The opposite of this is also 
true; i.e. an increase in co-insurance rates decreases the utilization of healthcare services. The 
following section provides the empirical evidence to support this theory, focusing on its 
relevance to prescription drug utilization. 
Empirical Evidence 
Empirical evidence suggests that the economic theory of cost sharing and demand for 
services is true for most healthcare products and services including prescription drugs. The 
breakthrough study by RAND Corporation in 1985 was among the first to provide evidence in 
support of the above theory. The study found that the quantity of prescription drugs demanded 
increased with a decrease in cost sharing.
4
 For example, the group with free care filled about 5 
prescriptions per month compared to 4 prescriptions used by enrollees of plans with 25% and 
50% cost sharing.  
Coulson et al. concluded that within a Pennsylvania Health Plan Medicare population, 
enrollees with some form of coverage for prescription drugs filled and refilled more prescriptions 
compared to those who did not have any form of coverage for prescription drugs.
5
 Upon 
analyzing the completed surveys, it was observed that enrollees with insurance for both 
physician visits and prescription drugs filled and refilled approximately 1.87 prescriptions 
whereas those without supplemental insurance filled and refilled only 0.80 prescriptions in the 
given two week reference period.   
Using data from the RAND Elderly Health Supplement to the 1990 panel study of 
income dynamics, Lillard et al. concluded that presence of insurance coverage for prescription 
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drugs significantly increased the probability of use of these drugs.
6
 Using simulations to estimate 
the effects of providing insurance to Medicare enrollees without prior drug coverage, the 
researchers observed that under such a provision, the probability of medication use would 
increase by 8.8% (p < 0.01) in this population. The study further estimated a 12.2% increase 
among beneficiaries with no private insurance (Medicare only) and 7.5% among beneficiaries 
with private insurance but with no drug coverage.  
A study of the existing data of 7,285 community dwelling Medicare beneficiaries from 
the Cost and Use files for the 2000 Medicare Current Beneficiary Survey (MCBS) found that 
enrollees with drug coverage had 4.5 times higher probability of any drug use compared to those 
with no coverage.
7
 A more recent study of Medicare beneficiaries from the MCBS of 1992-2000 
estimated that presence of prescription drug coverage increased utilization by 4%-10% 
depending on the type (i.e. public coverage vs. HMO or employer sponsored coverage) and 
generosity of coverage  compared to lack of coverage altogether.
8
  
There is ample literature indicating that the opposite of these findings is also true; i.e. the 
demand for prescription medications decreases with increased cost sharing. In a 2007 systematic 
review, Goldman et al.
9
 reviewed 132 articles to study the effect of cost sharing on utilization of 
prescription drugs from 1985 to 2006. The studies reviewed looked at several types of cost 
sharing strategies employed by insurers including incentive based formulary design, capped 
benefits and not providing coverage for certain classes of drugs. From this comprehensive 
review, the authors concluded that irrespective of the strategy used, increases in cost sharing  led 
to decreases in utilization of prescription medications. The authors summarize their findings 
using the principle of price elasticity of demand by stating that for every 10% increase in cost-
sharing prescription drug use decreased by 2%-6% depending on the drug and therapeutic class; 
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i.e. the price elasticity of demand for prescription drugs according to this study ranges from -0.2 
to -0.6.   
In other words, the result is consistent among the articles reviewed: presence (or absence) 
of insurance and the generosity of cost-sharing structures affects the demand for prescription 
drugs. The next section outlines the historical issues surrounding prescription drug coverage for 
seniors and presents an overview of the basic structure of the recently implemented Medicare 
Part D prescription drug benefit 
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Section 2: Prescription Drug Coverage and the seniors 
History of Medicare 
 The need for financial assistance for the seniors was first recognized in the United States 
with the passage of the Social Security Act (SSA) of 1935. While it was originally intended to 
include government sponsored health insurance for the seniors eligible for receiving Social 
Security, health insurance coverage was omitted from the final Act of 1935 due to political 
concerns
10
. Proponents of compulsory health plans were no more successful for the next two 
decades. However, immediately after his election in 1964, President Johnson, who was a strong 
proponent of health insurance for the aged even before his election, signed Medicare and 
Medicaid into law on June 30, 1965
10, 11
. Through this law, Medicare was established under Title 
XVIII of the SSA  to provide federally administered health insurance to individuals age 65 and 
older  regardless of income or medical history
12
. Under Title XIX of the SSA, Medicaid was 
established as a federal-state administered program to provide health insurance coverage to 
certain low-income groups of people who could not otherwise afford health insurance
10
. In 1972, 
Medicare expanded coverage to citizens under the age of 65 years who were either permanently 
disabled or suffered from End-Stage Renal Disease (ESRD)
11, 12
.  
Historically, Medicare provided compulsory hospital insurance (called Part A) to the 
seniors and disabled that helped pay for inpatient care, skilled nursing facility, and hospice care, 
with an optional medical insurance program (called Part B) that helped pay for physician 
services, home health and preventive services including physician administered drugs for 
beneficiaries who wish to subscribe. However, Medicare did not provide any coverage for 
outpatient drugs. 
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With the passage of the Medicare Catastrophic Coverage Act of 1988, Medicare 
proposed provision of outpatient prescription drug coverage to beneficiaries with a cap on out-
of-pocket (OOP) expenses
11
. Through this act, Medicare planned to cover a set percent of 
catastrophic expenses for outpatient drugs including insulin and immuno-suppressants used after 
organ transplant surgeries after meeting a certain deductible each year. The proposed timeline of 
implementation was that Medicare would cover 50% of the costs of such medications after a 
deductible of $500 in 1990 and $600 in 1991 and 60% of the costs after a deductible of $652 in 
1992
13
. In the long term, the deductible value was proposed to be set so that 16.8% of all 
Medicare beneficiaries would exceed the amount and Medicare paid 80% of the costs in excess 
of that amount. The program was proposed to be financed through an increase in premium based 
on a beneficiary‟s income13. The act was repealed in 1989 following increasing political pressure 
and protests by higher income seniors who were likely to be faced with increased premiums 
11, 14
. 
Since then, Medicare did not provide coverage for outpatient prescription drugs until the passage 
of the Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003
11
. 
The Need for a Medicare Drug Benefit 
Studies done before 2003 concluded that most seniors suffered from several chronic 
conditions, took a number of medications, and paid a significant proportion of their income 
towards prescription medications. For instance, results from the 1980 National Medical Care 
Utilization and Expenditure Survey indicated that four out of five seniors used prescription drugs 
in a given year
15
. It also found that although seniors constituted 10.1% of the national population, 
they accounted for about 33% of the total spending on prescription drugs. Approximately 68% of 
this cost was paid out-of-pocket. Mueller et al.
16
 used data from the 1987 National Medical 
Expenditure Survey and found similar results: 12% of the population comprised seniors, who in 
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turn accounted for 34% of total spending on prescription drugs. They also found that 36% of the 
seniors in their sample had more than three chronic conditions.  
Davis et al.
17
 used data from 1995 MCBS and found that Medicare beneficiaries paid half 
of their prescription costs OOP compared to the much lower national average OOP spending by 
the entire U.S population (34%) and an even lower percent paid by Medicaid enrollees (21%). 
Crystal et al.
18
 also used 1995 MCBS data.  They found that beneficiaries spent 19% of their 
income on healthcare, 50% of which was spent on prescription drugs and dental services. The 
burden was higher in sicker (28.5% of income) and low income beneficiaries (31.5% of income).  
Several studies reported that a lack of insurance for prescription drugs adversely affected 
medication adherence among seniors. The International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) defines medication adherence as “the extent to which a patient acts 
in accordance with the prescribed interval and dose of a dosing regimen”.19 Thus, to be adherent 
to a prescribed regimen, a patient must first purchase the medication and then utilize it as 
prescribed. A lack of insurance has been found to result in decreased procurement of drugs 
which in turn resulted in non-adherence among seniors. For example, Davis et al.
17
 reported that 
nearly 35% of Medicare beneficiaries living in the community did not have coverage for 
prescription drugs. It was further found that beneficiaries without prescription drug coverage 
used 31% less prescription drugs compared to the national average usage (12.7 vs. 18.5). 
Steinman et al. concluded that 8% of seniors without insurance reported medication restriction 
due to cost compared to 3% with partial coverage and 2% with full coverage
20
.   
A national survey of Medicare beneficiaries aged 65 and older revealed that almost a 
quarter of seniors did not have prescription drug coverage in 2003 and almost  half of low-
income seniors lacked coverage in some states
21
. The study also found that cost was cited as the 
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most common reason for non-adherence (26.3%) as compared to non-adherence due to 
unfavorable experiences like side effects (24.5%) or perceived need for taking the medications 
(14.5%). The effect was even more pronounced among beneficiaries with low income and/or 
multiple chronic conditions and/or no coverage. For example, among beneficiaries with low 
income and complex chronic conditions, almost 50% of those without coverage for prescription 
drugs reported some form of cost-related non-adherence compared to 25% of those beneficiaries 
who had some form of coverage for prescription drugs
21
.  
A number of studies have concluded that medication non-adherence leads to severe 
clinical and economic implications. A study by Mojtabai and Olfson used the Health and 
Retirement Study (HRS) data which is an ongoing longitudinal survey of community dwelling 
older Americans and concluded that participants with cost related poor adherence were more 
likely to have been hospitalized compared to their peers (43% vs. 33% respectively)
22
.  
In a study of hypertensive patients, Psaty et al. observed that patients with less than 80% 
adherence to their medication (as measured from a computerized pharmacy database) have a 4 
fold increase in risk of developing acute cardiac events compared to those with adherence ratio 
of 80% or higher
23
. Horwitz et al. reported that among patients on beta-blocker therapy, poor 
adherers (i.e. those who took less than or equal to 75% of the prescribed medication) were 2.6 
times more likely to die compared to good adherers (i.e. those who took more than 75% of the 
prescribed medication) (95% CI (1.2, 5.6)) and that such non-adherence to medications (i.e. 
taking less than or equal to 75% of the prescribed medication) was independently associated with 
a higher mortality risk
24
.  
A study involving epileptic patients
25
 found that non-adherence to medications (defined 
as Medication Possession Ratio, (MPR) less than or equal to 0.80) was associated with 
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significantly higher incidence of hospitalizations [incident rate ratio (IRR) = 1.39, 95% CI = 
1.37-1.41], inpatient days (IRR = 1.76, 95% CI = 1.75-1.78), and ED visits (IRR = 1.19, 95% CI 
= 1.18-1.21). Non-adherence was also associated with cost increases related to serious outcomes, 
including inpatient ($4,320 additional cost per quarter, 95% CI = $4,077-$4,564) and ED 
services ($303 additional cost per quarter, 95% CI = $273-$334).  
Balkrishnan et al. found that adherence to anti-diabetic medications (defined as MPR > 
0.70) was a greater driver of cost reduction than use of other medications in this population. The 
results indicated that a 10% increase in adherence to anti-diabetic medications resulted in 8.6% 
reduction in total annual health care costs (including ER visits and hospitalization)
26
.  
Svarstad et al. studied Medicaid patients suffering from mental illnesses and observed 
that within the total sample, patients with an irregular use of medications (defined as patients 
taking oral medications who had one or more quarters without a claim) had significantly higher 
rates of hospitalization than regular users (42 percent versus 20 percent), more hospital days (16 
days versus four days), and higher hospital costs ($3,992 versus $1,048). Irregular medication 
use was one of the strongest predictors of hospital use and costs even after the analyses 
controlled for other confounders
27
.  
From the  pre-MMA literature, it is reasonable to conclude that lack of sufficient 
financial assistance (in other words, “insurance”) posed a significant burden to seniors which 
compelled them to forego medications; this in turn increased their chances of developing adverse  
clinical outcomes that led to unnecessary increases in the treatment costs . A systematic review 
of the literature has indicated that non-adherence leads to anywhere from 5-40% of all hospital 
admissions in the seniors
28
. As noted by Haynes et al., “Increasing the effectiveness of adherence 
interventions may have a far greater impact on the health of the population than any 
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improvement in specific medical treatments” 29.  Partly in response to studies like these, the 
MMA was signed into law on December 8, 2003
14
. 
Structure of Medicare Part D    
Administration 
Beginning January 1, 2006, Medicare Part D, a voluntary outpatient prescription drug 
benefit program, was implemented for all Medicare beneficiaries except for those who are dually 
eligible for Medicare and Medicaid and certain low-income beneficiaries.  These patients are 
automatically enrolled into a plan if they did not choose one during the open enrollment period 
beginning in November of every year. Medicare Part D is delivered through private plans, either 
stand-alone prescription drug plans (PDPs) or Medicare Advantage prescription drug (MA-PD) 
plans, that contract with Medicare to provide either the “standard benefit” required by the MMA 
(explained in section: Benefit Structure), or a benefit structure that is “actuarially equivalent” or 
enhanced.  
As of April 2010, approximately 27.6 million beneficiaries were enrolled in Part D, of 
which two-thirds were enrolled in PDPs
30
. It is important to distinguish between beneficiaries 
enrolled in PDPs and MA-PDs because of the difference in the benefit structure offered. Most 
PDPs offer coverage using some modification of this basic structure 
31
. In 2010, about 60% of 
the PDPs required the standard deductible (compared to 11% of MA-PDs), 80% of PDP plans 
had the “coverage gap” and offered no coverage for drugs during that time (compared to 51% of 
MA-PDs). The 20% of the plans that did offer gap coverage limited it to generic drugs only. By 
comparison, 49% of MA-PD plans offered generic with some brand name drug coverage during 
the gap 
30, 32
. Thus, 80% of beneficiaries enrolled in PDPs were solely responsible for the full 
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cost of their medications during the coverage gap while about half of those enrolled in MA-PDs 
received some assistance. Now in its fifth year of implementation, Medicare Part D is funded by 
general revenues, beneficiary premiums, and state payments and accounted for 10% of the total 
Medicare spending in 2009 
12
.  
Benefit Structure 
The prescription drug coverage offered though Medicare Part D includes a small 
deductible at the front end and a major coverage gap inserted in the middle. The coverage gap, 
where the beneficiary is responsible for full cost, is also called the “doughnut-hole”; and the limit 
above which the coverage resumes is called the “catastrophic coverage limit”. In 2010, there was 
an initial deductible of $310, followed by 25% coinsurance until total drug spending reached 
$2,830. At this point the coverage gap began and continued until total drug spending reached 
$6,440 
30
. Thus, in addition to monthly premiums, in 2010, an average beneficiary paid $310 + 
25% ($2,830 - $310) = $940 in OOP costs before reaching the coverage gap. After this, the 
beneficiary was responsible for paying 100% of the cost until the total drug spending reached 
$6,440. In other words, the beneficiary was responsible for the next $3,610 in prescription 
spending before reaching the catastrophic coverage limit after which Medicare would cover 95% 
of drug costs. This structure is pictorially represented in Figure 2 below. 
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Figure 2: Standard Benefit Structure of Medicare Part D for 2010 
Medicare Part D beneficiaries have the choice to enroll in plans that offer coverage 
through either the Medicare defined standard benefit structure (shown above) or some alteration 
of the same. There are three different alternatives to the standard benefit design. The “actuarially 
equivalent” designs are those that have a deductible at the front end followed by Medicare 
defined limits for beginning of coverage gap and catastrophic coverage limits. They differ from 
the Medicare defined “standard benefit” only in the fact that these plans are allowed to charge 
beneficiaries various cost-sharing structures in lieu of the standard 25% co-insurance in the 
standard benefit. A “basic alternative” is a design where the deductible can be eliminated or 
reduced and the cost-sharing structures can be altered compared to the Medicare Standard but the 
limits for the coverage gap and catastrophic coverage are not altered. In contrast, plans offering 
coverage through an “enhanced alternative” have the freedom of whether or not to charge a 
deductible as well as whether or not to include a coverage gap. They can change the cost-sharing 
Catastrophic Coverage: 5% 
coinsurance after total 
spending exceeds $6,440 
(Very few beneficiaries reach 
this phase)
Coverage Gap: No coverage till 
total spending reaches $6,440
Deductible ($310) + 25% co-
insurance up to total spending of 
$2,830 (Most beneficiaries stay in 
this phase)
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structure as well as spending limits to determine the beginning of the coverage gap. The 
catastrophic limit and cost-sharing, however, stay in place similar to the other designs. In 
addition, these plans are allowed to offer coverage for some or all  drugs for beneficiaries in the 
coverage gap.   
The novel cost-sharing structure employed by Medicare Part D generated interest in 
trying to estimate the proportion and characteristics of beneficiaries who would reach the 
coverage gap under the standard Part D benefit structure using historical (pre-MMA) data. 
Further the research community was interested in estimating the effects of reaching the coverage 
gap on beneficiaries‟ medication taking behavior and costs. The following section summarizes 
the findings of the pre-MMA studies. 
Projections pertaining to the coverage gap 
 Stuart et al. used data from the MCBS for years 1998-2000 and estimated that about 40% 
of all Part D enrollees will spend some time in the coverage gap each year from 2006-2008 and 
only 15% of these would have spending high enough to reach the catastrophic coverage level
33
.   
Tjia and Schwartz studied medication utilization behavior of seniors with diabetes 
mellitus from the 2001 Medical Expenditure Panel Survey (MEPS) and estimated that the 
percentage of beneficiaries having expenditures in excess of the initial gap limit of 2006 ranged 
from 60% for those using traditional hypoglycemic agents to 75% for those on novel agents
34
. 
Tjia and Schwartz also concluded that having three or more co-morbid conditions as well as 
clinical indicators of greater illness burden and poorer health status significantly increased the 
likelihood of falling in the coverage gap
34
. However, they concluded that sociodemographic 
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factors were not significantly associated with the risk of falling in the coverage gap in their 
sample of diabetic beneficiaries.   
Using historical data of patients diagnosed with atrial fibrillation between January 2001 
and June 2003, Evans-Molina et al. projected that the percentage of beneficiaries in their sample 
expected to enter the coverage gap in 2006 ranged from 27% to 46%, of which 3% to 11% would 
have spending high enough to exit into catastrophic coverage before the end of the year
35
.  
Patel and Davis analyzed the MCBS data for 1997 through 2001 and estimated that 
approximately 43% of beneficiaries without ESRD would fall in the coverage gap in 2006 of 
which about 14% would be able to exit before the end of the year
36
. These numbers were even 
higher for those with ESRD. The researchers predicted that70% of those with ESRD would reach 
the coverage gap in 2006 and almost 40% of those would reach the catastrophic phase before the 
end of the year. 
There was much ado about beneficiaries reaching the coverage gap, because there is 
ample evidence to conclude that experiencing a gap in coverage or having an annual spending 
limit (cap) for prescription drugs leads to decrease in medication use and increase in OOP 
spending. The next section highlights the effects of such gaps and/or caps imposed on drug 
spending among non-Medicare Part D beneficiaries. 
Impact of caps and gaps  
Research aimed at examining the impact of gaps in coverage or caps on total spending for 
prescription drugs on non-Medicare Part D (pre or post implementation) seniors‟ utilization of 
medications has concluded that beneficiaries with caps or gaps in coverage were more likely to 
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forego medications due to cost. Studies outlined in the next few paragraphs also identified cost 
lowering strategies used by seniors having some form of insurance coverage with capped 
benefits.  These strategies include reducing drug use, reducing use of other necessities, 
borrowing money to pay for prescriptions, and finding less expensive prescriptions including 
free samples from their physicians.   
Stuart et al. studied a representative sample of Medicare beneficiaries with gaps in their 
coverage using information from MCBS files for 1998 and 2000 and concluded that such 
interruptions in drug coverage led to significant reductions in medication use and spending, 
especially among beneficiaries with many chronic illnesses
37
.  
A survey of beneficiaries with coverage for prescription drugs capped at $500 or $1,000 
annually found that almost 70% of the respondents engaged in one or more of the 
aforementioned cost-lowering strategies despite having some coverage for their drugs
38
. Another 
survey of Medicare beneficiaries with capped benefits found that taking less than prescribed 
amounts and discontinuing prescribed medications were among the top mentioned strategies to 
cope with prescription costs (23.6% and 16.3% respectively)
39
. Tseng et al.
40
 reported that a 
greater proportion of beneficiaries exceeding the cap imposed on their prescription spending or 
those who experienced a gap in their coverage used less medication compared to those who had a 
higher annual cap that they did not exceed (18% vs. 10%, p-value < 0.001). The researchers also 
found that a greater proportion of these beneficiaries reported shopping around for drugs and 
having difficulty with paying for prescriptions compared to their peers.  
Soumerai et al. analyzed responses to questions about cost-related non-adherence 
(measured as self-reported skipping or taking smaller doses to make the medicine last) as well as 
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cost-cutting strategies (e.g. obtaining free samples, using generic drugs, shopping for best price) 
added to the MCBS
41
. The researchers found that although only 13% of the elderly and 29% of 
the non-elderly disabled beneficiaries reported cost-related non-adherence; almost 70% of all 
Medicare beneficiaries (both elderly and non-elderly disabled) surveyed engaged in some form 
of cost-cutting strategy to cover prescription drug costs. The most frequently cited strategy was 
either using generic drugs or requesting samples from physicians (~50% for each), followed by 
shopping around for best pricing and spending less on other needs.   
In a cross-sectional study of 222 homebound older adults aged 60 and older, Sharkey et 
al. found that 20.3% of the sample population reported using one or more strategies to restrict 
medication use because of cost (skipping doses or taking less than prescribed) while another 
21.2% of the sample reported using strategies to cut OOP expenses (e.g. choose between food 
and medicine). While shopping around and reducing expenses on other household expenditures 
is prudent, to stop taking medications or to take less than prescribed or to reduce expenditures on 
daily necessities including food could adversely affect the health outcomes of these 
beneficiaries
38
. 
Conclusion 
 Medicare Part D is a major expansion to the Medicare program. In addition, the cost-
sharing structure used by this prescription benefit is highly unusual. Therefore, there has been a 
tremendous interest in studying the impact of the program as well as its design before and after 
its implementation.  
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Overview of the Remaining Document 
The remaining chapters of this document present a detailed review of the literature 
focused on studying the effects of Medicare Part D, the rationale for doing the study, followed by 
the research objectives and specific aims, methods used to achieve these aims, results and a 
discussion of the findings. Finally, we present the main conclusions drawn from the study 
findings and a bibliography of cited literature.  
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CHAPTER 2: 
 LITERATURE REVIEW 
 
This chapter is divided into two sections. The first section presents results of the literature 
that studied the overall impact of Medicare Part D program on Medicare beneficiaries. This 
includes a review of the impact on medication utilization and spending as well as medication 
adherence. This is followed by a section that presents a review of studies focused on examining 
the impact of the coverage gap on Medicare Part D enrollees. This includes studying the 
proportion of beneficiaries reaching the coverage gap and the characteristics of these 
beneficiaries, the impact on utilization of prescription medications and cost-cutting strategies 
used by beneficiaries affected by the coverage gap. Finally, the chapter discusses gaps in the 
existing literature that merit attention in future research. 
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Section 1: Impact of Medicare Part D 
On Overall Medication Use and Spending  
Despite its novel structure for cost-sharing, the intention of Medicare Part D was to 
improve utilization of necessary prescription medications by making them more affordable. Prior 
to its implementation, Pauly used the economic principles of price elasticity of demand for 
prescription drugs and healthcare utilization in the presence of insurance presented earlier and 
estimated that following implementation of Medicare Part D, there would be a 20% increase in 
utilization of prescription drugs for those who previously lacked coverage and a 6% increase for 
those who had some form of prior coverage
42
.  
Several studies done since the implementation of Part D uphold Pauly‟s estimates. 
Lichtenberg and Sun used prescription claims data from one of the nation‟s largest retail 
pharmacy chains for the period of September 2004-December 2006 to estimate the impact of 
Medicare Part D on user cost (defined as cost of a day of therapy to the beneficiary) and 
medication use (defined as days of therapy). They used a difference-in-difference research 
design to evaluate the impact of Medicare Part D on the elderly compared to the non-elderly. The 
researchers found that the average user cost for both the groups increased between September 
2004 and December 2005. However, the average cost of therapy decreased gradually for the 
seniors group from January 2006 through June 2006 while the cost for the non-seniors remained 
unchanged. They attribute this finding to the gradual enrollment in Part D from January 2006- 
June 2006. Overall, the study estimated that Medicare Part D reduced user cost by 18.4% and 
increased their use of prescription drugs by 12.8%
43
. These results, however, need to be 
interpreted with caution because of the lack of information on the characteristics of groups 
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compared. Additionally, the study used data from a single pharmacy chain and did not account 
for baseline characteristics like demographics and chronic conditions.  
Yin et al.
44
 used data from a 5% random sample of drug users from a single pharmacy 
chain aged 60 – 79 years from September 2004 to April 2007. The researchers compared the 
utilization pattern of the Part D eligible group (age 66-79 years as of January 1, 2006) to that of 
the Part D ineligible group (age 60-63 as of January 1, 2006). Using a generalized estimating 
equation modeling technique and accounting for baseline characteristics by including the similar 
(except for age) Part D ineligible comparison group, they estimated that the implementation of 
Medicare Part D reduced beneficiaries‟ OOP spending by 13% in 2006 compared to that in 2005. 
The researchers further estimated that implementation of Medicare Part D increased the number 
of prescriptions used by the eligible seniors by 7%.  
Ketcham and Simon used data from the Wolters Kluwer Health‟s Source Lx database for 
December 2004 through December 2007 to estimate the change in utilization and OOP costs for 
beneficiaries enrolled in Part D in 2006. To achieve their goals, the researchers compared the 
data for beneficiaries aged 66 and older to that of near-elderly (those aged 58-64 years)
45
. Their 
analysis indicated that the elderly had 8.1% greater increase in utilization in 2006 over their level 
of use in 2005 compared to the change in utilization for the near-elderly patients. However, the 
change from 2006 to 2007 was much smaller; with only about 1% increase in utilization in 2007 
over 2006. The researchers also found that the number of beneficiaries filling prescriptions in 
2006 increased by 4.8% when compared to the number in 2005. Additionally, their results 
indicate that Part D enrollees‟ OOP costs declined by 15.9% and 8.3% in 2006 and 2007 
respectively, as compared to a 1.39% increase and 2.42% decrease in the OOP of near-elderly 
patients in 2006 and 2007 respectively. The relative decrease in cost for the elderly compared to 
 
 
24 
 
the near-elderly was found to be 17.2% in 2006 and 5.8% in 2007.The price elasticity of demand 
based on utilization from 2005-2007 in this study was -0.44, which is in accordance with the 
previous literature.  
A common limitation of all three studies mentioned above is that they used a near-elderly 
or non-elderly comparison group. It is well known that elderly have different drug utilization 
patterns and requirements compared to the non-elderly. In addition, there is a difference in  
financial characteristics of the two groups and, therefore, comparing the cost and utilization 
among these two groups may generate spurious results.  
A study of nationally representative claims data for beneficiaries with Type 2 Diabetes 
Mellitus aged 65 years or older from July 1, 2004 through September 30, 2007 concluded that 
enrollees in PDPs experienced an 11.2% increase in utilization whereas those enrolled in MA-
PDs increased their use by 6.2%. The study also concluded that OOP costs per prescription were 
35% lower among PDP enrollees and 25% lower in MA-PD enrollees compared to beneficiaries 
not enrolled in Part D plans, some of who had coverage from other sources while others 
completely lacked drug coverage
46
 
Schneeweiss et al. performed a time-trend analysis of patient level dispensing data of 
seniors aged 65 years or older as obtained from three large pharmacy chains from January 1, 
2005 through December 31, 2006. The researchers reported that among seniors without prior 
coverage, the use of statins, clopidogrel and proton-pump inhibitors was 11%-37% higher than 
their expected utilization without implementation of Medicare Part D
47
.  
A recent study by Joyce et al. used administrative claims data to compare pharmaceutical 
use and OOP spending of beneficiaries enrolled in the 10 largest Part D plans in 2006 to that of 
 
 
25 
 
utilization information from 2004 MCBS cost and use data.
48
 The researchers found that 
enrollees of Medicare Part D plans had a 16% decrease in annual OOP costs with a 7% increase 
in utilization compared to utilization and spending as calculated from the 2004 MCBS data. 
Joyce et al. also concluded that poorer beneficiaries who are either dually eligible for Medicare 
and Medicaid or receive Low-Income Subsidies (LIS) benefitted the most from Medicare Part D.  
Zhang et al. analyzed data of beneficiaries continuously enrolled in a Medicare 
Advantage plan between 2004 and 2007 and compared several groups to identify the effect of 
Part D on OOP costs of the enrollees
49
. Their findings suggest that compared to beneficiaries 
with stable continuous coverage for prescription drugs, beneficiaries without prior coverage or 
those who had caps on spending had significant decreases in their OOP spending (13.4%, 95% 
CI (-17.1%, -9.1%) and 15.9%, 95% CI (-19.1%, -12.8%), respectively) after implementation of 
Medicare Part D.  
In 2006, Safran et al. conducted a follow-up survey
50
 of surviving Medicare enrollees 
surveyed in 2003
21
 to estimate the effect of Medicare Part D on their OOP spending and 
prescription utilization. In addition, they aimed to identify the strata of beneficiaries benefitting 
the most by the enactment of Part D. Upon completion of the study, the researchers found that 
except beneficiaries previously enrolled in Medicaid, all Part D enrollees reported a greater 
utilization of prescription medications compared to 2003 (p-value < 0.001). They also found that 
all Part D enrollees experienced a significant decrease in OOP spending, except those 
beneficiaries previously reporting employer-sponsored coverage (p-value < 0.001). These effects 
were more pronounced among beneficiaries without prior drug coverage and among those who 
had capped benefits prior to enrolling in Part D.  
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A recent systematic review by Polinski et al., appropriately summarizes the findings of 
these studies by estimating that implementation of Part D was associated with 6-13% increase in 
utilization of prescription drugs and 13-18% decrease in OOP spending for the enrollees
51
. 
On Medication Adherence 
A study by Madden et al. compared changes in use of self-reported cost-lowering 
strategies before and after implementation of Medicare Part D (2005 and 2006) and compared it 
to the changes from 2004 to 2005 from the MCBS
52
. The study design accounted for self-
reported covariates including socio-demographic characteristics and health status. In addition, 
the study design also accounted for interview sequence bias (i.e. when the same questions are 
asked to the participants at different intervals, their responses are affected by their knowledge of 
the purpose of the question from previous interview and this creates the interview sequence bias) 
and year-to-year changes in reporting trend. The adjusted analyses found that the 2006 vs. 2005 
odds ratio (OR) for self-reported cost-related non-adherence (CRN), as calculated from 
responses to questions pertaining to medication strategies like skipping doses, taking less than 
prescribed, not filling or refilling a prescription due to cost) relative to that for 2005 vs. 2004 was 
0.85 (95% CI (0.74, 0.98), and the corresponding OR for spending less on basic needs after 
implementation of Medicare Part D was 0.59 (95% CI (0.48, 0.72). This indicates that 
implementation of Medicare Part D decreased the proportion of beneficiaries reporting CRN or 
spending less on basic needs to cope with prescription costs. The subgroup analyses, however, 
suggested that beneficiaries in fair to poor health, those with more co-morbidities and those with 
higher incomes did not experience a significant change in self-reported CRN. This implies that 
the financial needs of the sickest beneficiaries may not be fully addressed by Medicare Part D; 
probably because they are more likely to reach the coverage gap. 
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Zivin and colleagues used a similar study design as Madden et al. to examine the impact 
of Medicare Part D on medication adherence among beneficiaries with and without depressive 
symptoms
53
. The study reported that after controlling for historical changes (2004-2005) and 
demographic characteristics, the group with depressive symptoms did not experience a 
significant decrease in CRN (ratio of ORs = 0.85, 95%CI (0.65, 1.12)) from 2005-2006. By 
contrast, there was a marginally significant decrease in CRN among beneficiaries without 
depressive symptoms (ratio of ORs = 0.83, 95%CI (0.70, 0.97)). However, when the two groups 
were compared with each other, the adjusted analyses indicate that there were no significant 
decreases in CRNs between the two groups studied (Ratio of ORs = 0.98, 95% CI (0.73, 1.32)). 
The study findings indicate that Medicare Part D did not improve CRN among beneficiaries with 
depressive symptoms.  
In another investigation, Safran and colleagues found similar results after comparing the 
survey responses of the same group of Medicare beneficiaries in 2003 and 2006
54
. The study 
used the same measure of CRN as used by Madden et al. and concluded that self-reported CRN 
significantly declined for beneficiaries who previously lacked prescription coverage (OR = 0.4, 
p-value < 0.001), as well as for those who were previously enrolled in Medicare HMO or 
Medigap/private plans (OR = 0.4 and 0.6, p-value < 0.001, and p-value < 0.01 respectively). By 
contrast, however, those who switched from employer sponsored programs in 2003 to a Part D 
plan in 2006 reported a significantly increased rate of CRN (OR = 1.7, p-value < 0.01). 
Beneficiaries who retained their employer sponsored coverage in 2003 and 2006 reported the 
lowest overall CRN rate and showed slightly lower rates in 2006 compared to 2003 (OR = 0.7, p-
value < 0.05). 
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Zhang et al. studied pharmacy and medical claims data for beneficiaries aged 65 years or 
older who were enrolled continuously from 2003 through 2007 with a large Pennsylvania insurer 
to identify the impact of Medicare part D on adherence to medications used to treat or prevent 
hypertension, hyperlipidemia and/or diabetes
55
. The researchers studied adherence behaviors 
(measured using MPR) among 3 groups with poor insurance coverage prior to implementation of 
Part D and compared them with a group that had continuous coverage through a retiree health 
benefit program throughout the study period. Among the three intervention groups, one group 
did not have drug coverage prior to 2006, one group had a quarterly spending cap of $150 and 
the third group had a quarterly spending cap of $350. The study results showed that after 
adjusting for covariates and applying propensity score weighting, the group with no prior 
coverage (irrespective of the disease condition) experienced the greatest increase in adherence 
after implementation of Part D (13.4% for patients taking anti- hyperlipidemics 95% CI (10.1, 
16.8), 17.9% for anti-diabetic 95% CI (13.7, 22.1) and 13.5% for anti-hypertensive group 95% 
CI (11.5, 15.5)). In comparison, the group with $350 quarterly cap experienced the lowest 
increases in adherence for every disease condition (4.4% for patients taking anti-hyperlipidemics 
95% CI (3.3, 5.6), 3.6% for anti-diabetic 95% CI (1.8, 5.3) and 2.5% for anti-hypertensive group 
95% CI (1.7, 3.2)).  
Based on the preceding literature review, it is reasonable to conclude that implementation 
of Medicare Part D increased the overall utilization of drugs for the beneficiaries by decreasing 
their OOP costs; however, the impact of the „coverage gap‟ still remains to be explored. The next 
section presents a detailed review of studies that have looked at the impact of this „coverage gap‟ 
incorporated in the Part D benefit since its enactment 4 years ago.  
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Section 2: Recent Literature on Medicare Part D Coverage Gap 
 Despite speculation of its potentially unfavorable effects on senior patients‟ adherence 
and health outcomes, the “coverage gap” was incorporated into Part D.  The purpose of the gap 
was to encourage financial discipline and contain healthcare expenditures 
56
. It was believed that 
in addition to encouraging cautious spending among the beneficiaries, the coverage gap would 
offset the impact of the availability of insurance coverage for prescription drugs on Medicare‟s 
overall costs. Given the brief time that has elapsed since the implementation of Medicare Part D, 
only a few studies have examined the effects of the coverage gap on beneficiaries‟ medication 
use and spending. The following sections describe the findings of this literature in detail. 
Proportion of beneficiaries reaching the “gap” 
Some studies have estimated the proportion of beneficiaries qualifying for entry and exit 
from the coverage gap for specific disease conditions. Schmittdiel et al. studied the entry and exit 
proportions from the coverage gap for beneficiaries enrolled in 2 large MA-PD health plans in 
California and diagnosed with Type 2 diabetes.  The study reported that 26% of the sample 
entered the coverage gap at some point in 2006 and only 2% exited the gap
57
. In another 
investigation using claims data for Type 2 Diabetes beneficiaries from Avalere Health‟s 
DataFrame database and the Wolters Kluwer‟s Source Lx database, Karaca and colleagues found 
that 43% of non-Medicaid beneficiaries enrolled in the PDPs reached the coverage gap in 2006 
compared to 33% of those in MA-PD plans
46
. Kim et al. used nationally representative data on 
patients hospitalized for atrial fibrillation between January, 2005 and December, 2006 and 
estimated that 58.8% of their cohort entered the coverage gap in 2006 in a mean of just 199 
days
58
.   
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Several other studies estimated the proportion of beneficiaries reaching the coverage gap 
for more diverse samples. Ettner et al. linked pharmacy, outpatient and inpatient claims data to 
Census data for beneficiaries enrolled in a large MA-PD plan that serves eight states and found 
that 15.9% of the beneficiaries who did not receive LIS, were not dually eligible for Medicare 
and Medicaid, and did not have gap coverage in their plan entered the coverage gap in 2006; 
with only 6.7% of these exiting into the catastrophic coverage zone
59
. Twelve percent of the 
sample analyzed by Schneeweiss et al. reached the coverage gap in 2006
47
. From a retrospective 
study of beneficiaries enrolled in a Kaiser Permanente MA-PD plan, Raebel et al. estimated that 
about 6% of their sample population reached the coverage gap in 2006
60
. Zhang et al. studied 
data from a large Pennsylvania insurer that offered MA-PD type coverage as well as employer 
sponsored coverage for Part D beneficiaries in 2006. The researchers estimated that among 
beneficiaries with employer-sponsored coverage, 40% reached the coverage gap in 2006, 
whereas 25% of MA-PD enrollees did so by the end of 2006
61
.  
A study by researchers at Kaiser Family Foundation estimated that in 2007, of those 
Medicare Part D beneficiaries who were neither dual eligible nor received low income subsidies, 
26% reached the coverage gap and that most spent the rest of the year in the gap; only about 4% 
of those who entered the coverage gap also reached the catastrophic coverage limit
62
. The study 
also reported that almost half of those who reached the coverage gap in 2007 did so by the end of 
August. Pedan et al.
63
 analyzed pharmacy claims data from 2 large retail pharmacy chains and 
found that 18.5% of their sample population reached the coverage gap in 2007. 
A few studies also reported the characteristics of beneficiaries reaching the coverage gap. 
Overall, it can be concluded that older beneficiaries suffering from a large number of chronic 
conditions were more likely to reach the coverage gap. A study by Kaiser Family Foundation 
 
 
31 
 
reported that the proportion of beneficiaries reaching the gap increased with age (25% of those 
aged 65-74 years vs. 33% aged 85 years and older)
62
. Raebel et al. also concluded that 
beneficiaries reaching the gap were older and had more diseases compared to those who either 
did not have a gap in coverage or did not reach it
60
 while Ettner et al. reported that age was 
inversely proportional to the likelihood of entering the coverage gap
59
. Zhang et al. estimated the 
effect of co-morbidities on reaching the coverage gap and found that the likelihood of having 
spending greater than the threshold for the coverage gap increased with an increase in the 
number of co-morbidities. For example, among the MA-PD enrollees, 17% of beneficiaries with 
„only hypertension‟ reached the coverage gap whereas 34% with both hypertension and diabetes 
and 61% with hypertension, diabetes and Congestive Heart Failure (CHF) did so in 2006
61
. 
Bayliss et al. studied the characteristics of beneficiaries reaching the coverage gap in both 2006 
and 2007 using data from a not-for-profit HMO offering many MA-PD plans and found that 
reaching the gap threshold in both years was a function of existence of chronic co-morbidities 
and utilization of brand-name drugs. The study, however, found that socio-demographic factors 
were not significant predictors of reaching the gap
64
.   
Impact on medication utilization and spending 
 A report published by the Kaiser Family Foundation in 2008 was among the first studies 
to present the consequences of the coverage gap in the Medicare Part D structure
62
. This study 
utilized the IMS Health Longitudinal Prescription Database containing information on 4.5 
million Part D enrollees using medications in 2007. The researchers reported that on average, 
20% of enrollees reaching the coverage gap in 2007 decreased their medication usage during the 
gap phase. Of these, 15% stopped taking one or more medications after reaching the coverage 
gap, while 1% reduced their medication use in some other way. The study further estimated that 
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monthly OOP expenditures nearly doubled during the gap (from $104 to $196), whereas for 
those who also entered the catastrophic coverage, the monthly OOP spending increased during 
the gap ($207 to $408) and then decreased after reaching the catastrophic coverage (from $408 to 
$285). For those who did not enter the coverage gap, overall spending was much lower 
throughout the year ($26 per month). One of the biggest strengths of this study was that it used 
the claims data from a nationally representative sample of PDP enrollees using some medication 
in 2007. However, this is also a limitation, because not including information on beneficiaries 
not using medications implies that the actual proportion of beneficiaries reaching the coverage 
gap might be much lower. Another limitation of the study is that the database did not contain 
information about a beneficiary‟s phase status or Low-Income Subsidy status; these were 
computed by the researchers. Therefore, any coding error in these might inflate or deflate their 
estimates. An additional limitation of the study is that there is no information about medications 
procured from pharmacy sources not included in the database (e.g. some patients also use mail-
order pharmacy - which are not included in the IMS data - to get their medications and some 
pharmacies do not submit data to IMS). This could affect the spending amounts that were used to 
determine whether a beneficiary entered the gap in 2007 or not.   
 Sun and Lee studied prescription claims data for beneficiaries aged 65 years or older who 
were continuously enrolled in either PDPs or non-Part D commercial plans from January 1, 2006 
through December 31, 2006 as presented in a large pharmacy benefit management database
65
. 
The study used a pre-post with control group study design.  Cases were beneficiaries enrolled in 
standard PDPs who reached the coverage gap by June 30, 2006. Controls were those enrolled in 
non-Part D commercial plans. Direct analysis of medication utilization and costs were done for 
both groups for two time periods: January 1, 2006 through June 30, 2006 (pre-period) and July 1, 
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2006 through December 31, 2006 (post-period). Among cases, the number days of therapy 
decreased by 15.85% while OOP spending increased by 88.94% after reaching the gap. Among 
controls days of therapy increased by 1.77% while OOP spending decreased by 5.54%. Using 
difference-in-difference models, the study found that being in the coverage gap decreased 
medication utilization by 187.49 days of therapy and increased OOP spending by $796.49. This 
study is of significance because it estimated the impact of the coverage gap on beneficiaries 
enrolled in PDPs and used a quasi-experimental study design which helped account for a number 
of biases. However, the results of this study need to be interpreted with caution because the PDP 
was a part of a large pharmacy benefit management program which may not have represented the 
nationally enrolled Medicare population.  
   Raebel and colleagues analyzed pharmacy claims data of beneficiaries enrolled in one of 
the several MA-PD plans offered by the Kaiser Permanente of Colorado from January 1, 2006 
through December 31, 2006
60
. The researchers measured medication refill adherence (MRA) for 
oral medications used for treating diabetes, hypertension, depression and anti-hyperlipidemics as 
well as beta-blockers and diuretics. In this study, cases were defined as those who reached the 
coverage gap at some time in 2006 and controls were those who either did not have a gap in 
coverage or those who did not reach the coverage gap in 2006. The two groups were matched 
using propensity scores and the controls were then assigned index dates to indicate the pre and 
post-periods corresponding to the matched cases. The findings suggest that being in the coverage 
gap significantly reduced MRA rates (p-value < 0.05) for all the therapeutic classes except anti-
diabetics and beta-blockers. The largest significant decrease in adherence (defined as MRA > 
80%) was observed for patients taking diuretics (8.3% + 29.2), followed by those using 
antidepressants (6.8% + 26.3), and anti-hypertensives (5.3% + 24.7). The smallest change in 
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adherence was observed for patients using statins or other anti-hyperlipidemic agents (3.6% + 
22.4). However, the study also found that the adherence rates decreased for the control group as 
well. Comparing the findings after matching, it was observed that the decreases in adherence for 
cases using anti-hyperlipidemics and anti-hypertensive agents were significantly greater than the 
decline in adherence rates for corresponding controls (p-value = 0.031 and 0.006 respectively). 
Additionally, compared to the corresponding matched cohort, beneficiaries reaching the gap also 
experienced greater decreases for beta-blockers (4.9% vs. 3.2% for controls), diuretics (9.7% vs. 
7.7% for controls), and anti-diabetic medications (4.0% vs. 2.8% for controls); however, these 
differences were not statistically significant.     
In another examination, Zhang et al. compared medication usage of beneficiaries enrolled 
in the MA-PD program of a large Pennsylvania health insurer to that of beneficiaries enrolled in 
employer sponsored programs
66
. The MA-PD program offered coverage through two plans: one 
plan offered some coverage for prescription drugs in the coverage gap while the other plan did 
not offer any drug coverage while in the coverage gap (cases). The employer sponsored 
programs did not have a gap in coverage throughout the year (controls). The control group was 
assigned index dates to correspond with the cases‟ pre-gap and within-gap periods. Medication 
utilization was measured as the number of prescriptions filled before and after reaching the 
$2,250 threshold where the coverage gap began in 2006. After adjusting for underlying 
characteristics like socio-demographics and chronic conditions, the researchers found that those 
beneficiaries who reached the coverage gap and had no coverage reduced their medication use by 
14% compared to those beneficiaries who did not experience gap. By comparison, beneficiaries 
with coverage for generic prescriptions during the gap decreased their medication use by only 
3%.  
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A recent exploration by Fung et al. utilized information on beneficiaries with diabetes 
from two different MA-PD sponsors who employed different delivery systems and offered 
different plans to beneficiaries
67
. One of the two sponsors used an integrated delivery system 
setting and offered a single plan without gap coverage. The responses of beneficiaries in this 
group were compared to those of beneficiaries in an employer sponsored plan with no gap in 
coverage throughout the year. The other was a network-model HMO that offered two plans: one 
with coverage for generic drugs during the gap and another plan without drug coverage during 
the gap. The study population comprised beneficiaries continuously enrolled in the plan from 
January 1, 2005 through December 31, 2006, 65 years of age or older and having used 1 or more 
anti-diabetic medications in 2005. The study examined the drug spending as well as OOP 
expenditure faced by beneficiaries in the two settings during the coverage gap. In addition, the 
study also measured adherence to oral anti-diabetic, hypertension and lipid-lowering medications 
using the Proportion of Days Covered (PDC), which was calculated from the pharmacy 
dispensing data. Adherence was defined as having PDC > 80% for the entire regimen. The study 
found that the drug spending was 3% and 4% lower among beneficiaries with a gap compared to 
beneficiaries with no gap and generic coverage respectively. Within the integrated system MA-
PD, beneficiaries with a gap had 189% higher OOP expenditures compared to those without gap 
(employer sponsored group) whereas for the network model HMO system, the difference was 
less pronounced (14% higher OOP costs for beneficiaries without coverage compared to those 
with coverage for generic drugs only). The study further found that odds of being adherent were 
significantly lower for beneficiaries reaching the gap versus employer sponsored group who had 
no gap within the integrated MA-PD setting for all the three therapeutic drug classes: OR= 0.83, 
95% CI (0.79 – 0.88) for oral anti-diabetic drugs, OR = 0.78, 95% CI (0.74, 0.83) for 
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hypertension drugs and OR = 0.69, 95% CI (0.65, 0.73) for lipid lowering agents. However, no 
significant decrease in the odds of adherence to these medications was found between the two 
groups using the network-model MA-PD setting.    
A common strength of the three studies using MA-PD plan data is that they used quasi-
experimental designs with matched control groups that helped account for a number of biases. 
However, they also share a common limitation that the generalizability of their findings is 
limited by the use of data from a managed care program that has greater control over utilization 
of medications by its enrollees. The generalizability of these results is further limited by the fact 
that most Part D enrollees are part of stand-alone PDPs and not MA-PDs.  
 All the aforementioned studies utilized data from drug plans. Another set of studies 
analyzed pharmacy chain dispensing data. Schneeweiss et al. analyzed data generated from 
computerized pharmacy dispensing information of three large pharmacy chains
47
. Among their 
many aims was to study the impact of Medicare Part D coverage gap on medication adherence 
measured using Defined Daily Doses (DDD) and on OOP spending in 2006. The study reported 
that among patients who reached the coverage gap, use of study drugs (clopidogrel, statins, PPIs 
and warfarin) decreased significantly compared to their usage in previous months. This decrease 
ranged from 4.8% for statins to 6.3% for warfarin. There was also an increase in OOP spending 
among these patients from $12 per 30 DDDs of warfarin to $65 per 30 DDDs of clopidogrel.  
Another study using data from pharmacy chains was conducted by Pedan and 
colleagues
63
. This study analyzed data for prescription drugs dispensed to beneficiaries aged 65 
years and older from November 2006 through February 29, 2008 as obtained from 2 large 
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pharmacy chains. The study reported that among the beneficiaries reaching the coverage gap in 
2007, medication use decreased by 9.47% compared to their pre-gap usage.  
Both studies mentioned above merit attention because they used pharmacy dispensing 
data irrespective of the insurance plans in which the beneficiaries were enrolled.  This increases 
the generalizability of the findings. The studies, however, have many limitations. The datasets 
used in both the studies did not contain plan related information which limited the ability to 
determine when a beneficiary entered the coverage gap. As a proxy, the researchers assigned a 
beneficiary to the gap when they had total spending more than the threshold for the start of 
coverage gap in the respective years and when there was a change in copayments from 25% to 
90%. This, however, is an important limitation because most Part D plans are required to offer a 
drug benefit similar to that proposed by the Government but not necessarily use the same 
thresholds. In such a situation, some beneficiaries classified as being in the gap might not 
actually be in the gap and vice versa. The datasets also did not contain information about 
prescriptions received by mail-order or other pharmacies. In addition, though the studies used a 
pre-post time trend design, the lack of a control group to account for the underlying temporal 
trends in medication use requires that the results be interpreted with caution. Despite this, these 
results continue to indicate that being in the coverage gap adversely affects medication 
utilization and OOP spending for Medicare Part D beneficiaries. 
The coverage gap and cost-cutting strategies 
 Two studies explored the cost-cutting strategies used by Medicare beneficiaries to cope 
with prescription drug expenditures after reaching the coverage gap. Cronk and colleagues 
conducted a review of electronic medical and pharmacy records of members continuously 
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enrolled in Kaiser Permanente Colorado MA-PD plans in 2006 to identify beneficiaries with and 
without a gap in coverage
68
. The researchers then surveyed enrollees who reached the coverage 
gap by October 1, 2006 (cases) and compared their responses to those of beneficiaries enrolled in 
a retiree drug subsidy plan that did not include a gap in coverage and had total spending 
corresponding to the threshold for the gap (i.e. $2,250 or more) by October 1, 2006 (controls). 
The questionnaire comprised 14 questions adapted from a questionnaire developed by Tseng and 
colleagues to identify the cost-lowering strategy/ies used to cope with high drug expenditures. 
The study concluded that the cases were three times more likely to report using a cost-lowering 
strategy compared to the controls (42% vs. 14%, p-value < 0.001). In particular, beneficiaries 
experiencing a gap in coverage were significantly more likely to use mail-order pharmacy 
(59.7% vs. 18.0%, p-value < 0.001) or switch to other medications because of cost (32.1% vs. 
10.9%, p-value < 0.001). In addition, a significantly greater proportion of the cases reported 
using less medication than prescribed because of cost (29.1% vs. 11.0%, p-value < 0.001), that 
they stopped taking a medication because of cost (20.1% vs. 4.6%, p-value < 0.001) or that they 
did not fill a new prescription because of cost (21.8% vs. 6.1%, p-value < 0.001). An equal 
number of respondents in both groups reported receiving free samples or buying medications 
outside the US because of cost. Significantly greater proportions of the cases also reported 
cutting back on other activities (e.g. enjoyment, paying bills) or not receiving other medical care 
because of their drug costs compared to the control group. In terms of predictors of using a cost-
lowering strategy, the study results indicate that younger beneficiaries with limited drug 
coverage, lower household income and poorer health status were at a higher risk of adopting one 
or more strategies to lower their prescription drug cost.   
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 In another investigation, Duru et al. estimated the effect of having coverage for generic 
medications during the gap on self-reported CRN by beneficiaries with diabetes who were 
enrolled in various MA-PD and PDP plans and who did and did not use insulin. The study setting 
utilized administrative claims information on generic drugs utilized by beneficiaries aged 65 
years or older in 2005 and 2006 and then administered a computer-assisted telephone interview 
(CATI) to eligible beneficiaries. The responses were compared for beneficiaries using insulin to 
those of beneficiaries not using insulin. After adjusting for demographic and clinical 
characteristics as well as non-response rates, the researchers observed that among insulin users, 
generic-only coverage was associated with significantly lower rates of self-reported CRN than 
those with no coverage in the gap (16% vs. 29%, p-value = 0.03). Among the insulin users, no 
significant differences were observed for reporting the use of cost-cutting strategies like 
switching to other medications, or shop around for lower prices. By contrast, for the group that 
did not use insulin, there was no significant difference in the rates of reported CRN but 
beneficiaries without gap coverage in this group were significantly more likely to switch to a 
cheaper alternative (46% vs. 36%, p-value = 0.01) and shop around for lowest prices (36% vs. 
22%, p-value < 0.001).   
Although both these studies indicate that beneficiaries enrolled in a Part D plan with a 
gap in coverage were more likely to adopt undesirable cost-lowering strategies, it is important to 
note that these behaviors were not assessed separately after reaching the gap and therefore, it 
cannot be concluded that the coverage gap was the cause of patients‟ utilizing more cost-
lowering strategies. In addition, the studies were cross-sectional surveys and therefore suffer 
from limitations related to response and recall biases. 
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Gaps in Literature 
The preceding review of the literature indicates that although Medicare Part D has 
increased utilization of prescription medications and decreased OOP costs, the coverage gap 
poses a significant challenge to beneficiaries‟ adherence. A few studies provide evidence that 
having partial coverage during the coverage gap is better than having no drug coverage during 
the coverage gap. However, there are several limitations to the studies reviewed that need to be 
addressed in future research. For example, several studies lacked use of control groups to 
account for selection bias introduced by the choice of enrolling in a plan that suits the 
beneficiary‟s requirements. For those studies that attempted to overcome this limitation, the 
design included use of comparison groups (e.g. non-elderly) that could not be considered as 
being equal to beneficiaries enrolled in Medicare Part D.  
In addition, the studies have primarily focused on MA-PD plans and therefore lack 
generalizability since a majority of the beneficiaries are enrolled in PDPs. Those using a more 
diverse population through pharmacy chains fail to account for variability introduced by being 
enrolled in plans that offer different benefit structures.  
Most studies have looked at either the difference in number of medications used after 
reaching the coverage gap or the difference in beneficiaries considered to be adherent after 
reaching the coverage gap. While these findings are significant, it is also important to understand 
the extent to which beneficiaries change their medication adherence patterns during the coverage 
gap using a standardized measure of medication adherence. For example, a 5% change in use of 
a medication is significantly different from a 50% change in use and this effect is not taken into 
account by studying the change in number of medications used.  
Our study attempts to overcome these limitations by using a quasi-experimental study 
design with a control group for comparison. In addition, the study utilizes data from a nationally 
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representative sample of Medicare beneficiaries enrolled in PDPs and also accounts for 
variability introduced by the availability of plans that offer coverage using different benefit 
structures. The following chapter describes the objectives and specific aims of this research, 
followed by a chapter presenting the detailed methods used in the conduct of this study before 
presenting the study results. 
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CHAPTER 3: 
 RESEARCH OBJECTIVES AND SPECIFIC AIMS 
  
This chapter presents the main objectives of this research as well as the specific aims to meet 
each objective. In this study, the „overall final sample‟ is defined as those who meet the general 
inclusion and exclusion criteria as outlined in Chapter 4. The “No Gap Coverage” group is 
defined as those who had no drug coverage when they reached the coverage gap; i.e. they had a 
complete gap in drug coverage during the coverage gap. The “Some Gap Coverage” group is 
defined as those who had coverage for some drugs when in the coverage gap; i.e. they had a 
„partial‟ gap in drug coverage during the coverage gap. 
Objective 1: To identify characteristics of beneficiaries reaching and not reaching the 
coverage gap in 2008 
Specific Aims: 
1. To review the overall demographic characteristics of the final sample of beneficiaries 
2. To compare the demographic characteristics of beneficiaries who did and did not have 
coverage for prescription drugs during the gap 
3. To compare the demographic characteristics of beneficiaries who did and did not reach 
the coverage gap 
4. To examine the medication related characteristics (i.e. total number of medications taken, 
total number of medications from the 7 classes being evaluated, total number of classes 
under evaluation across which medications are taken, total duration for which the 
beneficiaries should have been taking the medication since the first fill date) of the 
overall sample of beneficiaries 
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5. To compare the medication related characteristics of beneficiaries who did and did not 
have coverage for prescription drugs during the gap 
6. To compare the medication related characteristics of beneficiaries who did and did not 
reach the coverage gap 
7. To examine the plan enrollment characteristics of the final sample of beneficiaries 
8. To compare the plan enrollment characteristics of beneficiaries who did and did not have 
coverage for prescription drugs during the gap 
9. To compare the plan enrollment characteristics of beneficiaries who did and did not reach 
the coverage gap 
10. To compare the changes in Out-Of-Pocket expenses of beneficiaries in the overall sample 
who did or did not reach the coverage gap 
11. To compare the changes in Out-Of-Pocket expenses of beneficiaries in the “No Gap 
Coverage” group who did or did not reach the coverage gap  
12. To compare the changes in Out-Of-Pocket expenses of beneficiaries in the “Some Gap 
Coverage” group who did or did not reach the coverage gap  
13. To examine the demographic characteristics of beneficiaries for each therapeutic class of 
medications being evaluated (ACE inhibitors, beta-blockers, calcium channel blockers, 
diuretics, oral anti-diabetic agents, oral anti-hyperlipidemic agents, and proton pump 
inhibitors) 
14. To examine the medication related characteristics of beneficiaries for each therapeutic 
class of medications being evaluated  
15. To examine the plan enrollment characteristics of beneficiaries for each therapeutic class 
of medications being evaluated  
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16. To compare the demographic, medication, and plan related characteristics of beneficiaries 
in the “No Gap Coverage” group who did or did not reach the coverage gap for each 
therapeutic class of medications being evaluated before and after matching 
17. To compare the demographic, medication, and plan related characteristics of beneficiaries 
in the “Some Gap Coverage” group who did or did not reach the coverage gap for each 
therapeutic class of medications being evaluated before and after matching 
18. To compare the demographic, medication, and plan related characteristics of beneficiaries 
who did reach the coverage gap in the “Some Gap Coverage” group to those of 
beneficiaries who did reach the coverage gap in the “No Gap Coverage” group for each 
therapeutic class of medications being evaluated before and after matching 
Objective 2: To study the entry and exit times from the coverage gap in 2008 
Specific Aims: 
1. To estimate the proportion of beneficiaries reaching the coverage gap in the overall final 
sample  
2. To estimate the proportion of beneficiaries reaching the coverage gap for the “No Gap 
Coverage” and the “Some Gap Coverage” groups 
3. To estimate the proportion of beneficiaries reaching the coverage gap for each therapeutic 
class under evaluation in the “No Gap Coverage” group 
4. To estimate the proportion of beneficiaries reaching the coverage gap for each therapeutic 
class under evaluation in the “Some Gap Coverage” group 
5. To identify the month by which most beneficiaries reached the coverage gap in the final 
sample 
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6. To identify the month by which most beneficiaries reached the coverage gap within each 
therapeutic class being evaluated for the “No Gap Coverage” group 
7. To identify the month by which most beneficiaries reached the coverage gap within each 
therapeutic class being evaluated for the “Some Gap Coverage” group 
Objective 3: To study the impact of a complete gap in coverage on beneficiaries‟ adherence 
to prescription medications 
Specific Aims: 
1. To compare the change in medication adherence during the coverage gap for the 
beneficiaries of “No Gap Coverage” group who did or did not reach the coverage gap in 
each therapeutic class before and after matching 
2. To examine the proportion of beneficiaries who stopped taking medications during the 
coverage gap for each therapeutic class in the  “No Gap Coverage” group after matching 
3. To examine the proportion of beneficiaries considered adherent before and during the 
coverage gap for each therapeutic class in the “No Gap Coverage” group after matching 
Objective 4: To study the impact of a „partial‟ gap in coverage on beneficiaries‟ adherence 
to prescription medications 
Specific Aims: 
1. To compare the change in medication adherence during the coverage gap for the 
beneficiaries of “Some Gap Coverage” group who did and did not reach the coverage gap 
in each therapeutic class before and after matching 
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2. To examine the proportion of beneficiaries who stopped taking medications during the 
coverage gap for each therapeutic class in the  “Some Gap Coverage” group after 
matching 
3. To examine the proportion of beneficiaries considered adherent before and during the 
coverage gap for each therapeutic class in the “Some Gap Coverage” group after 
matching 
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CHAPTER 4: 
 METHODS 
 
 This chapter describes the methods used in the conduct of this study. It highlights the 
study design and the data sources used in the study followed by sample preparation and data 
analysis to meet each objective. 
Study Design  
This investigation employs a quasi-experimental study design with a “before-after” 
intervention and matched control groups. In an experimental setting, the investigator selects a 
group of people with similar characteristics and divides them into two groups: one receiving the 
intervention and the other not.  However, in our analysis we retrospectively explore the effect of 
a “natural intervention” (the Medicare Part D coverage gap) that could have effects on 
beneficiaries‟ medication usage. The following section presents the source of data used in this 
study. 
Database Preparation 
This was a retrospective analysis of claims and denomination (demographic and 
enrollment) data of a 5% random sample of all Medicare beneficiaries as provided by the CMS 
through its Research Data Assistance Center (ResDAC) located at University of Minnesota. The 
study utilizes four different data files from the entire database: 5% Beneficiary Summary File 
with Part D denomination, 5% Beneficiary Annual Summary File, 5% Part D Event Data File 
with drug characteristics (16 or less variables), and the Plan Characteristics Files for 2008. The 
following sections describe the variables used from each of these data files for further analyses. 
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The Beneficiary Summary File 
The Beneficiary Summary File provides demographic and enrollment information about 
beneficiaries. Beginning in 2006, this file also provides Part D enrollment information. Table 1 
shows the variables utilized from this file.  
Although the Beneficiary Summary File provides information about most of the 
demographic characteristics of the patients, it does not contain information about their income. 
Therefore, the next section outlines the methods to determine beneficiaries‟ median household 
income.  
Table 1: Variables used from the Beneficiary Summary File 
Variable Name Description 
BENE_ID Encrypted beneficiary ID 
SSA_STATE_CD State code of the residence of a beneficiary 
BENE_ZIP_CD Zip code of the mailing address of a beneficiary 
BENE_SEX_IDENT_CD gender of the beneficiary 
BENE_RACE_CD race of the beneficiary 
ESRD_SW presence or absence of End-Stage Renal Disease 
BENE_AGE_AT_END_REF_YR Chronological age of the beneficiary at the end of the 
year 
CST_SHR_GRP_CD_01 – 12 Beneficiary‟s subsidy and/or co-pay status for each 
month 
RDS_IND_01 – 12 Retiree drug subsidy for each month 
DUAL_STUS_CD_01 – 12 Medicaid eligibility by state for each month 
PLAN_CVRG_MOS_NUM Total number of months of Part D plan coverage  
BENE_HMO_CVRAGE_TOT_MONS  Total number of months in HMO coverage 
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Calculating Median Household Income 
 The median household income for the beneficiary‟s zip code was calculated from the US 
Census 2000 data. The paragraphs that follow present the methods to generate the income 
information based on the beneficiary characteristics.  
The zip code level information compatible with the CMS Beneficiary Summary File was 
not directly available through the Census website. Therefore, we used the ZCTA 2000 File 
available through the Research Triangle Institute (RTI) website at 
https://rtispatialdata.rti.org/Download/Data/tabid/56/Default.aspx.69  Although this data file is 
created from various sources, the median household income by zip code is extracted from the 
Census 2000 data. We used three variables from this file: P056007, median household income in 
1999 dollars age 65 – 74 years and P056008, median household income in 1999 dollars age 75+ 
years, and Location_Code; the 5-digit zip code. The zip code variable in The Beneficiary 
Summary File (Bene_Zip_Cd) provided the full 9 digit mailing zip code of a beneficiary. 
Therefore, it was re-formatted to retain the first 5 digits to correspond with the 5-digit zip code 
available from the RTI datafile. This new variable was named Location_Code to maintain the 
same variable name as available from the RTI datafile. The Beneficiary Summary File and the 
income file generated from the RTI database were then sorted and merged by zip code (variable: 
Location_Code) to include the two income variables in the denomination file.  
A new income variable (variable: Income) was then created using the age information 
from the denomination file and the two income variables used from the RTI file. This new 
income variable contained information representing the beneficiary‟s median household income 
based on their zip code and age. These income values were then converted to 2008 dollar values 
 
 
50 
 
using the Consumer Price Index (CPI) values for years 2000 through 2008 as explained in the 
next paragraph.  
The CPI is a measure of the average change over time (generally a year) in the prices 
paid by urban consumers for a market basket of consumer goods and services
70
 (e.g. food and 
beverages, transportation, housing, and medical expenses). The average annual change is 
calculated as a percentage; therefore, each value representing the percent change was converted 
to a number representing the proportional change adjusted for inflation over the last year. For 
example, the CPI value for 2000 was 3.4%. This means that the inflation-adjusted equivalent of 
1999 dollars in 2000 would be 103.4% of the 1999 value. In other words, in order to purchase 
the same product (that was worth $100 in 1999) in 2000, one needs to pay $103.4. For simplicity 
of calculation, we have converted all the percent change values to proportions. For example, if 
1999 dollar value is 1, then with a 3.4% annual inflation rate, the 2000 value would be 1.034. 
Since we wish to convert 1999 dollars to 2008, we need to account for annual inflation rates 
throughout this period (Table 2).  
Table 2: Consumer Price Index 2000-2008 
Year Annual % Annual Proportion 
2000 3.4 1.034 
2001 2.8 1.028 
2002 1.6 1.016 
2003 2.3 1.023 
2004 2.7 1.027 
2005 3.4 1.034 
2006 3.2 1.032 
2007 2.8 1.028 
2008 3.8 1.038 
Source: Bureau of Labor Statistics Available at http://www.bls.gov/cpi/data.htm
71
  
The following equation represents the formula used to obtain the 2008 dollar values. 
 
 
51 
 
𝟐𝟎𝟎𝟖 𝑫𝒐𝒍𝒍𝒂𝒓 𝑽𝒂𝒍𝒖𝒆
= 𝟏𝟗𝟗𝟗 𝑫𝒐𝒍𝒍𝒂𝒓 𝑽𝒂𝒍𝒖𝒆
×  𝑪𝑷𝑰′𝟎𝟎 × 𝑪𝑷𝑰′𝟎𝟏 × 𝑪𝑷𝑰′𝟎𝟐 × 𝑪𝑷𝑰′𝟎𝟑 × 𝑪𝑷𝑰′𝟎𝟒 × 𝑪𝑷𝑰′𝟎𝟓 × 𝑪𝑷𝑰′𝟎𝟔
× 𝑪𝑷𝑰′𝟎𝟕 × 𝑪𝑷𝑰′𝟎𝟖  
= 𝟏𝟗𝟗𝟗 𝑫𝒐𝒍𝒍𝒂𝒓 𝑽𝒂𝒍𝒖𝒆 × 𝟏. 𝟐𝟗𝟐  
 
The Beneficiary Annual Summary File (BASF)  
The BASF provides diagnosis and date of diagnosis of 21 chronic conditions. This file is 
used to identify whether a beneficiary was suffering from chronic obstructive pulmonary disease 
(COPD), chronic kidney disease (CKD), and/or any type of cancer. Specifically, the variables 
presented in Table 3 were scanned for a date of diagnosis and if there was a date of diagnosis for 
either of these variables for a beneficiary, then they were excluded from further analyses. 
 
Table 3: Variables used to identify beneficiaries with COPD/CKD/Cancer 
Variable Description 
CNCRBRSE Earliest indication of Female Breast Cancer  
CNCRCLRE Earliest indication of Colorectal Cancer  
CNCRPRSE Earliest indication of Prostate Cancer  
CNCRLNGE Earliest indication of Lung Cancer  
CNCENDME Earliest indication of Endometrial Cancer  
CHRNKDNE Earliest indication of Chronic Kidney Disease  
COPDE Earliest indication of Chronic Obstructive Pulmonary Disease  
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The Part D Event Data File and the Plan Characteristics File 
The Part D event (PDE) data and the Drug and Plan Characteristics Files contain 
elements that provide information on beneficiary demographics, plan characteristics, drug 
characteristics (e.g. NDC number, days of supply, quantity supplied, and fill number) and 
payment characteristics (e.g. patient paid amount, and Part D paid amount). The PDE data come 
directly from the plan sponsors; however, they are not the same as individual drug claim 
transactions recorded by the plan sponsors. Instead, these data are summary extracts using CMS-
defined standard fields to facilitate payments to the plan sponsors. Table 4 lists the variables used 
from the PDE data and the drug characteristics files. These variables were required to determine 
the beneficiary‟s gap status, adherence, and costs incurred by the beneficiary. In addition, the 
drug characteristics file was used to determine the generic equivalency of different medications 
as determined by the First Databank, whereas the plan characteristics file helped us identify the 
variation in benefit structures across plans. Specifically, the plan characteristics file was used to 
determine whether a particular plan was PDP or MA-PD, whether it offered coverage for some 
or all drugs during the coverage gap or not, whether it charged a deductible, used standard or self 
determined coverage gap threshold and the type of cost-sharing used before reaching the 
coverage gap. All the data files noted above can be linked using the de-identified variable called 
Bene_ID. The Part D utilization files, however, did not identify a drug‟s therapeutic class. This 
information was obtained from the First Databank proprietary classification system using the 
NDC information provided in the Part D utilization files
72
.  
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Table 4: Variables included from Part D utilization file 
Variable Name Description 
BENE_ID Encrypted Beneficiary ID 
SRVC_DT Date on which the prescription was filled 
PROD_SRVC_ID National Drug Code (NDC) number 
QTY_DSPNSD_NUM Number of dosage units dispensed (Quantity dispensed) 
DAYS_SUPPLY_NUM Number of days‟ supply of medication dispensed 
FILL_NUM Fill number of the current dispensed supply 
DRUG_CVRG_STUS_CD Drug Coverage status code (Part D covered or not) 
CTSTRPHC_CVRG_CD Catastrophic coverage code 
PTNT_PAY_AMT Non-reimbursed beneficiary paid amount 
OTHR_TROOP_AMT Payments that contribute to True Out of Pocket amount 
CVRD_D_PLAN_PD_AMT Net amount paid by Medicare Part D for a „covered‟ drug 
BENEFIT_PHASE Benefit Phase of the Part D event 
Drug Characteristics   
BN Brand Name of drug reported from First Data Bank 
GNN Generic Name of the drug reported from First Data Bank 
GCDF Dosage Form  Code 
GCDF_DESC Dosage form code description 
Plan Characteristics  
ORGANIZATION_TYPE Type of organization (PDP, MA-PD etc.) 
GAP_COVERAGE_TYPE Type of coverage offered in the gap 
DRUG_BENEFIT_TYPE Medicare Standard benefit or an equivalent benefit 
DED_APPLY How the deductible applies (if any) 
PRE_ICL_APPLY How the pre-coverage gap cost-sharing applies 
ICL_APPLY How the coverage gap cost-sharing applies 
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The following figure summarizes the steps involved in preparing the database for sample 
selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Methods to prepare the Dataset for sample selection 
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Selecting the sample of beneficiaries: general inclusion and exclusion criteria 
 The study examined the sampled beneficiaries‟ prescription drug usage of orally 
administered drugs from the following seven therapeutic classes: anti-diabetic agents, anti-
hyperlipidemic agents, beta-blockers, diuretics, angiotensin converting enzyme (ACE) Inhibitors, 
calcium channel blockers, and proton-pump inhibitors (PPIs). These classes have been identified 
by the Centers for Disease Control and Prevention (CDC) as a part of the 15 most widely used 
classes of medications among community-dwelling seniors aged 65 years and over
73
. The 
remaining classes of medications in this group could be used for either acute or chronic purposes 
(e.g. pain medications, thyroid hormones, sex hormones, anti-histamines, anti-convulsants and 
anxiolytics and antidepressants). The last class of drugs identified in this list by CDC is 
„bronchodilators‟ which are generally used in aerosol format and hence excluded from analysis. 
Beneficiaries were included in the analysis if they met the following inclusion criteria 
 Age 67 years and older: We include beneficiaries who were aged at least 67 years by the 
end of the 2008. In other words, only those beneficiaries who are aged 66 years or more 
in 2008 are included in our sample. By doing so, we ensured that the study population 
had at least one full year of Medicare enrollment.  
 Enrolled in stand-alone prescription drug programs (PDPs) from January 1, 2008 through 
December 31, 2008 (in other words, no MA-PD enrollees). 
 Non-subsidy recipients: The study aims to quantify the change in adherence rates after 
entering the coverage gap and hence does not include beneficiaries who are dually 
eligible for Medicare and Medicaid or who receive low-income subsidies (LIS) because 
these beneficiaries are not subject to the coverage gap. 
 Alive at the end of 2008 
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 Do not have cancer, COPD or end stage renal disease (ESRD): these beneficiaries are 
excluded from our analysis because they have a different medication utilization  and 
spending pattern compared to the beneficiaries with other disease conditions 
 The specific medication related criteria for inclusion was that the beneficiary be taking at 
least one oral medication (defined as either tablet or capsule) from one or more of the 
above mentioned therapeutic classes for more than 90 days (at least 2 fills).  
Following the selection of beneficiaries who met the above criteria, the sample was 
further divided into groups based on presence of drug coverage during the gap 
(„Gap_Coverage_type‟ = 10, and 20, 30, or 40). This resulted into creation of two groups: One 
with some coverage in the gap (the „Some Gap Coverage‟ group with N = 8,529) and another 
without any coverage in the gap (the “No Gap Coverage” group with N = 164,551). Within these 
two groups, beneficiaries were further divided into individual 7 therapeutic classes based on their 
medication use.  
Within each class of medication evaluated, beneficiaries included for final analyses must 
have had the first prescription in the class filled by March 31, 2008. Since no information was 
available for the dates of diagnoses for most diseases treated by medications in the above 
mentioned therapeutic classes, this criterion serves as a proxy to identify „established chronic 
users‟ of medications only. We intended to include “established chronic users” only because 
research has shown that the medication utilization pattern differs with the duration since the 
disease is diagnosed
74-76
. We extended the first fill date to March 31, 2008 instead of January 1, 
2008 to account for the receipt of a 90 day supply of a drug by December 31, 2007. i.e. if a 
beneficiary refilled a prescription on December 31, 2007 for a 90 day supply, that medication 
would last till March 30, 2008 and the beneficiary would need to refill it by March 31, 2008.  
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If a beneficiary took medications from more than one class then he or she was included in 
the analysis of all applicable classes. Figure 4 summarizes the creation of the required datasets 
from the Master Dataset. The sections following Figure 4 present the methods of selecting and 
preparing the sample to study the effect of losing all or some coverage while in the coverage gap 
on medication adherence of beneficiaries meeting the general inclusion and exclusion criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Methods for selecting the samples for the study 
 
 
Inclusion Criteria:  
 Age: 67 years or older at the end of the year 
(Alive) 
 Enrolled in PDPs for full year 
 No Subsidy or Dual Eligibility 
 No Cancer, COPD or ESRD  
Selected Beneficiaries 
N = 260,805 
Final Dataset  
N = 173,080  
Master Dataset (all 
beneficiaries) 
N = 2,631,860 
Medication related criteria: 
 Take Tablets or Capsules in one or 
more medications in one or more of 
the designated 7 classes 
Gap Coverage 
No Gap Coverage 
N = 164,551  
Some Gap Coverage 
N = 8,529  
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Methods to prepare the sample for each analysis 
 To test the different hypotheses of this study, it was necessary to create different 
comparison groups from the overall sample at a therapeutic class level based on whether or not 
the beneficiaries had coverage for drugs while in the coverage gap. For each comparison, the 
cohort of selected beneficiaries was divided into an intervention group and a matched control 
group. A control group is required in the study to account for biases introduced by variation in 
the baseline characteristics of the beneficiaries as well as their choice of enrolling in different 
plans. Patients in the intervention group (for each analysis) were identified from the claims 
database as those who met the afore-mentioned criteria and had at least one record of „PI‟, or II‟ 
values (indicating coverage gap) for the variable „benefit_phase‟ in the Part D event file. The 
remaining records were used as potential controls. Thus, the potential control group consisted of 
beneficiaries who did not experience the coverage gap during the year („Benefit_Phase‟ = „DD‟, 
„DP‟ or „PP), and those who were catastrophically high spenders and skipped the coverage gap 
by entering the catastrophic coverage phase after the initial coverage („Benefit_Phase‟ = „PC‟). 
The latter are excluded from further analysis. The two groups (who did and did not reach the 
coverage gap for each analysis) were then analyzed individually and also after being matched 
using a propensity score technique. 
Propensity Scoring  
 Propensity scores are useful in controlling for selection bias in situations where the 
experimental units are not allotted to the treatment groups in a random fashion and therefore 
have different distributions of the baseline covariates. A propensity score for an individual is 
“the conditional probability of his or her treatment given the observed pretreatment covariates”77.  
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Thus, units with similar propensity scores will tend to have similar levels of the covariates; 
thereby removing bias due to the covariates from the estimates
77
. 
Generally, a logistic regression is performed to calculate one‟s propensity to get one 
treatment over the other with the dependent variable being the treatment received (variable with 
1 and 0 values depending on the group they are in)
78
. While there is considerable debate about 
which variables should be included as independent variables, a recent study done by Austin et 
al.
79
 employed Monte Carlo simulations and found that “including only the true confounders 
(those that are associated with both treatment assignment and outcome) resulted in greater 
precision in estimating the treatment effect compared to the model that included variables 
associated with treatment assignment or outcome alone.” The researchers concluded that this was 
because the model that included scores calculated using the true confounders had the lowest 
Mean Square Error (MSE) estimate among all the four models and also resulted in 24% more 
matched pairs compared to any other model
79
. Therefore, only the „true confounders‟ will be 
included in estimating the propensity scores in our study. 
Following the calculation of propensity scores, the selection bias can be accounted for in 
one or more of the following three ways: stratification, adjustment in the regression analysis and 
matching
78
. Each of these techniques is a way to make an adjustment prior to or while 
calculating the treatment effect. Matching helps in removing the bias before calculating the effect 
whereas regression adjustment is made during the calculation. Stratification can be used in either 
way. The following sections provide brief description for each method. 
Stratification involves ranking of the observations based on the propensity scores and 
dividing them into various strata based on their scores. Thus, in this method, observations with 
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similar propensity scores are grouped together for the analysis. The outcome is then analyzed by 
strata and a weighted estimated mean is obtained per stratum. The results for each stratum are 
then combined and analyzed. Another method to analyze the information using stratification is to 
incorporate the strata in the multivariate analysis 
77, 78
. 
Another technique is to use the propensity score as an additional variable during the 
regression analysis and not use the variables used to generate this estimate. This can take into 
account the bias created by non-equivalent distribution of the variables between the two groups.  
Matching is generally employed when the sample size is large and when there are 
sufficient number of controls to match with the intervention group. If the sample size is not large 
enough, then removing those cases and controls that do not match will reduce the size of the 
sample and result in loss of power
77, 78
. If this technique can be used, then the procedure is to 
match the observations in the two groups on their propensity scores and then analyze the 
significance of differences in outcomes between the two groups using techniques for non-
independent samples (or matched pairs).  
Objective: To quantify the change in medication adherence among beneficiaries who had “No 
drug coverage” during the coverage gap 
Within the “No Gap Coverage” group, for each therapeutic class of medications to be 
analyzed, the beneficiary records were classified as being in the gap versus. not being in the gap 
using the criteria mentioned earlier. The purpose of this analysis was to study the impact of 
completely losing drug coverage during the coverage gap as compared to having stable coverage 
throughout the year. Ideally, to attain this aim, we needed to have a control group that reached 
the coverage gap and had no change in the coverage during the gap. Since our data did not 
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permit the use of such a control group, we compared the effects of losing coverage to those who 
did not reach the gap in 2008. This is because it can be inferred that by not reaching the coverage 
gap at any point in 2008, the beneficiaries maintained continuous coverage for their medications 
throughout the year.  
To account for the variation introduced by baseline characteristics as well as for the bias 
introduced by the voluntary enrollment in the Medicare Part D programs, the two groups were 
matched based on the propensity of a beneficiary to fall in the coverage gap (treatment 
assignment). This was calculated by performing a logistic regression with Dependent variable = 
“gap status” where (0 = No Gap and 1 = Gap) and covariates mentioned in a later section.   
Objective: To quantify the change in medication adherence among beneficiaries who had 
“some drug coverage” during the coverage gap 
 For this part of the analyses, we compared the group that reached the coverage gap and 
continued to have some coverage for their prescription drug expenses to two groups. First the 
group that retained some coverage during the gap was compared to the group that did not reach 
the gap from the “Some Gap Coverage” group. The purpose of this comparison is to compare the 
effectiveness of having some coverage during the gap to not losing the coverage throughout the 
year. Again, as with the analysis to study the effect of losing complete coverage during the gap; 
we needed to adjust for selection bias as well as variation introduced by differences in 
beneficiaries‟ baseline characteristics. To do so, we again calculated the propensity of reaching 
the gap (dependent variable = „Gap‟ where 0 = No Gap and 1 = Gap) and the independent 
variables being those described in the next section.  
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For the second part of the analyses, the change in these beneficiaries‟ adherence patterns 
was compared to the change in adherence patterns of the group that reached the gap and lost all 
coverage upon reaching the gap. Here, both the groups reached the coverage gap at some point in 
the year; however, we did have to account for the selection bias introduced by the choice to 
enroll in a plan with or without gap coverage rather than being randomly assigned to each plan. 
In addition, the variation introduced by the baseline characteristics of the two groups also needed 
to be adjusted for. Therefore, for this part of the analyses, we estimated the propensity of a 
beneficiary being enrolled in a plan that offered some coverage during the gap (treatment 
assignment dependent variable = „Gap_Coverage‟ where (0 = No Coverage and 1 = Coverage)) 
based on the independent variables explained in a later section. 
Independent variables for propensity score calculation 
In this study, the propensity scores were separately calculated for all comparison groups 
for all therapeutic classes based on age, race, gender, income, the Chronic Disease Score (CDS), 
total number of medications taken by the beneficiary, the duration of prescribed medication, drug 
benefit type, and type of cost sharing in each phase of Part D. These variables are identified as 
those that are known to be associated with experiencing the coverage gap (treatment) as well as 
medication adherence (outcome). The effect of these variables on reaching the coverage gap has 
been described elsewhere. The following paragraphs briefly describe how these variables affect 
adherence to medications  
Socio-demographic factors 
Age: The effect of age on medication adherence is not clear. Some studies conclude that younger 
patients are likely to be less adherent than older patients
75, 80-83
, whereas several others conclude 
that age is not a significant predictor of adherence 
84-87
.  
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Gender: Gender is found to be uncorrelated with adherence in general, with the exception of a 
few studies that did find differences in adherence rates among males and females
28, 81, 85
. 
Race: Race is a significant predictor of adherence with non-Caucasian race being significantly 
associated with lower adherence
76, 80, 83, 86, 88-91
. For example, Steinman et al. 
20
 found that non-
Caucasian Americans were almost 3 times more likely to report reduction in medication use 
when faced with higher costs compared to Caucasians after controlling for income, drug 
coverage and health status variables.  
Financial factors 
The literature indicates that low income translates into more cost related medication adherence 
21, 
22, 41, 92, 93
. Additionally, it has been established that absence of insurance coverage, as well as 
having caps or gaps in coverage, leads to medication non-adherence
9
.  
Medical factors 
Disease-Related: The literature on effects of co-morbidities on medication adherence is less 
conclusive. Some articles conclude that co-morbidity is not a significant predictor of medication 
adherence
85, 86
 but others conclude that higher  numbers of disease conditions led to higher rates 
of non-adherence
21, 41, 92, 93
. Depression is also often cited as a predictor associated with 
significantly lower adherence rates among patients across a range of different chronic 
conditions
83, 94-96
.Studies also suggest that the longer the duration of diagnosis of a disease, the 
more likely a patient is to adhere to the therapy
75, 76, 97
  
Medication-Related: Evidence clearly suggests that an increase in the frequency of 
administration of medications decreases adherence rates
74, 75, 82, 98, 99
 . In other words, regimens 
that require taking medications several times a day leads to lower adherence rates. However, the 
effect of number of prescriptions taken is not clear. For example, Col et al.
28
, Coons et al.
85
, 
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Donnan et al.
75
  as well as Mateo et al.
97
 report that the rates of non-adherence increase with an 
increase in the number of prescriptions taken, whereas Grant et al.
100
 and Shalansky et al.
101
 
conclude that non-adherence decreases with an increase in the number of prescription 
medications taken. 
Most of the above mentioned variables were directly available from the database. The 
following paragraphs present the methods to calculate the variables that were not obtained from 
the database. 
1. Calculating the CDS 
Von Korff et al. used automated pharmacy data from an HMO for one year to calculate a 
measure of severity of chronic diseases based on consensus of a multidisciplinary team of 
physicians, pharmacists, epidemiologists and health service researchers
102
. This measure is called 
the Chronic Disease Score or CDS. The CDS is calculated by grouping individual medications to 
their respective therapeutic classes and then assigning weights (scores) to the classes depending 
on the severity of the disease for which the class of medications is primarily used. The CDS 
assigns greater scores to potentially life-threatening and advanced disease conditions that require 
simultaneous use of medications from several therapeutic classes. By doing so, the CDS provides 
a measure of severity of illness by taking complexity of regimen and progress of the disease 
condition into account
102
.  
Originally, the CDS was developed to represent 30 therapeutic classes and was validated 
to predict hospitalization as well as mortality. From the results of their analyses, Von Korff et al. 
concluded that a CDS of 7 or greater was associated with a 5 fold increase in risk of 
hospitalization and a 10 fold increase in risk of mortality compared to CDS of 0
102
.  The CDS 
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was found to be a significant predictor of hospitalization and death even after adjusting for age, 
gender and ambulatory care visits. Several studies have replicated and/or extended the validity of 
the CDS since its development in 1991. Over time, the CDS has been shown to have good test-
retest reliability, construct validity with the RAND-36 instrument, and good predictive validity 
for hospitalizations, mortality and health care visits
103-109
. Since we are assessing the adherence 
patterns for selected classes of medications, the computation of the CDS for our study required 
modification of the original algorithm (which was based on 30 therapeutic classes
102
). Table 5 
describes the classes and associated weights involved in the calculation of the CDS for this 
study. 
Table 5: Chronic Disease Score Calculation  
Disease Indicator Therapeutic Class Score/Weight 
Heart Disease ACE Inhibitors 3 
Hypertension Calcium channel blockers 2 
  Beta-blockers 1 
  Diuretics 1 
Diabetes Oral Anti-diabetic Agent 2 
High Cholesterol Anti-hyperlipidemics 1 
Peptic Ulcers Proton Pump Inhibitors 1 
 
2. Calculating total number of medications taken 
The total number of medications was calculated as the total number of distinct generic 
medications taken by a beneficiary who meets the inclusion criteria for this study.  Thus the total 
number of medications taken by a beneficiary included the medications taken within the 7 
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therapeutic classes evaluated as well as medications from other classes not being evaluated for 
adherence. 
3. Calculating the total duration of prescribed medication  
 The total duration of a medication prescribed in any class was calculated as the number 
of days between the first fill date and December 31, 2008. Thus, for example, if a beneficiary 
had their first fill on January 1, 2008 then the total number of days that they should be taking the 
medication was calculated as (days between January 1, 2008 and December 31, 2008) 
irrespective of whether or not they reached the coverage gap. 
Propensity Score Matching 
Following calculation of propensity scores, for each comparison in this study, we 
matched the two comparison groups (e.g. those reaching the coverage gap were matched to those 
who did not in the “No Gap Coverage” group) using the  propensity score based Greedy 5     1 
digit matching technique for SAS
110
. In this technique, propensity scores are arranged in 
decreasing order and then observations are attempted to be matched on the first 5 digits of the 
score. If all cases are not matched, then a four digit match is attempted. This process is repeated 
until matches are attempted on the first digit of the propensity score. This maximizes the number 
of matched pairs formed while minimizing error. Observations that cannot be matched using this 
technique are excluded from the analysis.  
Observations in the matched control group were then allotted index dates to match the 
time of entrance into the coverage gap for the corresponding case. Thus, for example, if a 
beneficiary in the intervention group entered the coverage gap on August 1, 2008, and remained 
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in the gap for the rest of the year, he or she would have a “before” the intervention (coverage 
gap) period of January 1, 2008 until July 31, 2008 and an “after” the intervention period of 
August 1, 2008 through December 31, 2008. The matched control is then assigned an index date 
of August 1, 2008 and in this particular example, his or her “before” period was from January 1, 
2008 through July 31, 2008 and the “after” period was from August 1, 2008 through December 
31, 2008. This design allowed analyses of the two groups controlling for variation in baseline 
characteristics as well as potential secular trends that can affect adherence rates irrespective of a 
beneficiary‟s gap status. The methods used to calculate medication adherence are outlined in the 
next section. 
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Measuring Medication Adherence 
Methods to assess medication adherence include self-reporting, pill counting, patient 
diaries and using claims data
111
. In this study, pharmacy claims data were used to measure 
beneficiaries‟ adherence to prescribed medications in 2008. The use of retrospective claims data 
for assessing adherence generally requires slight alteration of the theoretical definition presented 
earlier, because claims data do not provide information on the act of taking the medication as 
indicated. Thus, for assessing adherence from claims data, the definition was operationalized as 
“the number of doses dispensed in relation to the dispensing period”19.  
Several methods of measuring adherence to medications using retrospective claims data 
have been proposed so far; however, the superiority of one method over the other is yet to be 
ascertained. These methods include but are not limited to calculating gaps in filling prescriptions, 
proportions of days covered and Medication Possession Ratio
111
. This study uses the most 
popular measure of calculating medication adherence using claims data: Medication Possession 
Ratio (MPR )
112
. 
MPR is calculated using the formula noted below: 
𝑴𝑷𝑹 =
𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒅𝒂𝒚𝒔 𝒐𝒇 𝒎𝒆𝒅𝒊𝒄𝒂𝒕𝒊𝒐𝒏 𝒔𝒖𝒑𝒑𝒍𝒊𝒆𝒅 𝒘𝒊𝒕𝒉𝒊𝒏 𝒕𝒉𝒆 𝒓𝒆𝒇𝒊𝒍𝒍 𝒊𝒏𝒕𝒆𝒓𝒗𝒂𝒍
𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒅𝒂𝒚𝒔 𝒊𝒏 𝒕𝒉𝒆 𝒓𝒆𝒇𝒊𝒍𝒍 𝒊𝒏𝒕𝒆𝒓𝒗𝒂𝒍
 
This is usually calculated by summing the number of days supplied for all but the last 
refill, divided by the number of days between the first and the last refill. Therefore, at least two 
fill dates are required to calculate this ratio.  
Since we wanted to assess adherence levels before and during the coverage gap for each 
comparison group in each therapeutic class, we calculated different MPR values for each period 
for both the cohorts in each therapeutic class. The MPR for the time when a beneficiary was not 
in the coverage gap was calculated as follows: The numerator equaled the total days of supply 
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between the first fill in 2008 and the last refill before the date that the beneficiary entered the 
coverage gap plus the days of supply between the last fill and the first date of reaching the 
coverage gap. The latter was calculated by splitting the days of supply obtained with the last fill 
to match the number of days left before reaching the coverage gap and carrying forward the 
remaining into the coverage gap phase calculations (the same time period was used for the 
matched control). The denominator was calculated as the total number of calendar days between 
the day the beneficiary first reached the coverage gap and the date of first fill.  
The MPR within the period when the beneficiary was in the coverage gap was calculated 
as follows: the numerator equaled the total days of supply between the refill when the 
beneficiary reached the coverage gap in 2008 and the refill when the beneficiary reached 
catastrophic coverage or December 31 in 2008; whichever came first (the same time period is 
used for the matched control). The denominator equaled the maximum of total number of 
calendar days between the two fill dates used in the numerator and the total number of days a 
beneficiary spent in the coverage gap. This is because when beneficiaries reach catastrophic 
coverage, they are no longer in the coverage gap. However, if beneficiaries do not reach 
catastrophic coverage by the end of December, they are still out of the coverage gap because 
they re-enroll in the plan beginning January of every year. Again, the excess days of supply 
before and during the coverage gap is split to match the corresponding days in that phase and the 
remaining are carried over into the next phase. If a beneficiary ended the year in the coverage 
gap phase but did have days of supply more than the days in the gap, then the excess days of 
supply were excluded from the analysis 
 In this study we calculated adherence to solid oral dosage forms (tablets and capsules) 
from one or more of the therapeutic classes mentioned earlier only. Generic drugs are 
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therapeutically equivalent to the corresponding brand name drugs. Hence, if a beneficiary 
switched from a brand name drug within a therapeutic class to a therapeutically equivalent 
generic drug in the same class during the study period (e.g. from Zocor® to simvastatin), he or 
she was considered as continuing with the same therapy in the calculation of MPR. Additionally, 
the study examines changes in adherence rates by therapeutic class and hence substitution to a 
chemically different but therapeutically equivalent drug within the same class (e.g. from 
Lipitor® to Zocor®) was also considered as continuing with the same therapy in the calculation 
of the MPR. However, switching between classes (e.g. from beta-blockers to diuretics for 
hypertension) was not considered as being adherent. Beneficiaries taking medications from 
multiple therapeutic classes were included in the analysis of every applicable class. 
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Measuring proportion of beneficiaries considered adherent before and during the coverage 
gap 
 MPR can be presented as a continuous measure of adherence or dichotomized into 
“adherent” or “non-adherent” groups. We used the most common threshold for this 
dichotomization: MPR value ≥80% was classified as adherent and those with MPR < 80% were 
classified as non-adherent.  
The first use of 80% as a cut-point was a study done by Psaty et al. in 1990
23
. This study 
examined the relation between adherence to hypertensive medications and risk of developing 
myocardial infarction. The researchers did not mention any rationale for selection of this cut-off, 
just that „it was assumed to be 80%‟. This was a randomized clinical trial that found that patients 
with less than 80% adherence to their medication (as measured by calculating MPR from a 
computerized pharmacy database) have a 4 fold increase in risk of developing acute cardiac 
events. As it appears, this was a disease specific measure.  
Over the last decade, there has been an increasing interest to evaluate whether being 
adherent to medications more than 80% of the time provided any clinical benefit. Several studies 
done in this time period have concluded that having MPR value ≥ 80% significantly improved 
clinical outcomes and/or reduced healthcare utilization and costs for specific disease condition 
and studies indicate that there are significant improvements at and beyond this threshold. For 
example, a study by Lau et al. found that among patients taking oral hypoglycemic agents to 
control their diabetes, those who had MPR values less than 80% had higher odds of being 
hospitalized compared to those who had MPR ≥ 80% (odds ratio: 2.53, with significant 95% 
CI)
113
. A recent study by Karve  et al. examined the validity of different cut-off values of MPR in 
terms of predicting hospitalizations in a large Medicaid population database (predictive 
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validity)
114
. This study found that the optimal cut-off value for MPR to predict any cause 
hospitalization ranged between 0.63 and 0.89 and for disease specific hospitalization, the values 
ranged from 0.58 to 0.85. Thus, it concluded that it is reasonable to select 0.80 as the cut-off 
point. Hansen et al. 
115
 attempted to measure the convergent validity of the measure with other 
measures of adherence (patient self-report and electronic adherence measures) at different cut-off 
points. This study found that at the widely used cut-point (80%), there was a balance between the 
sensitivity and specificity in classifying the subjects with heart failure or hypertension for all 
measures and that they correlate well with each other at this point. This study has limited 
generalizability because it was conducted on patients with a specific disease condition. However, 
both of these studies provide an empirical basis for using 80% as the cut-off value in classifying 
patients as being adherent and non-adherent  
Thus, we expect that using 80% as the cut-off in our study provides information of 
practical relevance for policy makers and define a beneficiary as being adherent if their MPR 
value is 0.8 or greater. This analysis is done by therapeutic class and by presence or absence of 
drug coverage during the coverage gap after matching for both the groups that did or did not 
reach the coverage gap. 
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Measuring proportion of beneficiaries who stopped taking their medications during the 
coverage gap 
 In this analysis, we examined the proportion of beneficiaries who stopped taking their 
medications after reaching the coverage gap for each therapeutic class. This analysis was done 
after matching to examine the effect on the matched control group as well.  For this purpose, we 
defined a person to have stopped taking their medications in the coverage gap phase if they were 
found to have reached the coverage gap but had no days of supply (as calculated earlier) of 
medications for that time. For example, if we assume that a person reached the coverage gap on 
December 1, 2008 but had a 90 day supply of medications dispensed to him/her on October 1, 
2008 This was included in the analysis by splitting the 90 day supply received on October 1 into 
a 60 day supply before the gap and 30 day supply in the gap. Thus, it would not appear as if the 
beneficiary discontinued the medication during the coverage gap phase. However, if the 
beneficiary received a 30 day supply on October 1 and did not have any refill thereafter, then it 
would indicate that s/he stopped taking his/her medications.  
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Data Analyses 
The following sections describe our data analysis: 
Descriptive analyses 
We performed several types of descriptive analyses. First, we studied the entire final 
sample in terms of their demographics (age, race, gender, income), total number of medications 
used, and out of pocket costs. The results were reported as means and standard deviations for the 
following variables: age, income, total number of medications used and out-of-pocket costs. The 
variables „race‟ and „gender‟ are reported as percentage of Caucasian population and percentage 
of males and females respectively. 
Next, we identified the percentage of beneficiaries who entered the coverage gap in 2008 
overall and for each therapeutic class as well as months spent in the coverage gap. Following 
this, within each therapeutic class, we studied the characteristics of beneficiaries who reached the 
coverage gap in 2008 to understand their demographics, month of entry in the coverage gap, 
CDS, total duration for which they should have taken their medication and total number of 
medications as well as plan characteristics. For all variables except the median annual household 
income (which was reported as median), results were reported as means and standard deviations 
for all the continuous variables (age, total medications, total duration and CDS). As before, race 
and gender are expressed as percentages. In addition, the percentage of beneficiaries having no 
deductible, tiered cost-sharing and Medicare defined standard gap threshold were also reported 
for each therapeutic class. 
We performed similar analyses for the group that did not reach the coverage gap to study 
the differences in the baseline characteristics of the two groups before matching.  Appropriate 
tests for significance in differences are reported in the next chapter depending on the variable 
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type. In general, the significance of differences between the two groups for the categorical 
variables was assessed by chi-square tests whereas that for the continuous variables was assessed 
using the Wilcoxon Rank Sum Test. 
  The two groups were reassessed on the same variables after matching to check the quality 
of matching. However, since the two groups were now matched pairs, the underlying assumption 
of using independent samples in comparisons using the Wilcoxon Rank Sum test as well as Chi-
square test is violated. Therefore, we used the appropriate tests of significance for paired data.  
For continuous variables, we used the Wilcoxon Signed Rank Test whereas for categorical 
variables the significance of difference was assessed using the McNemar‟s test.   
Measuring the Impact of Coverage Gap on Adherence 
 We studied the impact of coverage gap on adherence rates to medications prescribed in 
different therapeutic classes mentioned earlier. The main outcome of interest was change in 
adherence to prescription medications after reaching the coverage gap. This was measured as a 
difference of MPR before and MPR after reaching the gap. This value was obtained for each 
beneficiary for both the treatment and the control group. The statistical significance was then 
measured using the Wilcoxon signed rank test which tests for a significant difference between 
the paired data. The test was performed by therapeutic classes of the drugs for both the treatment 
and the control group. In other words, this first set of analysis tested for significance in change in 
adherence rates using the paired data of beneficiaries who entered the coverage gap and similar 
analysis was done for their matched controls. Thus, here, the beneficiaries in each group served 
as their own controls.  
The second set of analyses was done to account for the baseline characteristics of the 
beneficiaries and changing time trends using the simple difference in difference (DD) technique. 
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This technique involves comparison of differences in the difference between the before and after 
values of the outcome variable (here MPR values) for the treatment and control group. Thus, we 
calculated the difference in MPR values before and after reaching the coverage gap for each 
group and then calculated the difference of these differences.  
Let Mt,b and Mt,a respectively represent the MPR value before and after reaching the 
coverage gap for the treatment group and Mc,b and Mc,a respectively represent the MPR values 
for matching time for the control group. Then, the DD estimator was calculated as:  
𝑫𝑫 =  𝑴𝒕, 𝒃 − 𝑴𝒕, 𝒂 − (𝑴𝒄, 𝒃 − 𝑴𝒄, 𝒂) 
We employed this simple analysis technique instead of using a regression that can control 
for other baseline characteristics because we had already matched the two groups on other 
baseline characteristics using the propensity score technique. The matched control group was 
allotted index dates that correspond to the times before and within the coverage gap for the 
matched case. Thus, the DD estimate obtained in our analysis accounted for both observed and 
unobserved factors that can affect the change in adherence rates during the coverage gap and 
hence provide a more robust association between the coverage gap status and change in 
adherence rates
116
. The statistical significance of the differences between the groups was again 
assessed using the Wilcoxon signed rank test for paired data.  This analysis was done at 
therapeutic class level for the groups depending on whether or not they had drug coverage during 
the coverage gap. 
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CHAPTER 5 
 RESULTS 
 
This chapter presents the sample size and the results obtained for each objective. 
Sample Size 
 The master dataset created after merging all the CMS datasets as well as those created for 
income and therapeutic class consisted of claims, demographic and enrollment information of 
2,631,860 unique beneficiaries enrolled in Medicare in 2008. After applying the general 
inclusion and exclusion criteria, the dataset comprised 250,890 unique beneficiaries. Upon 
application of medication related criteria (i.e. taking one or more oral medications in one or more 
of the 7 therapeutic classes), the final sample contained information of 173,080 beneficiaries.  
These beneficiaries were then separated into two groups based on their enrollment in plans that 
did or did not offer drug coverage in the coverage gap.  Thus, the two groups were a) 
beneficiaries enrolled in plans that did not offer any coverage during the coverage gap (No Gap 
Coverage Group (N = 164,551) and b) beneficiaries enrolled in plans that offered some coverage 
during the coverage gap (Some Gap Coverage Group N = 8,529).  
Within each of these two groups, beneficiaries were separated into therapeutic classes 
being evaluated in this study. If a beneficiary took medications from more than one class among 
those evaluated, then they are included in each applicable class. However, within each class, if 
the first fill date was after March 31, 2008, then that record was deleted from further analyses. 
Due to this criterion, although several beneficiaries took medications from the classes being 
evaluated at some point in 2008, only those with a presumed full year of usage were included in 
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further analyses. For example, in the „No Gap Coverage group, 40,060 beneficiaries were taking 
ACE inhibitors in 2008; however, only 34,477 beneficiaries had records of filling the first 
medication by March 31, 2008. Therefore, the rest were excluded from further analyses in the 
study. Among the overall sample of beneficiaries included in the subsequent analyses, the most 
widely used class of drugs was anti-hyperlipidemic agents, followed by beta-blockers, diuretics, 
ACE inhibitors and calcium channel blockers. The classes of drugs used by a lesser proportion of 
beneficiaries were PPI and oral anti-diabetic agents. Table 6 shows the sample sizes for each 
therapeutic class being evaluated by the type of coverage during the gap. 
Table 6: Sample Size by Therapeutic Class 
Therapeutic Class No Gap Coverage Some Gap Coverage 
ACE inhibitors 34,477 1,499 
Beta-blockers 47,911 2,295 
Calcium channel blockers 29,229 1,384 
Diuretics 47,711 2,275 
Oral anti-diabetic agents 17,500 845 
Oral anti-hyperlipidemic agents 69,178 3,407 
Proton pump inhibitors 23,925 1,117 
 
The following section presents the descriptive characteristics of the overall sample as well as by 
therapeutic class.  
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Descriptive Characteristics  
All beneficiaries (N = 173,080)  
 Overall, our sample was found to be older and predominantly Caucasian. The mean age 
of the beneficiaries in our sample was 77.43 (+ 7.05) years. A little over 90% of the sample was 
found to be Caucasian and almost three - quarters of the sample (73.35%) comprised females. 
The sample had a median household income of $33,646. On average, beneficiaries in our sample 
took 7.94 (+ 4.30) unique medications, and were predominantly enrolled in stand-alone 
Prescription Drug Plans (PDPs) that offered coverage using some modification of the standard 
Medicare Part D benefit structure (58.10%).  
For the sample in our study, a majority were enrolled in plans that did not charge a 
deductible (75.93%), had tiered cost-sharing (in contrast to Medicare defined coinsurance of 
25%), had coverage gap and catastrophic coverage beginning at the Medicare defined amount 
($2,510 in total spending and $4,050 in OOP spending respectively) and did not offer coverage 
for any drugs in the coverage gap (95.07%).   
Presence or absence of coverage during the gap 
As with the overall sample, both groups (with or without coverage in the gap) were found 
to be older, predominantly Caucasian, female and on several medications. The group with some 
coverage in the gap was similar to the group without coverage in the gap in terms of 
demographics. However, there were significant differences in the benefit structures offered by 
the plans in the two groups. The beneficiaries in the “Some Gap Coverage” group were enrolled 
in plans that offered drug coverage through „enhanced alternative‟ structure that did not charge a 
deductible. By comparison, beneficiaries in the “No Gap Coverage” group were enrolled in plans 
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that offered drug coverage through a variety of benefit structures. Only about a third of these 
plans offered an „enhanced alternative‟ benefit structure, and a quarter of all plans charged a 
deductible. In spite of these variations, it was interesting to note that plans in both the groups had 
tiered cost sharing for covered prescription drugs and had coverage gap begin and end thresholds 
that were the same as those defined by Medicare.  Table 7 lists the characteristics of the overall 
sample and of the two groups. 
Table 7: Characteristics of beneficiaries overall and by type of coverage in the coverage 
gap 
Characteristic 
Total 
N=173,080 
No Gap 
Coverage 
N = 164,551 
Some Gap 
Coverage 
N = 8,529 
Age(Mean (Std. Dev*)) 77.43(7.05) 77.42(7.05) 77.8(7.01) 
Race (%Caucasian) 91.92 91.88 92.73 
Gender (% Females) 73.35 73.29 74.58 
Income** 
(Median) 
33,646 33,662 33,259 
Total # of medications 7.94(4.3) 7.92(4.29) 8.31(4.41) 
Drug benefit type  
(% Standard or equivalent) 
58.1 61.11 0 
Deductible (% No)  75.93 74.68 99.99 
Initial Coverage Limit  
(% beneficiaries with Medicare 
defined amount) 
98.78 98.72 99.91 
Initial cost sharing  
(% beneficiaries with tiers) 
99.24 99.2 99.99 
% beneficiaries with drug coverage 
in coverage gap 
4.93 N/A 100 
Note: * Std. Dev means Standard Deviation, ** Income = median household income of 
beneficiaries‟ zip-code   
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Characteristics of beneficiaries by class 
1. No Gap Coverage Group (N = 164, 551) 
(a) Demographic Characteristics 
As observed with the overall dataset, the mean age of the sample in each class was close 
to 78 years of age. Additionally, approximately 90% of the sample in each therapeutic class was 
Caucasian with most being females. Table 8 presents the demographic characteristics of the 
sample by therapeutic class. 
Table 8: Demographic characteristics of beneficiaries with no drug coverage in the 
coverage gap by therapeutic class 
Class N Age 
Mean 
(Std.Dev*) 
Race 
%Caucasian 
Gender 
%Males  %Females 
Income** 
Median $ 
ACE inhibitors 34,477 77.49(7.06) 91.76 31.69 68.31 32,704 
Beta-blockers 47,911 77.89(7.02) 93.17 26.47 73.53 32,612 
Calcium channel 
blockers 
29,229 78.52(7.29) 89.37 22.63 77.37 32,609 
Diuretics 29,229 78.36(7.31) 91.53 20.66 79.34 31,896 
Oral anti-
diabetic agents 
17,500 75.99(6.37) 85.38 34.75 65.25 32,867 
Oral anti-
hyperlipidemic 
agents 
69,178 76.39(6.41) 92.18 30.57 69.43 34,453 
Proton pump 
inhibitors 
23,925 77.04(7.01) 91.92 23.27 76.73 33,132 
 Note: * Std. Dev means Standard Deviation, ** Income = median household income of 
beneficiaries‟ zip-code 
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(b)  Medication Related Characteristics 
 As with the overall sample, the beneficiaries from each therapeutic class took at least 8 
unique medications. In addition, a majority of the beneficiaries in each class concurrently took at 
least 4 medications from an average of three of the classes being evaluated in this study.  For 
each class studied, the total duration that the beneficiaries were supposed to take the medications 
was around 345 days. The medication related characteristics of the beneficiaries in each class are 
outlined in Table 9 below: 
Table 9: Medication related characteristics of beneficiaries with no drug coverage in the 
coverage gap by therapeutic class 
Class Total Rx* 
Mean 
(Std.Dev**) 
Total Class† 
Mean 
(Std.Dev) 
Total Rx 
from classes†† 
Mean(Std.Dev) 
Total 
Duration††† 
Mean 
(Std.Dev) 
ACE inhibitors 7.70(3.71) 3.11(1.29) 3.43(1.60) 346.79(19.82) 
Beta-blockers 7.94(3.79) 3.06(1.25) 3.32(1.54) 345.32(20.96) 
Calcium channel 
blockers 
8.13(3.67) 3.11(1.32) 3.46(1.82) 345.53(21.01) 
Diuretics 8.35(3.91) 3.04(1.27) 3.37(1.53) 345.76(20.59) 
Oral anti-diabetic 
agents 
8.18(3.73) 3.27(1.34) 3.86(1.72) 350.01(16.18) 
Oral anti-
hyperlipidemic agents 
7.45(3.67) 2.77(1.29) 3.09(1.59) 344.29(21.67) 
Proton pump 
inhibitors 
9.08(4.17) 2.98(1.36) 3.38(1.59) 342.89(22.89) 
Note: * Rx = Prescription Medications, ** Std. Dev = Standard Deviation, †Total Class = 
number of classes under evaluation from which the beneficiaries took medications 
simultaneously, †† Total Rx from classes = number of medications from the 7 classes evaluated, 
††† Total Duration = number of days beneficiaries were supposed to take their medication since 
the first fill date 
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(c)  Plan Characteristics 
Less than 1% of all enrollees in the No Gap Coverage group were enrolled in plans that 
offered coverage through the standard Medicare Part D benefit structure. Most beneficiaries were 
enrolled in plans that offered drug coverage through benefit structures that are considered 
equivalent or enhanced when compared to the standard Part D design. A majority of plans did 
not charge a deductible and had tiered cost-sharing as opposed to the standard 25% co-insurance 
during the initial coverage period. As with the overall sample, almost all plans imposed Medicare 
defined spending limits to determine a beneficiary‟s gap entry and exit times. Table 10 presents 
these results in detail. 
Table 10: Plan characteristics of beneficiaries with no drug coverage in the coverage gap by 
therapeutic class 
Class Drug Benefit Type 
 
Actuarially  Basic  Enhanced 
Equivalent   Alt.** Alt. 
Deductible 
Applied 
(%No) 
Pre-Gap 
Cost-
sharing 
(%Tiers) 
Gap 
Threshold 
(%Std.amt*) 
ACE inhibitors 20.79 40.49 38.71 75.72 99.26 98.77 
Beta-blockers 21.41 39.17 39.42 75.37 99.17 98.64 
Calcium channel 
blockers 
21.48 40.25 38.27 74.92 99.16 98.67 
Diuretics 22.09 39.02 38.89 74.74 99.27 98.73 
Oral anti-diabetic 
agents 
21.67 40.18 38.15 74.28 99.13 98.67 
Oral anti-
hyperlipidemic 
agents 
20.63 40.19 39.18 76.10 99.36 98.85 
Proton pump 
inhibitors 
21.19 39.94 38.87 75.64 99.15 98.71 
Note: *Std.amt = Medicare defined Standard amount ($2,510 for 2008) ** Alt. = Alternative 
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2. Some Gap Coverage Group (N = 8,529) 
(a) Demographic and Medication related characteristics 
The demographic characteristics of the beneficiaries in this group were in concordance 
with the findings for the overall sample. In other words, within each therapeutic class, 
beneficiaries with some drug coverage during the coverage gap were also older, predominantly 
Caucasian and female. In addition, the medication taking behavior of the beneficiaries in this 
group was also similar to that of the overall sample and the “No Gap Coverage” group. Tables 11 
and 12 present the demographic and medication related characteristics of the beneficiaries in this 
group.  
Table 11: Demographic characteristics of beneficiaries with some drug coverage in the 
coverage gap by therapeutic class 
Class N Age 
Mean 
(Std.Dev*) 
Race 
%Caucasian 
Gender 
%Males %Females 
Income** 
Median($) 
ACE 
inhibitors 
1,499 77.67(6.87) 92.66 31.49 68.51 32,489 
Beta-blockers 2,295 78.13(6.92) 93.99 25.66 74.34 32,507 
Calcium 
channel 
blockers 
1,384 78.92(7.12) 89.74 20.66 79.34 31,827 
Diuretics 2,275 78.77(7.26) 93.23 19.74 80.26 32,211 
Oral anti-
diabetic agents 
845 76.41(6.45) 87.22 34.67 65.33 33,241 
Oral anti-
hyperlipidemic 
agents 
3,407 76.75(6.36) 93.01 29.26 70.74 33,915 
Proton pump 
inhibitors 
1,117 77.40(6.86) 92.87 23.46 76.54 32,531 
Note: * Std.dev = Standard Deviation, ** Income = the median household income of the 
beneficiaries‟ zip-code 
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Table 12: Medication related characteristics of beneficiaries with some drug coverage in 
the coverage gap by therapeutic class 
Class Total Rx* 
Mean 
(Std.Dev**) 
Total Class† 
Mean 
(Std.Dev) 
Total Rx 
from classes†† 
Mean(Std.Dev) 
Total 
Duration††† 
Mean 
(Std.Dev) 
ACE inhibitors 7.83(3.61) 3.32(1.28) 3.54(1.60) 346.94(20.05) 
Beta-blockers 8.07(3.78) 3.03(1.24) 3.39(1.54) 344.31(21.31) 
Calcium channel 
blockers 
8.21(3.87) 3.21(1.29) 3.48(1.57) 344.14(21.67) 
Diuretics 8.33(3.74) 3.08(1.23) 3.38(1.56) 345.12(21.39) 
Oral anti-diabetic 
agents 
8.35(3.68) 3.43(1.33) 3.96(1.67) 343.12(23.26) 
Oral anti-
hyperlipidemic agents 
7.51(3.59) 2.76(1.28) 3.15(1.59) 343.18(22.37) 
Proton pump 
inhibitors 
9.02(4.06) 3.02(1.36) 3.33(1.69) 341.77(23.89) 
Note: * Rx = Prescription Medications, ** Std. Dev = Standard Deviation, †Total Class = 
number of classes under evaluation from which the beneficiaries took medications 
simultaneously, †† Total Rx from classes = number of medications from the 7 classes evaluated, 
††† Total Duration = number of days beneficiaries were supposed to take their medication since 
the first fill date 
 
(b) Plan Characteristics 
 Since this group of beneficiaries are documented to have coverage for some drugs while 
in the coverage gap, as expected, all the beneficiaries were enrolled in plans that offered 
coverage through an „enhanced alternative‟ benefit design. In addition, no plan in this group 
charged a deductible and all had tiered cost-sharing structures during the initial coverage limit 
phase. In spite of these „enhanced‟ offerings, all the plans had a coverage gap starting at the 
Medicare defined amount of $2,510 in total spending and catastrophic limits starting at $4,050 in 
total OOP spending. It was interesting to note that although these beneficiaries had coverage for 
drugs when in the coverage gap, this benefit was limited to some or all generic drugs only. 
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Specifically, 54% of all beneficiaries in this group had all generic drugs covered during the 
coverage gap, 38% had coverage limited to „preferred generics‟ and the remaining 8% had 
coverage limited to only „a few‟ generic drugs when in the coverage gap. No plan in our sample 
offered coverage for any brand name drugs during the coverage gap for this group. 
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Characteristics of beneficiaries based on whether or not they reached the coverage gap 
1. Overall (N = 173,080) 
 Overall, 24.42% (N = 42,264) of our sample reached the coverage gap in 2008. Of these, 
only 6.29% beneficiaries (N = 2,660) had some coverage for their prescription medications 
during the coverage gap. The remaining 93.71% beneficiaries had no coverage for their 
prescription drugs during the coverage gap. Among the “No Gap Coverage” group, 24.07% 
reached the coverage gap. By comparison, 31.19% of those with some gap coverage reached the 
coverage gap in 2008 (Figure 5). Overall, a little over half of the beneficiaries reaching the 
coverage gap (59.92%) did so by September and spent about 97 days (+ 67 days) in the coverage 
gap. Of these, 12.10% (3% of the total sample) reached the catastrophic coverage phase. It was 
found that those reaching the catastrophic coverage phase were primarily beneficiaries reaching 
the coverage gap in the first half of the year. In addition, beneficiaries receiving catastrophic 
coverage spent approximately 83 days (+ 72 days) in that phase, which is consistent with the 
finding that a majority of these beneficiaries reached the phase early in the year. Irrespective of 
the level of analysis, the beneficiaries reaching the coverage gap did not have different 
demographic characteristics when compared to those who did not reach the coverage gap. Figure 
6 presents the demographic characteristics of the two groups by level of analysis. 
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Figure 5: Percentage of beneficiaries reaching the coverage gap in 2008 
 
 
Figure 6: Demographic characteristics by gap and gap coverage status 
 
0
5
10
15
20
25
30
35
Total No Gap 
Coverage
Some Gap 
Coverage
% reaching the coverage gap
0
10
20
30
40
50
60
70
80
90
100
Reached Gap Did not Reach 
gap
Reached gap Did not reach 
gap
Reached gap Did not reach 
gap
Total No Gap Coverage Some Gap Coverage
Age
%Caucasian
%Female 
 
 
89 
 
Although the two groups had similar demographic attributes, those who did reach the 
coverage gap had higher prescription medication use and OOP spending compared to those that 
did not reach the coverage gap in 2008. An average beneficiary reaching the coverage gap took 
11.25 (+ 4.63) different medications compared to 7.39 (+ 3.75) medications taken by a 
beneficiary not reaching the coverage gap throughout the year.  The OOP spending for a 
beneficiary reaching the gap was found to be higher during both the pre-gap as well as the 
coverage gap periods compared to stable lower spending experienced by beneficiaries not 
reaching the coverage gap. Beneficiaries reaching the coverage gap spent an average $763.95 (+ 
$330.46) before reaching the coverage gap and $945.70 (+ $986.22) during the coverage gap. By 
comparison, beneficiaries not reaching the coverage gap had an average OOP spending of only 
$400.00 (+ $286.59) throughout the year.  These numbers were similar when the groups were 
compared based on presence or absence of gap coverage during the gap. For instance, for those 
reaching the coverage gap in the “No Gap Coverage” group, the pre-gap spending was $768.30 
(+ $329.50) and the „during gap‟ spending was $951.65 (+ $987.13) compared to an average 
$396.00 (+ $285.85) in annual OOP spending for those who did not reach the coverage gap in 
this group. Similarly, for those reaching the coverage gap in the “Some Gap Coverage” group, 
the pre-gap as well as the „during gap‟ spending were found to be  higher than the annual OOP 
spending for those who did not reach the coverage gap in this group ($699.14 + $337.91 and 
$857.07 + $968.34 respectively vs. $418.17 + $301.36).  
Similar proportions of beneficiaries in both the groups were enrolled in coverage designs 
considered to be equivalent or enhanced adaptations of the standard Medicare Part D benefit 
structures. Figure 7 summarizes the enrollment statistics for each plan benefit design based on 
presence or absence of drug coverage in the gap. 
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Figure 7: Plan Characteristics of beneficiaries by gap and gap coverage status  
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2. Characteristics by therapeutic class before and after matching 
No Gap Coverage Group 
The comparison groups comprised those who did and did not reach the coverage gap in 
the “No Gap Coverage” group. Within the “No Gap Coverage” group, the beneficiaries were 
divided into 7 therapeutic classes being studied and within each therapeutic class they were 
further divided into two groups based on whether or not they reached the coverage gap in 2008. 
The beneficiaries in the two groups in each class shared a few similar characteristics but there 
was also variability with respect to some other baseline attributes. In order to generate reliable 
estimates of the effect of losing all coverage in the coverage gap on beneficiaries‟ adherence 
measures, it was necessary to make the two groups more comparable in terms of their baseline 
characteristics. Therefore, the beneficiaries reaching the coverage gap were matched to those not 
reaching the coverage gap on a variety of variables. These variables were: age, race, gender, 
income, number of medications taken, duration of therapy, severity of disease as calculated using 
CDS, type of benefit design, presence or absence of deductible, type of cost sharing before 
reaching the coverage gap, and coverage gap threshold amount. The following paragraphs 
outline the characteristics of the groups that did and did not reach the coverage gap by 
therapeutic class before and after matching. 
(a) Oral anti-hyperlipidemic agents 
 This was the most widely used class of medications in the sample; with around 80,000 
beneficiaries using one or more medications from this class at some point in 2008. However, the 
proportion of beneficiaries having usage beginning in the first quarter of 2008 was less; only 
69,178 beneficiaries were prescribed the medication since the beginning of the year. From this 
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pool, 7,636 beneficiaries (11.04%) reached the coverage gap in 2008. A majority of beneficiaries 
reached the coverage gap by November, with the largest proportion doing so between October 
and November (41% and 70% respectively).  However, only two of beneficiaries reached the 
catastrophic phase and therefore the results after reaching the catastrophic phase are not shown. 
 Although the two groups were similar in a few characteristics (e.g. income and disease 
severity), there were a number of other attributes that differed between the two (p-value < .05). A 
greater proportion of the beneficiaries reaching the gap were Caucasians and male compared to 
those not reaching the coverage gap (93.07% vs. 92.08% and 32.24% vs. 30.40% respectively). 
In addition, beneficiaries reaching the coverage gap were a little older compared to those not 
reaching the coverage gap in 2008. Beneficiaries reaching the coverage gap took about 10 
different medications (vs. 7 for those not reaching the gap) over a relatively short duration of 
time (312 days vs. 349 for those not reaching the gap). Greater proportions of beneficiaries 
reaching the coverage gap were enrolled in plans that offered no additional benefit over a 
standard benefit structure (61.38% vs. 60.75%) and that charged a deductible (26.9% vs. 23.53% 
from those not reaching the gap).  The use of propensity score matching resulted in 5,041 
matched pairs (66.02% of the beneficiaries reaching the gap) that were similar to each other in 
all the observed characteristics. Table 13 presents these results in detail. 
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Table 13: Characteristics of beneficiaries in the “No Gap Coverage” group taking oral 
anti-hyperlipidemic agents before and after matching 
Variable Before matching 
Treatment       Control       p-value 
N = 7,636       N = 61,542 
After matching 
Treatment     Control     p-value 
 N = 5,041      N = 5,401 
Age 
Mean(Std.dev**) 
76.52 
(6.47) 
76.19 
(6.33) 
0.0002* 76.19 
(6.32) 
75.98 
(6.33) 
0.0886 
Race (%Caucasian) 93.07 92.08 0.0328* 92.82 92.44 0.9964 
Gender  
(% Females) 
67.76 69.60 0.0010* 66.46 66.55 0.9150 
Income†(Median) 34,022 34,259 0.543 34,677 34,700 0.3500 
# Medications 
taken (Mean 
(Std.Dev)) 
9.63 
(3.93) 
7.19 
(3.51) 
<0.0001* 8.43 
(3.34) 
8.29 
(3.91) 
0.0594 
CDS†† 
Mean(Std.dev) 
3.62 
(2.12) 
3.41 
(1.92) 
0.23 3.48 
(2.11) 
3.42 
(2.15) 
0.1060 
Total Duration††† 
Mean(std.dev) 
311.57 
(24.28) 
349.35 
(17.47) 
<0.0001* 321.37 
(22.84) 
319.71 
(24.32) 
0.1344 
Benefit Type 
(% Basic Design) 
61.38 60.75 <0.0001* 61.20 61.79 0.3114 
Deductible (% No) 73.1 76.47 <0.0001* 74.49 75.76 0.0580 
Pre-Gap 
Costsharing 
(% Tiers) 
99.28 99.38 0.3176 99.35 99.39 0.7995 
Gap Threshold 
(% Std. amt***) 
98.73 98.85 0.3435 98.73 98.97 0.2611 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries, †† CDS = Chronic Disease Score, ††† Total 
Duration = total number of days beneficiaries were supposed to take the medications since the 
first fill date 
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(b) Beta-blockers 
 Out of 53,315 users of beta-blockers in this sample, 47,911 unique beneficiaries had 
documented usage beginning by March 31. Among these beneficiaries, 11.06% reached the 
coverage gap three-quarters of these did so by November. Only four beneficiaries reached the 
catastrophic coverage; the remainder either stayed in the coverage gap for the rest of the year or 
stopped taking the medication in this class.  
Beneficiaries reaching the coverage gap in this group were found to be similar to those 
not reaching the coverage gap in terms of age, race, income and disease severity; but had 
different gender, medication and plan related characteristics. Beneficiaries reaching the coverage 
gap had a significantly higher medication use for a significantly shorter duration of therapy. In 
addition, a greater proportion of these beneficiaries were enrolled in plans that offered coverage 
through basic alterations of the Standard Part D benefit design and that charged a deductible. 
Again, the differences between the two groups were eliminated by matching those reaching the 
coverage gap to those not reaching the coverage gap. However, in the process, we lost 18% of 
the beneficiaries reaching the coverage gap because no match was found from the group not 
reaching the coverage gap. Table 14 presents the characteristics of these beneficiaries before and 
after matching. 
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Table 14: Characteristics of beneficiaries in the “No Gap Coverage” group taking Beta-
blockers before and after matching 
Variable Before matching 
Treatment      Control        p-value 
N = 5,928       N = 42,613 
After matching 
Treatment    Control     p-value 
 N = 3,821      N = 3,821 
Age 
Mean(Std.dev**) 
77.94 
(6.97) 
77.88 
(7.02) 
0.5148 77.74 
(6.93) 
77.75 
(6.96) 
0.9200 
Race (%Caucasian) 93.74 93.03 0.3746 93.54 92.25 0.5578 
Gender  
(% Females) 
71.64 73.75 0.0012* 71.32 70.43 0.3791 
Income†(Median) 32,905 32,590 0.1020 32,975 32,401 0.2907 
# Medications 
taken (Mean 
(Std.Dev)) 
10.24 
(3.88) 
7.66 
(3.67) 
<0.0001* 9.38 
(3.34) 
9.31 
(5.14) 
0.4276 
CDS††  
Mean(Std.dev) 
3.80 
(2.05) 
3.63 
(2.11) 
0.0900 3.74 
(2.04) 
3.71 
(2.17) 
0.4586 
Total Duration††† 
Mean(std.dev) 
313.51 
(24.14) 
349.27 
(16.73) 
<0.0001* 322.59 
(21.31) 
322.38 
(26.45) 
0.4548 
Benefit Type 
(% Basic Design) 
62.74 60.32 <0.0001* 62.68 62.21 0.1999 
Deductible  
(% No) 
71.03 75.91 <0.0001* 72.10 73.38 0.3769 
Pre-Gap 
Costsharing 
(% Tiers) 
98.81 99.28 <0.0001* 98.98 99.24 0.2184 
Gap Threshold 
(% Std. amt***) 
98.33 98.73 0.0766 98.46 98.93 0.069 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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(c) Diuretics 
 Although 47,900 beneficiaries used a diuretic at some point in 2008, 47,711 had used a 
medication from this class since the first quarter of the year. Of these, 10.37% reached the 
coverage gap; a majority of which (70.78%) did so by November. Only two of these 
beneficiaries reached the catastrophic coverage. Beneficiaries reaching the coverage gap were 
found to be slightly older compared to those who did not reach the coverage gap. They took 
almost 11 unique medications compared to 8 medications taken by beneficiaries not reaching the 
coverage gap. As with the other groups, a greater proportion of beneficiaries reaching the 
coverage gap were enrolled in plans that charged a deductible and offered coverage through a 
benefit design considered equivalent to the standard Part D benefit structure (Table 15).   
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Table 15: Characteristics of beneficiaries in the “No Gap Coverage” group taking Diuretics 
before and after matching 
Variable Before matching 
Treatment       Control         p-value 
N = 4,948       N = 42763 
After matching 
Treatment    Control     p-value 
 N = 3530      N = 3,530 
Age 
Mean(Std.dev**) 
78.59 
(7.28) 
78.37 
(7.29) 
0.0129* 78.31 
(7.26) 
78.17 
(7.25) 
0.3661 
Race (%Caucasian) 92.91 91.28 0.0011* 92.46 90.85 0.1344 
Gender  
(% Females) 
78.35 79.52 0.0556 78.75 78.64 0.9065 
Income† 
(Median) 
32,120 31,838 0.2517 32,460 33,035 0.0556 
# Medications 
taken (Mean 
(Std.Dev)) 
10.99 
(3.98) 
8.05 
(3.78) 
<0.0001* 10.03 
(3.47) 
9.99 
(5.33) 
0.6397 
CDS††  
Mean(Std.dev) 
3.97 
(2.11) 
3.81 
(2.13) 
0.6100 3.94 
(2.11) 
3.93 
(2.23) 
0.8084 
Total Duration††† 
Mean(std.dev) 
314.04 
(24.14) 
349.43 
(16.62) 
<0.0001* 323.48 
(21.19) 
323.23 
(27.23) 
0.4879 
Benefit Type 
(% Basic Design) 
62.91 60.9 <0.0001* 62.35 62.04 0.5917 
Deductible  
(% No) 
70.17 75.27 <0.0001* 71.42 73.06 0.2075 
Pre-Gap 
Costsharing 
(% Tiers) 
98.77 99.32 0.0034* 98.95 98.98 0.9955 
Gap Threshold 
(% Std. amt***) 
98.45 98.76 0.3961 98.56 98.87 0.2489 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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(d) ACE Inhibitors 
Among all beneficiaries using ACE inhibitors (N = 40,060), 34,477 had usage beginning 
in the first quarter of 2008 and hence were included in further analyses. In this group, only 
5.64% reached the coverage gap in 2008; 61% of whom did so by November. None of these 
beneficiaries reached catastrophic coverage in 2008. A lesser proportion of those reaching the 
coverage gap were females compared to those who did not reach the coverage gap (65.26% vs. 
68.57% respectively). In addition, a greater proportion of those reaching the coverage gap were 
enrolled in plans with basic benefit designs that charged a deductible. The beneficiaries reaching 
the coverage gap also took a significantly greater number of medications compared to 
beneficiaries who did not reach the coverage gap (10.17 vs. 7.55). In addition, the severity of 
disease in the group reaching the coverage gap was greater compared to those not reaching the 
coverage gap. The differences between the two groups were eliminated by creating propensity 
score based matched groups (Table 16). 
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Table 16: Characteristics of beneficiaries in the “No Gap Coverage” group taking ACE 
inhibitors before and after matching 
Variable Before matching 
Treatment       Control         p-value 
N = 1,943       N = 32,534 
After matching 
Treatment    Control     p-value 
 N = 1,373      N = 1,373 
Age 
Mean(Std.dev**) 
77.55 
(7.21) 
77.39 
(7.04) 
0.5640 77.26 
(7.08) 
77.17 
(7.21) 
0.7390 
Race (%Caucasian) 92.57 91.61 0.3761 92.28 90.68 0.1060 
Gender  
(% Females) 
65.26 68.57 0.0023* 65.33 65.77 0.8023 
Income† 
(Median) 
32,232 32,710 0.2312 32,838 34,213 0.1126 
# Medications 
taken (Mean 
(Std.Dev)) 
10.17 
(3.92) 
7.55 
(3.67) 
<0.0001* 9.06 
(3.47) 
8.96 
(4.45) 
0.2052 
CDS††  
Mean(Std.dev) 
5.71 
(1.62) 
5.34 
(1.53) 
<0.0001* 5.61 
(1.61) 
5.56 
(1.69) 
0.4032 
Total Duration††† 
Mean(std.dev) 
306.22 
(22.78) 
349.22 
(16.77) 
<0.0001* 314.14 
(21.83) 
313.46 
(26.74) 
0.1808 
Benefit Type 
(% Basic Design) 
63.05 61.18 <0.0001* 62.35 62.78 0.6011 
Deductible  
(% No) 
70.87 76.01 <0.0001* 72.91 73.05 0.8939 
Pre-Gap 
Costsharing 
(% Tiers) 
99.54 99.24 0.1900 99.42 99.56 0.5930 
Gap Threshold 
(% Std. amt***) 
99.28 98.76 0.0521 99.05 98.76 0.4328 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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(e) Calcium channel blockers 
 From an aggregate of 31,346 beneficiaries taking calcium channel blockers at sometime 
in 2008; 29,229 beneficiaries had a full year of medication use according to our criteria. Of 
these, 3482 beneficiaries (11.91%) reached the coverage gap in 2008 and only two beneficiaries 
reached the catastrophic coverage. Almost three quarters (73%) of beneficiaries reaching the 
coverage gap did so by November. 
 A significantly greater proportion of beneficiaries reaching the coverage gap were 
Caucasians (91.51% vs. 89.07%) and had a higher median annual household income compared to 
those who did not reach the coverage gap ($32,933 vs. $31,971). In addition, beneficiaries 
reaching the coverage gap were of similar age and gender but used significantly larger number of 
prescription medications over a significantly shorter duration of therapy compared to those who 
did not reach the coverage gap. Most of the beneficiaries reaching the coverage gap were 
enrolled in plans offering coverage through actuarially equivalent Part D benefit with a 
deductible. The propensity score matching resulted in 2,373 matched pairs with similar 
characteristics beneficiaries who reached the coverage gap (68.15%).  Table 17 presents the 
results in detail: 
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Table 17: Characteristics of beneficiaries in the “No Gap Coverage” group taking Calcium 
channel blockers before and after matching 
Variable Before matching 
Treatment       Control         p-value 
N = 3,482       N = 25,747 
After matching 
Treatment    Control     p-value 
 N = 2,373     N = 2,373 
Age 
Mean(Std.dev**) 
78.59 
(7.32) 
78.48 
(7.27) 
0.4916 78.38 
(7.21) 
78.14 
(7.26) 
0.2699 
Race (%Caucasian) 91.51 89.07 <0.0001* 90.86 91.45 0.9972 
Gender  
(% Females) 
76.88 77.43 0.4641 76.53 77.08 0.6536 
Income† 
(Median) 
32,933 31,971 .0013* 33,269 33,309 0.6284 
# Medications 
taken (Mean 
(Std.Dev)) 
10.41 
(3.85) 
7.82 
(3.71) 
<0.0001* 9.46 
(3.45) 
9.39 
(5.04) 
0.5319 
CDS††  
Mean(Std.dev) 
4.57 
(1.92) 
4.54 
(2.01) 
0.0535 4.61 
(1.95) 
4.54 
(2.02) 
0.2415 
Total Duration††† 
Mean(std.dev) 
313.81 
(24.46) 
349.82 
(16.29) 
<0.0001* 324.16 
(21.71) 
323.57 
(26.29) 
0.1115 
Benefit Type 
(% Basic Design) 
63.3 61.53 .0011* 63.55 61.53 0.6328 
Deductible  
(% No) 
71.86 75.34 <0.0001* 72.69 74.04 0.2988 
Pre-Gap 
Costsharing 
(% Tiers) 
99.05 99.28 0.2754 98.99 99.21 0.4458 
Gap Threshold 
(% Std. amt***) 
98.62 98.79 0.4028 98.76 98.48 0.4602 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
 
(f) Proton-Pump Inhibitors (PPI) 
 Approximately 25,000 beneficiaries took PPIs during 2008 and 23,925 had used them 
since the first quarter of the year.  Almost 18% of these beneficiaries (N=4,204) reached the 
coverage gap and four beneficiaries reached the catastrophic coverage phase. Three-quarters 
(74%) of the beneficiaries using PPIs reached the coverage gap by November. As with the other 
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groups, the existing differences between the characteristics of beneficiaries in the two groups 
were eliminated after employing propensity score matching technique which yielded 2,678 
matched pairs (Table 18).  
Table 18: Characteristics of beneficiaries in the “No Gap Coverage” group taking Proton 
Pump Inhibitors before and after matching 
Variable Before matching 
Treatment       Control         p-value 
N = 2,492       N = 11,355 
After matching 
Treatment    Control     p-value 
 N = 2,068      N = 2,068 
Age 
Mean(Std.dev**) 
77.43 
(7.28) 
76.95 
(6.99) 
<0.0001* 77.08 
(6.99) 
76.89 
(6.92) 
0.3113 
Race (%Caucasian) 92.84 91.73 0.0140* 92.61 92.98 0.9926 
Gender  
(% Females) 
76.15 76.73 0.4271 75.43 74.38 0.3788 
Income† 
(Median) 
33,226 33,107 0.2851 33,523 34,029 0.2306 
# Medications 
taken (Mean 
(Std.Dev)) 
10.74 
(4.36) 
8.67 
(4.04) 
<0.0001* 9.73 
(3.85) 
9.59 
(4.63) 
0.2778 
CDS††  
Mean(Std.dev) 
3.37 
(2.01) 
3.35 
(2.12) 
0.0348* 3.32 
(1.98) 
3.27 
(2.19) 
0.1845 
Total Duration††† 
Mean(std.dev) 
313.11 
(24.11) 
349.23 
(16.83) 
<0.0001* 324.85 
(20.81) 
324.24 
(24.77) 
0.4230 
Benefit Type 
(% Basic Design) 
62.02 60.96 <0.0001* 61.69 61.46 0.7878 
Deductible  
(% No) 
71.97 76.42 <0.0001* 73.00 73.49 0.4691 
Pre-Gap 
Costsharing 
(% Tiers) 
99.04 99.20 0.4084 98.99 98.98 0.7893 
Gap Threshold 
(% Std. amt***) 
98.62 98.72 0.5939 98.81 98.81 1 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
 
(g) Oral anti-diabetic agents 
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An aggregate of 22,836 beneficiaries from the overall sample took one or more oral anti-
diabetic agents in 2008. However, only 17,500 beneficiaries had a full year of medication use 
and were included in further analyses. Almost 13% of these beneficiaries experienced the 
coverage gap in 2008; 73% of whom did so by November and only one passed into the 
catastrophic coverage phase.  
 The two groups within this therapeutic class were significantly different from each other 
(Table 19). Those reaching the coverage gap were older beneficiaries who used more 
medications in a shorter duration of time. The severity of their disease, however, was similar to 
their peers who did not reach the coverage gap. As with other groups, greater proportions of 
beneficiaries reaching the coverage gap were enrolled in plans that charged a deductible and 
offered no additional benefit over the standard Part D structure. These differences were 
accounted for after finding appropriate matched pairs from the two groups. However, in doing 
so, 36.67% of beneficiaries who reached the coverage gap were not matched to anyone not 
reaching the gap and were therefore excluded from the analyses. 
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Table 19: Characteristics of beneficiaries in the “No Gap Coverage” group taking oral 
anti-diabetic agents before and after matching 
Variable Before matching 
Treatment       Control         p-value 
N = 2,613       N = 14,887 
After matching 
Treatment    Control     p-value 
 N = 1,655      N = 1,655 
Age 
Mean(Std.dev**) 
76.69 
(6.31) 
76.08 
(6.42) 
0.0190* 75.58 
(6.11) 
75.55 
(6.03) 
0.9291 
Race (%Caucasian) 88.52 84.83 <0.0001* 87.37 87.43 0.7893 
Gender  
(% Females) 
63.57 65.61 0.0439* 63.14 64.77 0.2855 
Income† 
(Median) 
33,053 32,839 0.0269* 33,304 34,238 0.229 
# Medications 
taken (Mean 
(Std.Dev)) 
10.45 
(4.12) 
8.18 
(3.27) 
<0.0001* 9.46 
(3.57) 
9.48 
(4.69) 
0.5353 
CDS††  
Mean(Std.dev) 
5.09 
(1.99) 
5.08 
(2.03) 
0.7705 5.07 
(2.07) 
5.08 
(2.16) 
0.7129 
Total Duration††† 
Mean(std.dev) 
312.73 
(24.34) 
350.01 
(16.19) 
<0.0001* 324.28 
(21.69) 
324.28 
(25.41) 
0.9962 
Benefit Type 
(% Basic Design) 
63.91 61.48 <0.0001* 63.26 64.77 0.5518 
Deductible  
(% No) 
71.18 74.82 0.0002* 73.11 72.57 0.8658 
Pre-Gap 
Costsharing 
(% Tiers) 
98.74 99.19 0.0030* 99.03 99.27 0.4497 
Gap Threshold 
(% Std. amt***) 
98.55 98.69 0.5525 98.85 98.79 0.8658 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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Some Gap Coverage 
Within the “Some Gap Coverage” group, the beneficiaries were divided into 7 
therapeutic classes being studied and within each therapeutic class they were further divided into 
two groups based on whether or not they reached the coverage gap in 2008. The beneficiaries in 
the two groups in each class shared similar demographic and plan enrollment characteristics but 
there was variability with respect to their medication taking behavior.  As with the analyses for 
the “No Gap Coverage” group, it was necessary to make the two groups more comparable in 
terms of these characteristics before making reliable estimates of the effect of being in the 
coverage gap on the beneficiaries‟ adherence to medications. The following paragraphs outline 
the characteristics of the groups that did and did not reach the coverage gap by therapeutic class 
before and after matching. 
As with the “No Gap Coverage” group, oral anti-hyperlipidemic agents were the most 
frequently used class of medications in this group, followed by beta-blockers, diuretics and ACE 
inhibitors. Again, the least frequently used classes of medications were calcium channel 
blockers, followed by PPIs and oral anti-diabetic agents. The greatest impact was seen in the 
group taking PPIs; with almost a fifth (19.96%) of the beneficiaries in that group reaching the 
coverage gap in 2008. This was followed by beneficiaries taking oral anti-diabetic agents 
(16.33%), calcium channel blockers (14.81%), oral anti-hyperlipidemic agents (13.09%), beta-
blockers (12.68%) and diuretics (11.34%). Only 6% of beneficiaries using ACE inhibitors 
reached the coverage gap in this group.  
As with the “No Gap Coverage” group, between 40% of beneficiaries reaching the 
coverage gap (for all therapeutic classes) did so by October and 70% did so by November. As 
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mentioned earlier, all the beneficiaries in this group had similar demographic and plan 
enrollment characteristics, irrespective of whether or not they reached the coverage gap in 2008. 
However, beneficiaries reaching the coverage gap were more likely to use a greater number of 
prescription medications over a shorter duration of time compared to those who did not reach the 
coverage gap.  Detailed characteristics of beneficiaries by therapeutic class evaluated are 
presented in Tables 20-26. 
Table 20: Characteristics of beneficiaries in the “Some Gap Coverage” group taking anti-
hyperlipidemic agents before and after matching 
Variable Before matching 
Treatment       Control       p-value 
   N = 446         N = 2,961 
After matching 
Treatment       Control         p-value 
  N = 235           N =235 
Age Mean 
(Std.dev**) 
76.81 
(6.08) 
76.86 
(6.41) 
0.9992 76.67 
(6.01) 
77.27 
(6.19) 
0.1854 
Race 
(%Caucasian) 
95.07 92.71 0.3500 97.02 93.62 0.058 
Gender  
(% Females) 
70.19 70.82 0.7814 72.77 71.70 0.0903 
Income† 
(Median) 
32,945 34,039 0.0546 33,915 33,208 0.8216 
#Medications 
taken (Mean 
(Std.dev)) 
9.74 
(3.99) 
7.17 
(3.43) 
<0.0001* 8.46 
(3.54) 
8.15 
(3.98) 
0.3878 
CDS††  
Mean(Std.dev) 
2.89 
(1.87) 
2.66 
(1.78) 
0.0101* 2.82 
(1.93) 
2.69 
(1.81) 
0.4597 
Total 
Duration††† 
Mean(std.dev) 
310.65 
(23.79) 
348.05 
(17.53) 
<0.0001* 324.79 
(21.53) 
323.67 
(25.75) 
0.2425 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS = 
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed 
to take the medications since the first fill date 
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Table 21: Characteristics of beneficiaries in the “Some Gap Coverage” group taking beta-
blockers before and after matching 
Variable Before matching 
Treatment     Control         p-value 
   N = 291      N = 2,004 
After matching 
Treatment       Control         p-value 
  N = 163           N =163 
Age Mean 
(Std.dev**) 
78.21 
(6.78) 
78.08 
(7.19) 
0.6651 78.49 
(6.88) 
76.97 
(6.46) 
0.0535 
Race 
(%Caucasian) 
94.16 93.96 0.3736 94.48 90.80 0.6398 
Gender  
(% Females) 
73.88 74.41 0.8500 74.85 70.55 0.3621 
Income† 
(Median) 
31,784 32,662 0.2447 31,641 32,133 0.1948 
#Medications 
taken (Mean 
(Std.dev)) 
10.43 
(4.24) 
7.71 
(3.58) 
<0.0001* 9.17 
(3.53) 
8.69 
(4.47) 
0.1217 
CDS††  
Mean(Std.dev) 
3.01 
(2.03) 
2.84 
(1.81) 
0.3921 2.87 
(1.95) 
2.85 
(1.99) 
0.8282 
Total 
Duration††† 
Mean(std.dev) 
312.55 
(22.52) 
348.65 
(16.71) 
<0.0001* 323.62 
(20.33) 
323.32 
(24.81) 
0.5417 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS = 
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed 
to take the medications since the first fill date 
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Table 22: Characteristics of beneficiaries in the “Some Gap Coverage” group taking 
diuretics before and after matching 
Variable Before matching 
Treatment        Control         p-value 
   N = 258          N = 2,017 
After matching 
Treatment       Control         p-value 
  N = 128           N =128 
Age Mean 
(Std.dev**) 
78.89 
(7.39) 
78.63 
(7.21) 
0.6055 79.51 
(7.29) 
78.43 
(6.95) 
0.3291 
Race 
(%Caucasian) 
94.57 93.06 0.4856 95.31 92.62 0.5998 
Gender  
(% Females) 
84.11 79.77 0.0994 83.59 79.87 0.6949 
Income† 
(Median) 
33,060 31,752 0.7989 30,920 31,798 0.863 
#Medications 
taken (Mean 
(Std.dev)) 
10.99 
(3.95) 
7.99 
(3.58) 
<0.0001* 10.05 
(4.11) 
10.23 
(3.58) 
0.3075 
CDS††  
Mean(Std.dev) 
3.26 
(1.98) 
2.97 
(1.87) 
0.0359* 3.25 
(1.85) 
3.21 
(1.97) 
0.4563 
Total 
Duration††† 
Mean(std.dev) 
312.59 
(24.04) 
349.28 
(17.05) 
<0.0001* 328.51 
(19.59) 
336.16 
(34.85) 
0.3852 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS = 
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed 
to take the medications since the first fill date 
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Table 23: Characteristics of beneficiaries in the “Some Gap Coverage” group taking ACE 
inhibitors before and after matching 
Variable Before matching 
Treatment     Control         p-value 
   N = 86         N = 1,413 
After matching 
Treatment      Control         p-value 
  N = 36           N =36 
Age Mean 
(Std.dev**) 
79.09 
(7.06) 
77.57 
(6.84) 
0.0435* 79.37 
(7.99) 
79.25 
(6.22) 
0.952 
Race 
(%Caucasian) 
94.19 92.57 0.8954 90.63 90.63 1 
Gender  
(% Females) 
72.09 68.29 0.4615 65.63 81.25 0.1317 
Income† 
(Median) 
29,573 32,589 0.0976 29,708 30,631 0.3024 
#Medications 
taken (Mean 
(Std.dev)) 
9.64 
(3.76) 
7.72 
(3.54) 
<0.0001* 8.22 
(3.58) 
9.41 
(3.92) 
0.1403 
CDS††  
Mean(Std.dev) 
5.57 
(1.96) 
4.07 
(1.91) 
<0.0001* 4.88 
(2.09) 
4.59 
(1.96) 
0.872 
Total 
Duration††† 
Mean(std.dev) 
304.21 
(20.94) 
349.55 
(16.77) 
<0.0001* 318.93 
(21.72) 
318.41 
(31.66) 
0.9345 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS = 
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed 
to take the medications since the first fill date 
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Table 24: Characteristics of beneficiaries in the “Some Gap Coverage” group on calcium 
channel blockers before and after matching 
Variable Before matching 
Treatment     Control         p-value 
   N = 205       N = 1179 
After matching 
Treatment     Control         p-value 
  N = 97           N =97 
Age Mean 
(Std.dev**) 
78.69 
(7.08) 
78.78 
(7.14) 
0.9411 78.65 
(6.85) 
78.42 
(6.96) 
0.8230 
Race 
(%Caucasian) 
93.17 89.14 0.4717 91.75 85.57 0.1537 
Gender  
(% Females) 
79.02 79.39 0.9052 79.38 78.35 0.8575 
Income† 
(Median) 
32,587 31,744 0.3939 30,954 31,093 0.1601 
#Medications 
taken (Mean 
(Std.dev)) 
10.05 
(3.93) 
7.88 
(3.57) 
<0.0001* 8.68 
(2.98) 
8.84 
(4.52) 
0.7605 
CDS Mean†† 
(Std.dev) 
3.74 
(1.82) 
3.57 
(1.81) 
0.1437 3.44 
(1.55) 
3.62 
(2.02) 
0.4591 
Total 
Duration††† 
Mean(std.dev) 
312.86 
(21.73) 
349.58 
(16.42) 
<0.0001* 326.32 
(19.05) 
327.24 
(26.46) 
0.6155 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS = 
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed 
to take the medications since the first fill date 
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Table 25: Characteristics of beneficiaries in the “Some Gap Coverage” group taking PPIs 
before and after matching 
Variable Before matching 
Treatment     Control         p-value 
   N = 223       N = 894 
After matching 
Treatment       Control         p-value 
  N = 108           N =108 
Age Mean 
(Std.dev**) 
77.98 
(7.14) 
77.24 
(6.64) 
0.2106 78.39 
(7.25) 
77.54 
(6.37) 
0.2824 
Race 
(%Caucasian) 
94.17 92.81 0.8098 93.26 89.81 0.1060 
Gender  
(% Females) 
79.37 75.84 0.2653 80.56 75.00 0.3428 
Income† 
(Median) 
32,531 32,548 0.8039 33,312 32,259 0.4872 
#Medications 
taken (Mean 
(Std.dev)) 
10.57 
(4.22) 
8.54 
(3.88) 
<0.0001* 9.68 
(3.96) 
9.32 
(4.15) 
0.6281 
CDS††  
Mean(Std.dev) 
2.56 
(1.87) 
2.67 
(1.87) 
0.5034 2.72 
(1.98) 
2.66 
(1.98) 
0.7924 
Total 
Duration††† 
Mean(std.dev) 
316.37 
(24.94) 
348.85 
(17.53) 
<0.0001* 331.16 
(20.92) 
330.47 
(25.21) 
0.5952 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS = 
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed 
to take the medications since the first fill date 
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Table 26: Characteristics of beneficiaries in the “Some Gap Coverage” group on oral anti-
diabetic agents before and after matching 
Variable Before matching 
Treatment     Control         p-value 
   N = 138        N =707  
After matching 
Treatment      Control         p-value 
  N = 61            N =61 
Age Mean 
(Std.dev**) 
76.55 
(6.52) 
76.37 
(6.52) 
0.9536 76.52 
(7.38) 
75.85 
(5.77) 
0.9343 
Race 
(%Caucasian) 
89.86 86.70 0.2548 93.44 90.33 0.2531 
Gender  
(% Females) 
65.70 65.49 0.8223 68.85 62.3 0.4927 
Income† 
(Median) 
33,942 33,213 0.8287 33,068 34,133 0.4236 
#Medications 
taken (Mean 
(Std.dev)) 
10.14 
(4.06) 
8.08 
(3.71) 
<0.0001* 9.16 
(3.51) 
8.49 
(3.57) 
0.2850 
CDS††  
Mean(Std.dev) 
4.35 
(2.05) 
3.95 
(1.95) 
0.0673 4.11 
(1.96) 
4.09 
(2.29) 
0.9149 
Total 
Duration††† 
Mean(std.dev) 
311.66 
(25.52) 
349.26 
(17.01) 
<0.0001* 329.48 
(22.02) 
327.89 
(26.33) 
0.4150 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS = 
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed 
to take the medications since the first fill date 
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To study the effect of having “Some Gap Coverage” compared to not having any 
coverage during the gap, we compared, within each therapeutic class, those beneficiaries from 
the “Some Gap Coverage” group who reached the coverage gap and those from the “No Gap 
Coverage” group who also reached the coverage gap.  For almost every therapeutic class, the two 
groups were similar in terms of demographics and medication related behavior except the CDS. 
In addition, beneficiaries from both the groups were primarily enrolled in plans that had tiered 
cost-sharing and coverage gap starting at the Medicare defined amount. The only major 
difference was in the type of benefit structure used by the plans in which the beneficiaries were 
enrolled. For the “Some Gap Coverage” everyone was enrolled in plans that offered coverage 
through an „enhanced‟ alternative to the standard structure whereas a greater proportion of 
beneficiaries with “No Gap Coverage” were enrolled in plans that offered coverage through 
basic alteration of the standard Part D structure. In addition, no beneficiary from the “Some Gap 
Coverage” group had a deductible whereas a significant proportion of beneficiaries in the “No 
Gap Coverage” group were enrolled in plans that charged a front-end deductible. 
 Ideally, as with other analyses, it would be useful to eliminate these differences using the 
propensity score matching technique. However, the sample size restriction as well as the 
variables on which the two groups differed prevented the use of the matching technique. For 
example, in the group that took oral anti-hyperlipidemic agents, 446 had “Some Gap Coverage” 
whereas 7,636 had “No Gap Coverage”. Among the latter, only 38.62% (295) beneficiaries were 
enrolled in an „enhanced alternative‟ benefit structure and even that did not offer coverage during 
the gap. Thus, the sample sizes of the two groups were so similar that it would be difficult to 
perform a match. In addition, since the benefit structure is what defines and differentiates them 
into these two groups, there would not be any additional utility to match on this particular 
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variable even if there was sufficient sample size.  Therefore, no matching was performed for this 
analysis. Tables 27-33 present the characteristics of the two comparison groups used for this 
analysis by therapeutic class. 
Table 27: Characteristics of beneficiaries on oral anti-hyperlipidemic agents based on “gap 
coverage” status 
Variable Some Gap Coverage 
N=446 
No Gap Coverage 
N = 7,636 
p-value 
Age Mean(Std.dev**) 76.81(6.08) 76.52(6.47) 0.2185 
Race (%Caucasian) 95.07 93.07 0.3701 
Gender (% Females) 70.19 67.76 0.2871 
Income† 
(Median) 
32,945 34,022 0.0239* 
# Medications taken  
(Mean (Std.Dev)) 
9.74(3.99) 9.63(3.93) 0.8055 
CDS††  
Mean(Std.dev) 
2.89(1.87) 3.62(2.12) <0.0001* 
Total Duration††† 
Mean(std.dev) 
310.65(23.79) 311.57(24.28) 0.4963 
Benefit Type 
(% Basic Design) 
0 61.38 <0.0001* 
Deductible  
(% No) 
100 73.1 <0.0001* 
Pre-Gap Costsharing 
(% Tiers) 
100 99.28 0.0721 
Gap Threshold 
(% Std. amt***) 
100 98.73 0.0299 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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Table 28: Characteristics of beneficiaries on beta-blockers based on “gap coverage” status 
Variable Some Gap Coverage 
N=291 
No Gap Coverage 
N = 5,298 
p-value 
Age  
Mean(Std.dev**) 
78.21(6.78) 77.94(6.97) 0.3879 
Race 
(%Caucasian) 
94.16 93.74 0.8676 
Gender  
(% Females) 
73.88 71.64 0.4138 
Income† 
(Median) 
31,784 32,905 0.1466 
# Medications taken  
(Mean (Std.Dev)) 
10.43(4.24) 10.24(3.88) 0.7948 
CDS††  
Mean(Std.dev) 
3.01(2.03) 3.80(2.05) <0.0001* 
Total Duration††† 
Mean(std.dev) 
312.55(22.52) 313.51(24.14) 0.6400 
Benefit Type 
(% Basic Design) 
0 62.74 <0.0001* 
Deductible  
(% No) 
100 71.03 <0.0001* 
Pre-Gap Costsharing 
(% Tiers) 
100 98.81 0.0614 
Gap threshold 
(% Std. amt***) 
100 98.33 0.0553 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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Table 29: Characteristics of beneficiaries on diuretics based on “gap coverage” status 
Variable Some Gap Coverage 
N=198 
No Gap Coverage 
N = 2,899 
p-value 
Age  
Mean(Std.dev**) 
78.89(7.39) 78.59(7.28) 0.5334 
Race  
(%Caucasian) 
94.57 92.91 0.5045 
Gender  
(% Females) 
84.11 78.35 0.0279* 
Income† 
(Median) 
33,060 32,120 0.8454 
# Medications taken  
(Mean (Std.Dev)) 
10.99(3.95) 10.99(3.98) 0.9870 
CDS††  
Mean(Std.dev) 
3.26(1.98) 3.97(2.11) <0.0001* 
Total Duration††† 
Mean(std.dev) 
312.59(24.04) 314.04(24.14) 0.3642 
Benefit Type 
(% Basic Design) 
0 62.91 <0.0001* 
Deductible  
(% No) 
100 70.17 <0.0001* 
Pre-Gap Costsharing 
(% Tiers) 
100 98.77 0.0887 
Gap Threshold 
(% Std. amt***) 
100 98.45 0.0599 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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Table 30: Characteristics of beneficiaries using ACE inhibitors based on “gap coverage” 
status 
Variable Some Gap Coverage 
N=86 
No Gap Coverage 
N = 1,943 
p-value 
Age  
Mean(Std.dev**) 
79.09(7.06) 77.55(7.21) 0.0319 
Race  
(%Caucasian) 
94.19 92.57 0.8106 
Gender  
(% Females) 
72.09 65.26 0.1919 
Income† 
(Median) 
29,573 32,232 0.2192 
# Medications taken  
(Mean (Std.Dev)) 
9.64(3.76) 10.17(3.92) 0.2306 
CDS††  
Mean(Std.dev) 
5.57(1.96) 5.71(1.62) 0.3773 
Total Duration††† 
Mean(std.dev) 
304.21(20.94) 306.22(22.78) 0.5540 
Benefit Type 
(% Basic Design) 
0 63.05 <0.0001* 
Deductible  
(% No) 
100 70.87 <0.0001* 
Pre-Gap Costsharing 
(% Tiers) 
100 99.54 0.5270 
Gap Threshold 
(% Std. amt***) 
100 99.28 0.4296 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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Table 31: Characteristics of beneficiaries on calcium channel blockers based on “gap 
coverage” status 
Variable Some Gap Coverage 
N=205 
No Gap Coverage 
N = 3,842 
p-value 
Age  
Mean(Std.dev**) 
78.69(7.08) 78.59(7.32) 0.6456 
Race  
(%Caucasian) 
93.17 91.51 0.7706 
Gender  
(% Females) 
79.02 76.88 0.4785 
Income† 
(Median) 
32,587 32,933 0.9296 
# Medications taken  
(Mean (Std.Dev)) 
10.05(3.93) 10.41(3.85) 0.1083 
CDS††  
Mean(Std.dev) 
3.74(1.82) 4.57(1.92) <0.0001* 
Total Duration††† 
Mean(std.dev) 
312.86(21.73) 313.81(24.46) 0.7814 
Benefit Type 
(% Basic Design) 
0 63.30 <0.0001* 
Deductible  
(% No) 
100 71.86 <0.0001* 
Pre-Gap Costsharing 
(% Tiers) 
100 99.05 0.1615 
Gap Threshold 
(% Std. amt***) 
100 98.62 0.1109 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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Table 32: Characteristics of beneficiaries using PPIs based on “gap coverage” status 
Variable Some Gap Coverage 
N=223 
No Gap Coverage 
N = 4,204 
p-value 
Age  
Mean(Std.dev**) 
77.98(7.14) 77.43(7.28) 0.2251 
Race  
(%Caucasian) 
94.17 92.84 0.9463 
Gender  
(% Females) 
79.37 76.15 0.2707 
Income† 
(Median) 
32,531 33,226 0.2563 
# Medications taken  
(Mean (Std.Dev)) 
10.57(4.22) 10.74(4.36) 0.3955 
CDS††  
Mean(Std.dev) 
2.56(1.87) 3.37(2.01) <0.0001* 
Total Duration††† 
Mean(std.dev) 
316.37(24.94) 313.11(24.11) 0.9256 
Benefit Type 
(% Basic Design) 
0 62.02 <0.0001* 
Deductible  
(% No) 
100 71.97 <0.0001* 
Pre-Gap Costsharing 
(% Tiers) 
100 99.04 0.2629 
Gap Threshold 
(% Std. amt***) 
100 98.62 0.1187 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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Table 33: Characteristics of beneficiaries using oral anti-diabetic agents based on “gap 
coverage” status 
Variable Some Gap Coverage 
N=138 
No Gap Coverage 
N = 2,613 
p-value 
Age  
Mean(Std.dev**) 
76.55(6.52) 76.69(6.31) 0.2542 
Race  
(%Caucasian) 
89.86 88.52 0.5560 
Gender  
(% Females) 
65.7 63.57 0.8256 
Income† 
(Median) 
33,942 33,053 0.7402 
# Medications taken  
(Mean (Std.Dev)) 
10.14(4.06) 10.45(4.12) 0.2793 
CDS††  
Mean(Std.dev) 
4.35(2.05) 5.09(1.99) <0.0001* 
Total Duration††† 
Mean(std.dev) 
311.66(25.52) 312.73(24.34) 0.5342 
Benefit Type 
(% Basic Design) 
0 63.91 <0.0001* 
Deductible  
(% No) 
100 71.18 <0.0001* 
Pre-Gap Costsharing 
(% Tiers) 
100 98.74 0.1841 
Gap Threshold 
(% Std. amt***) 
100 98.55 0.1537 
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard 
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income = 
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, ††† 
Total Duration = total number of days beneficiaries were supposed to take the medications since 
the first fill date 
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Medication Adherence 
1. Impact of having „No Drug Coverage‟ during the coverage gap on beneficiaries‟ 
adherence 
To determine whether the coverage gap affected the extent to which beneficiaries having 
no coverage during the coverage gap remained adherent to their prescribed regimen, the 
medication possession ratios of beneficiaries reaching the coverage gap are first compared with 
themselves before and after reaching the coverage gap and then with that of matched 
beneficiaries that did not reach the coverage gap. Initially, the beneficiaries serve as their own 
controls and any change in the adherence can be attributed to factors other than the observed 
demographic, medication related and plan enrollment related characteristics. These „other 
factors‟ can be being in the coverage gap or situations that cannot be captured in the database 
(e.g. selection into specific plans or sudden changes in economic conditions). 
 Before matching the beneficiaries reaching the coverage gap to those who did not reach 
the coverage gap, it was found that beneficiaries in most of the therapeutic classes exhibited 
significantly less adherent behavior in the gap compared to their own filling pattern before 
reaching the gap. The significance of the difference in the two values is estimated using the 
Wilcoxon Signed Rank Test for paired data. The decrease in MPR ranged from 11% for oral 
anti-diabetic agents to 38% for PPIs. Table 34 presents the MPR values before and after reaching 
the coverage gap among beneficiaries with “No Gap Coverage” as well as for those who did not 
reach the coverage gap in 2008. 
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Table 34: Decrease in MPR† in the “No Gap Coverage” group before matching 
Class Did not reach 
the gap 
Reached the Gap 
Pre-Gap   In Gap  Difference    p-value 
ACE inhibitors 0.73 0.86 0.59 0.27 <0.0001* 
Beta-blockers 0.88 0.95 0.61 0.34 <0.0001* 
Calcium channel blockers 0.86 0.96 0.60 0.36 <0.0001* 
Diuretics 0.88 0.95 0.59 0.36 <0.0001* 
Oral anti-diabetic agents 0.98 0.98 0.87 0.11 <0.0001* 
Oral anti-hyperlipidemic 
agents 
0.79 0.99 0.75 0.24 <0.0001* 
Proton pump inhibitors 0.68 0.96 0.58 0.38 <0.0001* 
Note: † MPR = Medication Possession Ratio* indicates significant differences between the 
groups at p-value <0.05 
To reliably attribute the change in adherence values to the fact that the beneficiary was in 
the coverage gap and not some other mediator, it was necessary to compare the change in 
medication usage patterns of those reaching the coverage gap to those not experiencing the 
coverage gap throughout the year. Therefore, for this part of the analyses, the change in 
beneficiaries‟ adherence during the coverage gap phase was compared to the change in 
adherence experienced by corresponding matched beneficiaries who did not reach the coverage 
gap. After performing the match as specified earlier, the matched pairs were analyzed for the 
change in adherence before and during the gap. Then these differences were compared using the 
Wilcoxon Signed Rank Test.  
The results indicate that for the most part, both groups experienced significant decreases 
in adherence (Table 35). However, compared to those who did not reach the coverage gap, the 
beneficiaries reaching the coverage gap decreased their adherence to medications to a greater 
extent. For example, the decrease in adherence to beta-blockers after reaching the coverage gap 
 
 
123 
 
was 3% greater than the decrease in adherence observed for the corresponding beneficiaries not 
reaching the coverage gap during the same period. In absolute terms, beneficiaries using beta-
blockers who reached the coverage gap decreased their adherence by 33% while in the gap; 
whereas beneficiaries not reaching the coverage gap experienced a decrease of 30% in their MPR 
for the same period (p-value = 0.006). Similar results were obtained for beneficiaries using oral 
anti-diabetic agents (difference-in-difference = 9%, p-value < 0.0001), oral anti-hyperlipidemic 
agents (difference-in-difference = 7%, p-value < 0.0001) and PPIs (difference-in-difference = 
7%, p-value < 0.0001). 
Beneficiaries using ACE inhibitors, calcium channel blockers or diuretic agents also 
experienced greater reductions in adherence values compared to those reaching the coverage gap, 
but these differences were not statistically significant. Among those who used calcium channel 
blockers, the decrease in adherence for those reaching the coverage gap was 1% more than the 
decrease observed for those not reaching the coverage gap (p-value 0.1906). The decrease in 
adherence was 2% higher among those using diuretic medications and reaching the coverage gap 
compared to those that did not reach the coverage gap (p-value 0.1572). However, the results 
were reversed for beneficiaries taking ACE inhibitors. In this group, beneficiaries reaching the 
coverage gap experienced a 1% smaller reduction in adherence compared to those who did not 
reach the gap (p-value .3888). 
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Table 35: Difference-In-Difference analyses of the decreases in MPR†s in the “No Gap 
Coverage” group by therapeutic class after matching 
Class Reached the 
Gap 
Did not reach 
the Gap 
Diff-in-Diff** p-value 
ACE inhibitors 
(N = 1,373 pairs) 
0.25 0.26 -0.01 0.3888 
Beta-blockers 
(N = 3,821 pairs) 
0.33 0.30 0.03 0.006* 
Calcium channel blockers 
(N = 2,373 pairs) 
0.33 0.32 0.01 0.1572 
Diuretics 
(N = 3,530 pairs) 
0.35 0.33 0.02 0.1906 
Oral anti-diabetic agents 
(N = 1,655 pairs) 
0.41 0.32 0.09 <0.0001* 
Oral anti-hyperlipidemic agents 
(N = 5,041 pairs) 
0.33 0.26 0.07 <0.0001* 
Proton pump inhibitors 
(N = 2,678 pairs) 
0.36 0.29 0.07 <0.0001* 
Note: † MPR = Medication Possession Ratio, * indicates significant differences between the 
groups as p-value <0.05 ** means Difference-In-Difference, calculated as (Change in MPR after 
reaching the gap for the „Reached Gap‟) – (Change in MPR after reaching the gap for „Did not 
reach the Gap‟),  
 
In a second set of analyses, the percentage of beneficiaries found to have stopped taking 
their medications after reaching the coverage gap was estimated for the matched pairs. In 
addition, we compared the proportion of beneficiaries considered to be adherent (MPR > 0.80) 
before and after reaching the coverage gap for each therapeutic class. 
The results indicate that a greater proportion of beneficiaries not reaching the coverage 
gap appeared to have stopped taking their medications at the time corresponding to the coverage 
gap. Overall, the group taking PPIs was most likely to stop taking the medications during the 
coverage gap. A little over one fifth (21.51%) of the beneficiaries reaching the gap and 28.90% 
of beneficiaries not reaching the gap in this group stopped taking their medications in the time 
corresponding to the coverage gap. Beneficiaries using diuretics was another group in which 
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12.85% and 23.40% of the beneficiaries who did and did not experience the coverage gap 
stopped taking the medication during the time corresponding to the coverage gap. For all other 
groups, the proportion of beneficiaries who discontinued taking medications during the time 
corresponding to the coverage gap was in the range of 9% - 19%. The differences in the 
proportion of beneficiaries stopping medications from the groups that did and did not reach the 
coverage gap were statistically significant for all the classes evaluated. Table 36 presents these 
results in detail. 
Table 36: Percent of beneficiaries in the “No Gap Coverage” group stopping medications 
during the coverage gap 
Class Reached the 
gap (%) 
Did not reach 
the gap (%) 
p-value 
ACE inhibitors 
(N = 1,373 pairs) 
15.37 18.43 <0.0001* 
Beta-blockers 
(N = 3,821 pairs) 
10.49 15.18 <0.0001* 
Calcium channel blockers 
(N = 2,373 pairs) 
12.85 18.71 <0.0001* 
Diuretics 
(N = 3,530 pairs) 
18.53 23.40 <0.0001* 
Oral anti-diabetic agents 
(N = 1,655 pairs) 
9.49 13.41 <0.0001* 
Oral anti-hyperlipidemic agents 
(N = 5,041 pairs) 
11.60 16.43 <0.0001* 
Proton pump inhibitors 
(N = 2,678 pairs) 
21.51 28.90 <0.0001* 
 
The proportion of beneficiaries considered adherent before and during the coverage gap 
decreased for both the groups in all classes of medications evaluated. For example, among 
beneficiaries using beta-blockers, 80.81% of the beneficiaries reaching the coverage gap were 
considered adherent before reaching the coverage gap. However, only half of these beneficiaries 
(44.21%) were found to be adherent during the coverage gap phase. For beneficiaries not 
reaching the coverage gap, the numbers were 72.52% in the pre-gap period and 42.97% in the 
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„during gap‟ period. These findings were consistent across all the remaining therapeutic classes 
being evaluated. Table 37 presents these results in detail. 
Table 37: Percentage of beneficiaries in the “No Gap Coverage” group considered 
adherent* in the Pre-Gap and the During Gap periods by therapeutic class 
Class Reached gap 
%adherent         % adherent 
 Pre-Gap              During Gap 
Did not Reach Gap 
%adherent         % adherent 
  Pre-Gap             During Gap 
ACE inhibitors 
(N = 1,373 pairs) 
72.54 44.51 70.12 40.64 
Beta-blockers 
(N = 3,821 pairs) 
80.81 44.21 72.52 42.97 
Calcium channel blockers 
(N = 2,373 pairs) 
82.68 46.08 71.35 40.18 
Diuretics 
(N = 3,530 pairs) 
72.27 42.72 64.43 40.37 
Oral anti-diabetic agents 
(N = 1,655 pairs) 
84.65 68.61 72.71 48.88 
Oral anti-hyperlipidemic 
agents 
(N = 5,041 pairs) 
78.82 49.64 76.86 42.99 
Proton pump inhibitors 
(N = 2,678 pairs) 
66.43 36.45 46.11 30.85 
Note: * considered adherent = beneficiaries whose Medication Possession Ratio (MPR) > 0.80 
 Further, we evaluated the differences in percentage of beneficiaries considered adherent 
before and after reaching the coverage gap in both the groups for statistical significance. The 
tests indicate that the differences between the groups were statistically significant for all 
therapeutic classes except ACE inhibitors. The decrease in percentages of beneficiaries 
considered adherent was greater among those taking beta-blockers, calcium channel blockers, 
diuretics or PPIs and reaching the coverage gap compared to those not reaching the coverage 
gap. However, greater percentages of beneficiaries taking ACE inhibitors, oral anti-diabetic 
agents, or oral anti-hyperlipidemic agents and not reaching the coverage gap were found to be 
non-adherent at the time corresponding to the matched group‟s coverage gap (Table 38). 
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Table 38: Difference-in-difference of decreases in percentages of beneficiaries in the “No 
Gap Coverage” group considered adherent† during the coverage gap 
Class Reached the 
Gap 
Did not reach 
the Gap 
Diff-in-Diff** p-value 
ACE inhibitors 
(N = 1,373 pairs) 
28.03 29.48 -1.45 0.4010 
Beta-blockers 
(N = 3,821 pairs) 
36.60 29.55 7.05 <0.0001* 
Calcium channel blockers 
(N = 2,373 pairs) 
36.60 31.17 5.43 <0.0001* 
Diuretics 
(N = 3,530 pairs) 
29.55 24.06 5.49 <0.0001* 
Oral anti-diabetic agents 
(N = 1,655 pairs) 
16.04 23.83 -7.79 <0.0001* 
Oral anti-hyperlipidemic agents 
(N = 5,041 pairs) 
29.18 33.87 -4.69 <0.0001* 
Proton pump inhibitors 
(N = 2,678 pairs) 
29.98 15.26 14.72 <0.0001* 
Note: † considered adherent = beneficiaries whose Medication Possession Ratio (MPR) > 0.80 * 
indicates significant differences between the groups as p-value <0.05 ** means Difference-In-
Difference, calculated as (decrease in percent adherent after reaching the gap for the „Reached 
the Gap‟) – (decrease in percent adherent after reaching the gap for „Did not reach the Gap‟) 
 These results indicate that among the beneficiaries taking beta-blockers and PPIs, those 
reaching the coverage gap were more likely to reduce their medication usage to some extent 
(inferred from the reduction in percentage considered adherent) rather than stopping it 
completely as compared to those who did not reach the coverage gap. The net effect was that the 
observed decrease in adherence (in other words, MPR) during the coverage gap for those 
reaching it was significantly greater than for those not reaching the coverage gap. However, for 
those taking oral anti-diabetic agents and oral anti-hyperlipidemic agents, the results indicate that 
though beneficiaries reaching the coverage gap were less likely to stop taking their medications 
altogether, there is still a significantly greater decrease in their MPR values compared to those 
not reaching the coverage gap. Among those taking calcium channel blockers and diuretics, a 
lesser proportion of beneficiaries reaching the coverage gap stopped the medications during that 
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time compared to those not reaching the coverage gap. This was nullified by the fact that a 
greater proportion of beneficiaries not reaching the coverage gap became non-adherent (MPR < 
0.80) during the coverage gap period compared to those who reached the coverage gap. In other 
words, there was no significant difference in the decrease in adherence (MPR) values between 
the two groups for these therapeutic classes. 
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2. Impact of having „Partial Drug Coverage‟ during the coverage gap on beneficiaries‟ 
adherence 
To study the impact of having partial drug coverage during the gap, comparisons of 
changes in MPR values before and after reaching the coverage gap were made with themselves 
in the “Some Gap Coverage” group. It was found that the decrease in beneficiaries‟ adherence to 
medications during the coverage gap was significant compared to their adherence values before 
reaching the coverage gap for all therapeutic classes being studied. The greatest decline in 
adherence was exhibited by the group taking PPIs (41%) whereas the smallest decrease was in 
the group using oral anti-diabetic agents (18%). An analysis of the changes in adherence after 
adding the comparison group that did not reach the coverage gap revealed that the percent 
decrease in adherence in the group reaching the coverage gap was not significantly different than 
the percent decrease experienced by the corresponding comparison group for any therapeutic 
class. Tables 39 and 40 present these results in detail. 
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Table 39: Decreases in MPR in the “Some Gap Coverage” Group by gap status before 
matching 
Class Did not reach 
the gap 
Reached the Gap 
Pre-Gap   In Gap  Difference    p-value 
ACE inhibitors 0.73 0.81 0.49 0.32 <0.0001* 
Beta-blockers 0.88 0.96 0.66 0.30 <0.0001* 
Calcium channel blockers 0.89 0.96 0.62 0.34 <0.0001* 
Diuretics 0.88 0.95 0.59 0.36 <0.0001* 
Oral anti-diabetic agents 0.98 1.02 0.84 0.18 <0.0001* 
Oral anti-hyperlipidemic 
agents 
0.79 0.98 0.67 0.31 <0.0001* 
Proton pump inhibitors 0.67 0.86 0.45 0.41 <0.0001* 
Note: * indicates significant differences between the groups at p-value <0.05 
Table 40: Difference-In-Difference analyses of decreases in MPR†s in the “Some Gap 
Coverage” group by therapeutic class after matching 
Class Reached the 
Gap 
Did not reach 
the Gap 
Diff-in-Diff** p-value 
ACE inhibitors 
(N = 36 pairs) 
0.18 0.17 0.01 0.8935 
Beta-blockers 
(N = 163 pairs) 
0.3 0.29 0.01 0.9786 
Calcium channel blockers 
(N = 97 pairs) 
0.32 0.36 -0.04 0.5614 
Diuretics 
(N = 128 pairs) 
0.32 0.2 0.12 0.6842 
Oral anti-diabetic agents 
(N = 61 pairs) 
0.47 0.29 0.18 0.0512 
Oral anti-hyperlipidemic agents 
(N = 235 pairs) 
0.34 0.32 0.02 0.2426 
Proton pump inhibitors 
(N = 108 pairs) 
0.42 0.2 0.22 0.0015 
Note: † MPR = Medication Possession Ratio, * indicates significant differences between the 
groups as p-value <0.05 ** means Difference-In-Difference, calculated as (Change in MPR after 
reaching the gap for the „Reached Gap‟) – (Change in MPR after reaching the gap for „Did not 
reach the Gap‟) 
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 As with the “No Gap Coverage” group, we estimated the proportion of beneficiaries who 
stopped taking medications from a particular therapeutic class while in the coverage gap. We 
also estimated the change in proportion of beneficiaries considered to be adherent (MPR > 0.80) 
before and during the coverage gap phases. Among those with some gap coverage, a 
considerable percentage of beneficiaries stopped taking medications during the coverage gap 
phase. These percentages in this group ranged from 7.98% for beta-blockers to 30.56% for PPIs. 
However, unlike the “No Gap Coverage” group, the percentage of beneficiaries not reaching the 
coverage gap but stopping the medications was greater among those taking beta-blockers, 
calcium channel blockers, diuretics and oral anti-hyperlipidemic agents; but less among those 
taking ACE inhibitors, PPIs or oral anti-diabetic agents. None of these differences (except ACE 
inhibitors), however, was statistically significant (Table 41). 
Table 41: Percent of beneficiaries in the “Some Gap Coverage” group stopping medications 
during the time corresponding to the coverage gap 
Class Reached the 
gap (%) 
Did not reach 
the gap (%) 
p-value 
ACE inhibitors 
(N = 36 pairs) 
28.13 6.25 0.0102 
Beta-blockers 
(N = 163 pairs) 
7.98 11.66 0.2628 
Calcium channel blockers 
(N = 97 pairs) 
9.28 14.43 0.2670 
Diuretics 
(N = 128 pairs) 
17.97 19.53 0.7490 
Oral anti-diabetic agents 
(N = 61 pairs) 
11.48 3.28 0.0802 
Oral anti-hyperlipidemic agents 
(N = 235 pairs) 
10.64 11.91 0.6600 
Proton pump inhibitors 
(N = 108 pairs) 
30.56 27.78 0.6528 
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The proportion of beneficiaries considered adherent during the coverage gap decreased 
from the pre-gap values for both groups (those who did and did not reach the coverage gap). A 
greater proportion of those taking ACE inhibitors, beta-blockers, calcium channel blockers and 
oral anti-diabetic agents and not reaching the coverage gap were considered non-adherent at the 
time corresponding to the matched group‟s coverage gap while the results were opposite for the 
other classes evaluated. Only the difference for those taking PPIs was statistically significant. 
Table 42 and 43 presents these results in detail.  
Table 42: Percentage of beneficiaries considered adherent* in the Pre-Gap and the During 
Gap periods by therapeutic class 
Class Reached gap 
%adherent         % adherent 
 Pre-Gap              During Gap 
Did not Reach Gap 
%adherent         % adherent 
  Pre-Gap             During Gap 
ACE inhibitors 59.38 46.88 74.19 47.88 
Beta-blockers 88.34 54.6 89.76 47.24 
Calcium channel blockers 82.47 49.48 81.45 45.36 
Diuretics 73.44 45.31 67.72 49.22 
Oral anti-diabetic agents 85.25 57.48 85.25 57.27 
Oral anti-hyperlipidemic 
agents 
78.3 44.25 71.55 42.13 
Proton pump inhibitors 58.33 30.55 34.58 26.85 
Note: * considered adherent = beneficiaries whose Medication Possession Ratio (MPR) > 0.80 
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Table 43: Difference-in-difference of decreases in percentages of beneficiaries in the “Some 
Gap Coverage” group considered adherent† during the coverage gap 
Class Reached the 
Gap 
Did not reach 
the Gap 
Diff-in-Diff** p-value 
ACE inhibitors 
(N = 36 pairs) 
12.50 26.31 -13.81 0.1310 
Beta-blockers 
(N = 163 pairs) 
33.74 42.42 -8.78 0.1032 
Calcium channel blockers 
(N = 97 pairs) 
32.99 36.09 -3.10 0.6528 
Diuretics 
(N = 128 pairs) 
28.13 18.50 9.63 0.0672 
Oral anti-diabetic agents 
(N = 61 pairs) 
27.77 27.98 -0.21 0.9760 
Oral anti-hyperlipidemic agents 
(N = 235 pairs) 
34.05 29.42 4.63 0.2846 
Proton pump inhibitors 
(N = 108 pairs) 
27.78 7.73 20.05 <0.0001* 
Note: † considered adherent = those with MPR > 0.80* indicates significant differences between 
the groups as p-value <0.05 ** means Difference-In-Difference, calculated as (decrease in 
percent adherent after reaching the gap for the „Reached the Gap‟) – (decrease in percent 
adherent after reaching the gap for „Did not reach the Gap‟) 
 
The results for those with “Some Gap Coverage” indicate that the proportions of 
beneficiaries considered adherent or stopping the medications did not differ between those who 
did and did not reach the coverage gap for all therapeutic classes except PPIs. For those taking 
PPIs, similar proportions of beneficiaries stopped taking medications at the time of the coverage 
gap but a greater proportion of those reaching the coverage gap were considered non-adherent 
compared to those not reaching the coverage gap. Therefore, overall, it appears that there is a 
significantly greater reduction in adherence (MPR) for those reaching the coverage gap in this 
group compared to those not reaching the coverage gap. 
From the previous analyses, it can be concluded that the decreases in adherence to 
medications for beneficiaries reaching the coverage gap relative to the decreases in adherence of 
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beneficiaries not reaching the coverage gap varied across therapeutic classes. Further, it is found 
that the extent to which beneficiaries‟ MPR decreased within a therapeutic class also varied by 
presence or absence of drug coverage in the gap. To study the significance of this variability 
within the groups reaching the coverage gap, the differences in beneficiaries‟ adherence values 
(i.e. MPRs) before and after reaching the coverage gap based on their “gap coverage” status were 
compared using the Wilcoxon Rank Sum Test. As can be noted from Table 44 below, the 
decreases in adherence values during the coverage gap were not significantly different between 
groups for any of the therapeutic classes.  
Table 44: Decreases in MPR†s during the coverage gap by gap coverage type and 
therapeutic class 
Class Some Gap Coverage 
      N          Decrease 
No Gap Coverage 
      N          Decrease 
p-value 
ACE inhibitors 86 0.32 1,943 0.27 0.2918 
Beta-blockers 291 0.30 5,298 0.34 0.0727 
Calcium channel blockers 205 0.34 3,842 0.36 0.4529 
Diuretics 198 0.36 2,899 0.36 0.9123 
Oral anti-diabetic agents 138 0.18 2,613 0.11 0.2918 
Oral anti-hyperlipidemic 
agents 
446 0.31 7,636 0.24 0.9006 
Proton pump inhibitors 223 0.41 4,204 0.38 0.1911 
Note: † MPR = Medication Possession Ratio, * indicates significant differences between the 
groups as p-value <0.05 
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Main Conclusions 
 A significant proportion of beneficiaries reached the coverage gap in 2008. However, 
most did so late in the year and spent the rest of the year in the gap. Also, the impact of coverage 
gap on beneficiaries‟ adherence is mixed depending on whether or not they had coverage for 
some drugs during the gap. The following chapter discusses the results as well as the study 
strengths and limitations in detail. It also highlights the practical applications of these results. 
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CHAPTER 6 
 DISCUSSION 
 
This chapter discusses the results of the study as well as the strengths and limitations of 
the study design. It also presents an overview of practical implications of the study results, 
concluding remarks, and ideas for future research.  
Objective 1: 
 The sample for our analysis was older, sicker and predominantly Caucasian. Almost 
three-quarters of the sample comprised females and the median annual household income ranged 
around $33,000. Most seniors in our sample took several medications simultaneously and used at 
least 3 classes of medications being evaluated. A greater proportion of beneficiaries from our 
sample were enrolled in stand-alone PDP plans and 95.07% did not have any coverage for drugs 
during the coverage gap. Moreover, these beneficiaries were enrolled in plans that did not charge 
a deductible and in those that had tiered cost-sharing structures rather than the standard 25% 
coinsurance rate set by Medicare. Beneficiaries with drug coverage in the gap were limited to 
coverage for generic drugs only. These socio-demographic characteristics as well as plan 
enrollment profile are similar to the national estimates indicating that our sample was a 
representative sample of all Medicare beneficiaries
117
.  
 Overall, the beneficiaries in our sample were found to have similar socio-demographic 
characteristics irrespective of whether or not they reached the coverage gap or whether or not 
they had coverage during the gap. This indicates that the socio-demographic characteristics of 
beneficiaries that were included in this study are not significant in determining whether or not 
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beneficiaries reached the coverage gap in a given year. These results are consistent with prior 
findings that socio-demographic characteristics are not significant predictors of reaching the 
coverage gap threshold64. The results however, do indicate that beneficiaries reaching the 
coverage gap used significantly greater numbers of unique medications and had higher OOP 
spending before and during the gap. The use of greater numbers of medications can be used as a 
proxy for having greater number/severity of co-morbidities. In addition, though the differences 
between the socio-demographic and plan enrollment characteristics varied by therapeutic class, 
the number of medications and CDS were consistently higher among those who reached the 
coverage gap compared to those who did not. These results are in accordance with prior 
estimations that the likelihood of reaching the coverage gap increases with increases in co-
morbidity64, 66, 118. 
Objective 2: 
 Almost a quarter of all beneficiaries in our sample reached the coverage gap in 2008. 
This finding is similar to prior estimates by researchers at Kaiser Family Foundation62. However, 
this proportion is greater than found by other studies that estimated that between 6 and 19% of 
their samples reached the coverage gap in a given year118-121. It should be noted, however, that the 
study done by Kaiser Family Foundation used data from a representative sample of beneficiaries 
enrolled in PDPs whereas the other studies used data from beneficiaries enrolled in MA-PD 
plans, which are inherently different from PDPs.  
When comparing beneficiaries with some drug coverage during the gap to those without 
any drug coverage during the gap, we found that the two groups were similar in terms of their 
demographic and medication taking behavior, but that a greater proportion of beneficiaries with 
“Some Gap Coverage” reached the coverage gap. These results hold at the therapeutic class level 
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analyses as well. In our opinion, these findings are consistent with the basic economic theory of 
insurance and demand; the presence of some drug coverage during the gap may lead to an 
increased utilization of medications before the gap, and therefore increase the chances of 
reaching the coverage gap.  
At the therapeutic class level, the greatest proportion of beneficiaries reaching the gap 
were those who took proton pump inhibitors group, followed by those taking oral anti-diabetic 
agents, beta-blockers and oral anti-hyperlipidemic agents. Beneficiaries using ACE inhibitors 
were the least likely to have experienced the coverage gap. These results were consistent in 
groups with and without gap coverage. 
A majority of our sample reaching the coverage gap did so by September which is a 
month later than the previous estimates of beneficiaries reaching the gap by August
62
. This could 
be due to adaptation to the benefit structure. To the best of our knowledge this is the first study to 
estimate the effect of coverage gap two years into its implementation and we hypothesize that 
since the beneficiaries were exposed to the Part D benefit design for at least a couple of years, 
they would have been able to adjust their medication usage accordingly. A study by Hsu et al.122 
tested a similar assumption and found that those who were aware of having a gap in coverage 
were significantly more likely to adopt one or more cost-cutting strategies throughout the year 
which could be translated as a measure to delay their entry to the coverage gap.  
On average, beneficiaries reaching the coverage gap spent about three months in the 
phase. Only 3% of the total sample reached the catastrophic coverage phase. These beneficiaries 
were those who reached the coverage gap in the first quarter of the year and had quite high 
expenditures on medications.  There was no difference in the time taken to reach the coverage 
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gap based on presence or absence of gap coverage. These estimates are also consistent with prior 
research indicating that a very small percentage of beneficiaries reach the catastrophic coverage 
level and that most of the beneficiaries reaching the coverage gap remain in that phase through 
the rest of the year62, 119, 123.  
Objectives 3 and 4: 
 Our study results indicate that the impact of experiencing a coverage gap on 
beneficiaries‟ adherence to prescription medications depends on the therapeutic class of 
medication evaluated as well as presence or absence of drug coverage during the coverage gap.  
When compared with themselves, beneficiaries in all therapeutic classes experienced a 
significant reduction in their adherence during the coverage gap irrespective of the presence or 
absence of gap coverage. For the group with “No Gap Coverage”, the decrease in MPR values 
during the gap ranged from 11% for those using oral anti-diabetic agents to 38% for those using 
PPIs. Similar results were obtained for those reaching the coverage gap and having “Some Gap 
Coverage” (18% for oral anti-diabetic users and 41% for PPIs). These estimates are consistent 
with the hypothesis that adherence would be adversely affected during the coverage gap, but are 
greater than previous studies62, 66, 118.  
In the “No Gap Coverage” group, the decrease in adherence (MPR) for beneficiaries 
reaching the coverage gap was 1% (for calcium channel blockers) to 9% (for oral anti-diabetic 
agents) more than the decrease in adherence for beneficiaries not reaching the coverage gap. The 
difference in the differences was statistically significant for those using beta-blockers, oral anti-
diabetic agents, oral anti-hyperlipidemic agents or PPIs. For those in the “Some Gap Coverage” 
group also, MPR values declined during the time corresponding to the coverage gap irrespective 
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of whether or not they reached it, but the difference between these decreases were not 
statistically significant for any class except PPI, the group in which the MPR values for 
beneficiaries reaching the coverage gap decreased by 22% more than those not reaching the 
coverage gap. Overall, the findings that adherence decreased for both the groups is consistent 
with a prior study in which Raebel et al found that adherence decreased more for those reaching 
the coverage gap and, to a lesser but still substantial extent, for those who did not reach the 
gap
60
. 
In addition, the results indicate that a substantial proportion of beneficiaries stopped 
taking their medications during the coverage gap phase for both those who did and did not reach 
the coverage gap, independent of gap coverage. The extent of beneficiaries stopping their 
medications ranged from about 10% to 25% depending on the class and group being evaluated. 
This finding is consistent with that of the study by Kaiser Family Foundation that found that as 
many as 20% of their sample stopped taking medications during the coverage gap
62
.  
The proportion of beneficiaries considered to be adherent also decreased during the 
coverage gap phase for both those who did and did not reach the coverage gap, for all classes of 
medications irrespective of gap coverage. The extent of decrease in percentage of beneficiaries 
considered adherent during the coverage gap in both groups varied with therapeutic class and 
presence of gap coverage. These results, however, are counter-intuitive in the fact that the 
percentages of beneficiaries stopping medications or becoming non-adherent at the time of the 
coverage gap were greater for those not reaching the coverage gap compared to those who did 
reach the coverage gap for most comparisons. 
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A possible explanation for the findings that a significant proportion of beneficiaries either 
stopped or became non-adherent even though they did not reach the coverage gap can be drawn 
from the studies that estimated the impact of having a cap on spending for prescription 
medications. This is because the group that did not reach the coverage gap in our study did have 
a „cap‟ of $2,510 on their drug spending and an awareness of this cap could lead to decreased 
utilization of medications. A study by Hsu et al. tested a similar hypothesis and found that the 
group not reaching the coverage gap was more aware of having a gap in coverage compared to 
those who did reach the coverage gap and therefore modified their medication taking behaviors 
accordingly
122
. Such findings have also been noted in the literature before the implementation of 
Medicare Part D among seniors with capped benefits
38-40, 124
.  
Given this, it is reasonable to state that our results indicate a greater need for providing 
„uninterrupted‟ and/or „uncapped‟ drug coverage to all Medicare beneficiaries. As proposed by 
the newly signed health reform law, provision of uninterrupted coverage is proposed to be 
achieved by phasing in subsidies for drugs during the coverage gap every few years until the gap 
is eliminated completely. For example, the current timeline
125
 suggests provision of a rebate 
worth $250 to beneficiaries reaching the gap between July and December of 2010. For the 
following years, the manufacturers have agreed to provide 50% rebate for the brand name drugs 
purchased by beneficiaries in the gap. Beginning in January 2011, the Government will start 
offering 7% discount on generic drugs and increase the discount gradually till 2020 when the gap 
is proposed to be eliminated. The subsidies for brand name drugs will be offered from January 
2013 till the total cost to beneficiaries reaches 25% (50% by manufacturer and upto 25% by the 
Government) in 2020.  
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These are a few steps in the right direction, but as is apparent from the plan, it will take 
several years to be fully implemented. Implementing this policy reform might not be feasible in 
the long run because providing coverage throughout the year will lead to increase in utilization 
of the medications and, in turn, increase government spending on prescription drugs. A recent 
publication in the Kaiser Health News bulletin, reported that the Congressional Budget Office 
has estimated the cost of elimination the coverage gap by 2019 to be $42.6 billion
126
. There is 
also a possibility of further delay in implementation of all the provisions due to political as well 
as financial pressures that may develop over the course of time. Thus, the beneficiaries still have 
to cope with having interruptions and/or caps in drug coverage for several more years to come. 
An additional possible reason for finding decreases in adherence as well as percentage of 
beneficiaries considered adherent during the coverage gap for both the groups that did and did 
not reach the coverage gap can be due to financial barriers like having limited income or 
changing economic times like the Great Recession of 2008. However, we believe that we were 
able to account for these effects to some extent through techniques like propensity score 
matching and the difference-in-difference analysis.  
Another possible reason for such findings may be the availability of non-recorded 
medications (e.g. cash pays for $4 generics or over the counter medications; especially for PPIs). 
In other words, it is possible that the beneficiaries utilized their medications as prescribed but 
purchased them from sources that were not recorded in the insurance claims data. The 
availability of such medications could have a significant beneficial effect on beneficiaries‟ OOP 
spending as well as help them delay reaching the coverage gap.  As a result, there could have 
been significant use of such medications, especially, among those not reaching the coverage gap 
than those who did reach it. Therefore, together, it would appear that the beneficiaries not 
 
 
143 
 
reaching the gap stopped or reduced their medication utilization to a greater extent as compared 
to those reaching the gap.   
In addition, a review of the literature suggests that cost-related medication non-adherence 
is a very complex phenomenon. A model developed by Piette et al. summarizes the known 
predictor/s  of medication non-adherence (either alone or in combination of more than one) to be 
socio-demographic, complexity of regimen, drug coverage, OOP costs, number of co-morbid 
conditions, physical, emotional and social health status, perceived need of medications, adverse 
effects of medications, patient – provider relationship, effect on Health Related Quality of Life 
(HRQoL) and health system characteristics
127
. Therefore, it is possible that non-financial barriers 
to medication adherence may exist for not only those who experience a coverage gap, but also 
for the entire senior population enrolled in stand-alone PDP plans, due to which the entire sample 
in our analysis experienced varied degree of decreases in adherence during the time 
corresponding to the coverage gap. While we were able to account for a few of these factors 
(socio-demographic factors, drug coverage, co-morbid conditions, health system characteristics 
and complexity of drug regimen), the effect of a number of predictors (health beliefs, perceived 
need for medications, effects on HRQoL and physician patient relationship) remains to be 
explored. Therefore, it is possible that a lack of awareness among the patients, personal beliefs or 
other non-financial factors might increase the rates of non-adherence despite the availability of 
uninterrupted drug coverage through the proposed health reform.  
In summary, we believe that it is reasonable to state that our study results have policy 
implications for all beneficiaries enrolled in Medicare Part D and beyond. Firstly, our results 
indicate that there is a need to provide uninterrupted and/or uncapped coverage for prescription 
drugs to the seniors. Secondly, we also suggest that it would be beneficial to educate all 
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Medicare beneficiaries; especially those with multiple chronic diseases and who take several 
medications at a time; about the importance of medication adherence as well as strategies that 
can help them continue taking their medications as prescribed throughout the year while enrolled 
in the Part D program. These strategies include choosing a plan that has providers and a 
formulary structure that meet the beneficiary‟s requirements, obtaining supplemental coverage, 
and switching to generic medications early in therapy. 
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Strengths and Limitations  
Evidence from the literature suggests that beneficiaries reduce the use of medications 
during the coverage gap. However, the degree to which a lack of coverage in the gap reduces 
adherence rates remained to be explored. Ours is one of the first studies to quantify the extent to 
which adherence rates decreased during the coverage gap for beneficiaries taking one more of 
the most widely used medications among seniors. Further, most studies to date limited their 
analyses to data from single health plans offering MA PD drug plans and thus may have limited 
application to beneficiaries enrolled in stand-alone PDPs. In addition, the studies done to date are 
limited to data up to the year of 2007. To the best of our knowledge, ours is the first study to use 
the CMS claims and denomination data files to estimate the impact of Medicare Part D coverage 
gap on adherence of beneficiaries enrolled in stand-alone PDPs two years into the program‟s 
implementation. As a result, our findings reflect the impact of the gap after the beneficiaries have 
had two years to learn about the program and develop strategies to cope with it.  
The study design accounts for different types of effects that can introduce biases in our 
estimates. First, it uses eligible beneficiaries as their own controls in assessing the change in 
medication adherence rates during the coverage gap. Since the same cohort of patients is 
observed before and after the intervention, this reduces potential bias introduced due to 
differences in beneficiary characteristics between the two study periods. This is further 
controlled by using a matched control group that did not experience a coverage gap. The second 
stage of analysis estimates the difference in change in adherence rates (before and during the 
gap) between cases and matched controls. This helps us to control biases introduced by choices 
in plan selection as well as potential temporal trends like the changing economy and changing 
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overall prevalence of diseases. Together, these controls help us to more accurately measure the 
association between the gap and change in adherence.  
The study, however, also has limitations. The use of retrospective claims data implies that 
the study is affected by limitations related to secondary data sources. One of the main limitations 
is that using only the information from the database compels us to assume that all the filled 
prescriptions were taken as prescribed
128
. Despite this, it is known that claims data are relatively 
accurate measures of the dates and times at which most prescription medications are taken by a 
patient and therefore do provide information about „possessing‟ a medication128.  In addition, we 
believe that the population studied for this research had limited incentives to „not‟ take their 
medications if they were filled because our sample included senior Medicare beneficiaries who 
generally have limited sources of income and several concomitant chronic diseases that require 
continuous use of medications.  
We could not, however, account for medications taken by the beneficiaries that are not 
billed through Medicare as those transactions are not recorded in the claims data.  Examples 
include free samples, over-the-counter medicines, borrowed medicines, and prescriptions paid 
for with cash (such as $4 generics at Wal-Mart or Target).  The result of this is that we could 
have underestimated the adherence to medications in our sample. In other words, it is possible 
that some beneficiaries did not really stop treatment for their conditions, but since they moved to 
alternatives that are not captured in the database (e.g. $4 generics), they were considered as being 
non-adherent according to our definition.  This supports the argument for forming a 
comprehensive dataset that also captures information of such drugs that are not paid for by the 
insurance but are still dispensed as being equivalent to the prescription medications.  
 
 
147 
 
In addition, switching between therapeutic classes of medications was not allowed in our 
adherence calculations which might also lead to underestimation of adherence to medications. 
However, we believe that since the report was generated at a therapeutic class level, allowing the 
switch between classes would have generated inaccurate estimates of effects of the coverage gap 
within a particular therapeutic class.  
Our results indicate that being in the coverage gap was not a significant indicator of 
decrease in adherence in the group with “Some Gap Coverage”.  This is because among those 
with some drug coverage during the coverage gap, the extent of decreases in adherence for those 
reaching the coverage gap was similar to those not reaching the coverage gap. However, in a 
separate analysis, it was found that having some drug coverage during the gap was not 
significantly different from having no drug coverage during the gap. Previous results indicate 
that having some coverage during the coverage gap was beneficial for the seniors66, 67, 129 but the 
impact of “Some Gap Coverage” during the coverage gap on medication adherence was not clear 
in our study. These results need to be interpreted with caution because the sample size of groups 
with some form of coverage during the coverage gap was close to about 100 beneficiaries only. 
In addition, even though the groups that did and did not have gap coverage were similar to each 
other in terms of most of their characteristics, there were differences in their plan enrollment 
characteristics which could affect their medication taking behavior. Owing to sample size issues, 
it was not possible to match these two groups with each other to generate reliable estimates. 
We were not able to evaluate the effects of other known predictors of medication non-
adherence (e.g. side effects or adverse reactions of the drugs, health beliefs, and patients‟ 
relationship with the physician) because this database did not collect information on these 
variables. These predictors could have affected our adherence values in either direction. 
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Additionally, we did not eliminate the overlaps caused by using multiple drugs in the same 
therapeutic class and hence we might have overestimated the adherence rates.112  
The income and therapeutic class information were not available in the CMS database 
and were obtained by linking our database with other data sources. The income information was 
gathered from Census data which has been widely used as a measure of a person‟s financial 
status. The concern is that the Census data presents the median household income in a zip-code, 
not at the level of a beneficiary‟s individual income. The therapeutic classification was obtained 
from First Databank based on the NDC numbers provided in the CMS Part D event file. 
However, the NDC as well as the classification system used both came from First Data Bank and 
therefore, we are less concerned about the differences introduced by use of an external source for 
this information. In addition, it is reasonable to believe that all the study limitations had similar 
effects on the groups that did and did not reach the coverage gap. Therefore, much of the bias 
introduced because of these limitations would be minimized between the groups.  
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Conclusions and Future Research 
 In conclusion, the impact of „coverage gap‟ in our sample is not clear. Though there are 
reductions in adherence values for those reaching the coverage gap independent of presence of 
gap coverage, medication adherence decreased for all beneficiaries as the year progressed. The 
reductions were greater for some therapeutic classes for those reaching the coverage gap in the 
“No Gap Coverage” group compared to those not reaching the coverage gap; however, the 
coverage gap did not seem to significantly affect the adherence values of those with “Some Gap 
Coverage”.  
Future research should study the effects of the coverage gap for the same group of 
beneficiaries over several years because it would provide information about whether prior 
experiences help beneficiaries make effective choices in subsequent years or not. In addition, it 
would be useful to compare the effects of being in the coverage gap with no coverage to 
beneficiaries who reached the coverage gap and had full coverage during the gap. As evidence 
from the literature suggests, decreases in adherence to medications leads to worse clinical 
outcomes which can increase the cost of therapy. Therefore, future research should be directed at 
studying the impact of Medicare Part D coverage gap on utilization of other health care services. 
It would also be useful to conduct studies that examine the effects of non-financial barriers like 
health beliefs, effects on HRQoL, patient-physician relationship and awareness about Part D on 
medication adherence while being in the coverage gap. 
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